

State of Georgia Department of Community Health

Measurement Year (MY) 2020 Validation of Performance Measures

for Amerigroup Community Care for Georgia Families 360°

Measurement Period: Calendar Year 2020 Validation Period: January–June 2021 Publish Date: August 2021





Table of Contents

Validation of Performance Measures1
Validation Overview1
Care Management Organization (CMO) Information2
Performance Measures Validated
Description of Validation Activities
Pre-Audit Strategy
Validation Team
Technical Methods of Data Collection and Analysis 4
Virtual Review Activities
Data Integration, Data Control, and Performance Measure Documentation9
Data Integration
Data Control9
Performance Measure Documentation
Validation Results
Medical Service Data (Claims and Encounters) 10
Enrollment Data
Provider Data11
Medical Record Review Validation (MRRV)
Supplemental Data
Data Integration
Performance Measure Specific Findings 14
Appendix A. Data Integration and Control FindingsA-1
Appendix B. Denominator and Numerator Validation FindingsB-1
Appendix C. Performance Measure Rate Submission File C-1
Appendix D. HEDIS Interactive Data Submission System DataD-1



Validation of Performance Measures

Validation Overview

The Centers for Medicare & Medicaid Services (CMS) requires that states, through their contracts with managed care organizations (MCOs), measure and report on performance to assess the quality and appropriateness of care and services provided to members. Title 42 of the Code of Federal Regulations (CFR) §438.350(a) requires states that contract with MCOs, prepaid inpatient health plans (PIHPs), prepaid ambulatory health plans (PAHPs), or a primary care case management (PCCM) entity to have a qualified external quality review organization (EQRO) perform an annual external quality review (EQR) that includes validation of contracted entity performance measures (42 CFR §438.358[b][1][ii]). HSAG conducted performance measure validation (PMV) for the Georgia Department of Community Health (DCH), validating the data collection and reporting processes used to calculate the performance measure rates by the MCOs (referred to by the State as care management organizations [CMOs]) in accordance with the CMS publication, *Protocol 2: Validation of Performance Measures: A Mandatory EQR-Related Activity*, October 2019.¹ The purpose of the PMV is to assess the accuracy of performance measures reported by the MCOs and to determine the extent to which performance measures reported by the MCOs follow State specifications and reporting requirements.

The DCH is responsible for administering the Medicaid program and the Children's Health Insurance Program (CHIP) in the State of Georgia. The State refers to its CHIP program as PeachCare for Kids[®]. Both programs include fee-for-service (FFS) and managed care components and deliver services through a statewide provider network. The FFS program has been in place since the inception of Medicaid in Georgia. The DCH contracts with four privately owned CMOs to deliver services to certain categories of members enrolled in the State's Medicaid and PeachCare for Kids[®] programs. Children in state custody, children receiving adoption assistance, and certain children in the juvenile justice system are enrolled in the Georgia Families 360° (GF 360°) managed care program. The Georgia Families (GF) program, implemented in 2006, serves all other Medicaid and PeachCare for Kids[®] managed care members not enrolled in the GF 360° program. Approximately 1.3 million beneficiaries are enrolled in the GF program.²

HSAG validated a set of performance measures identified by DCH that were calculated and reported by Amerigroup for its GF 360° population. The DCH identified the measurement period as calendar year (CY) 2020. HSAG conducted the validation in accordance with the CMS publication, *Protocol 2: Validation of Performance Measures: A Mandatory EQR-Related Activity*, October 2019.

¹ Department of Health and Human Services, Centers for Medicare & Medicaid Services. *EQR Protocol 2: Validation of Performance Measures: A Mandatory EQR-Related Activity*, October 2019. Available at:

https://www.medicaid.gov/medicaid/quality-of-care/downloads/2019-eqr-protocols.pdf. Accessed on: Mar 24, 2020. ² Georgia Department of Community Health. Medicaid Management Information System. Georgia Families Monthly Adjustment Summary Report June 2016.



Care Management Organization (CMO) Information

Basic information about Amerigroup Community Care for Georgia Families 360° (Amerigroup 360°) appears in Table 1, including the office location(s) involved in the 2021 validation of performance measures audit that covered measurement year (MY) 2020.

CMO Location:	5800 Northampton Blvd., Norfolk, VA 23502
Virtual Audit or On-site Visit:	Virtual Audit Review
Audit Contact:	Yvette Terry
Contact Telephone Number:	(678) 587-4852
Contact Email Address:	yvette.t.harris@amerigroup.com
Audit Review Date:	March 23–24, 2021

Table 1—Amerigroup 360° Information

Performance Measures Validated

HSAG validated rates for a set of performance measures selected by DCH for the GF 360° population. All performance measures were selected from CMS' Core Set of Children's Health Care Quality Measures for Medicaid and CHIP (Child Core Set)³ and Core Set of Adult Health Care Quality Measures for Medicaid (Adult Core Set)⁴. The measurement period was identified by DCH as CY 2020 for all measures. Table 2 lists the performance measures that HSAG validated, the methodology (i.e., Administrative [Admin] or Hybrid) required by DCH for data collection, and the specifications required by DCH.

	Performance Measure		Methodology	Measure Specifications
1	Developmental Screening in the First Three Years of Life	DEV-CH	Hybrid	Custom (Child Core Set)*
2	Percentage of Eligibles Who Received Dental Services	PDENT- CH	Admin	Child Core Set
3	Screening for Depression and Follow-Up Plan: Ages 12–17	CDF-CH	Admin	Child Core Set

Table 2—List of MY 2020 Performance Measures for Amerigroup 360°

³ The Centers for Medicare & Medicaid Services. Core Set of Children's Health Care Quality Measures for Medicaid and CHIP, March 2020.

⁴ The Centers for Medicare & Medicaid Services. Core Set of Adult Health Care Quality Measures for Medicaid, March 2020.



Performance Measure		Acronym	Methodology	Measure Specifications
4	Screening for Depression and Follow-Up Plan: Ages 18 and Older	CDF-AD	Admin	Adult Core Set
5	Use of Multiple Concurrent Antipsychotics in Children and Adolescent	APC	Admin	Custom**

*The CMOs followed the Child Core Set dated March 2020 and applied the following modifications: All claims must have EP modifier 96110; claims that also have a UA modifier must be excluded as these indicate autism services.

**CMOs followed specifications provided by DCH.

In addition to the AHRQ and the CMS Adult and Child Core Set measures audited by HSAG, DCH required Amerigroup 360° to report a selected set of Healthcare Effectiveness Data and Information Set (HEDIS[®])⁵ measures to DCH. Amerigroup 360° was required to contract with a National Committee for Quality Assurance (NCQA)-licensed audit organization and undergo an NCQA HEDIS Compliance Audit^{TM,6}. Final audited HEDIS measure results from NCQA's Interactive Data Submission System (IDSS) were submitted to HSAG and provided to DCH. Appendix D displays the final audited HEDIS MY 2020 results for all required measures.

Description of Validation Activities

Pre-Audit Strategy

HSAG conducted the validation activities as outlined in the CMS performance measure validation protocol. To complete the validation activities for Amerigroup 360°, HSAG obtained a list of the performance measures that were selected by DCH for validation.

HSAG then prepared a document request letter that was submitted to Amerigroup 360° outlining the steps in the performance measure validation process. The document request letter included a request for source code for each performance measure, a completed MY 2020 Information Systems Capabilities Assessment Tool (ISCAT), and any additional supporting documentation necessary to complete the audit. The letter also included an introduction to the medical record review validation (MRRV) process; a timetable for completion; and instructions for submission. HSAG responded to ISCAT-related questions received directly from Amerigroup 360° during the pre-audit phase.

Approximately one month prior to the virtual audit review, HSAG provided Amerigroup 360° with an agenda describing all virtual audit review activities and indicating the type of staff needed for each session. HSAG also conducted a pre-audit review conference call with Amerigroup 360° to discuss

⁵ HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

⁶ NCQA HEDIS Compliance Audit[™] is a trademark of the National Committee for Quality Assurance (NCQA).



review logistics and expectations, important deadlines, outstanding ISCAT documentation, and any questions from Amerigroup 360° regarding the process.

Validation Team

The HSAG Performance Measure Validation Team was composed of a lead auditor and several validation team members. HSAG assembled the team based on the skills required for the validation and requirements of Amerigroup 360°. Some team members, including the lead auditor, participated in the virtual meetings with Amerigroup 360°; others conducted their work at HSAG's offices. Table 3 lists the validation team members, their roles, and their skills and expertise.

Validation Team Member	Role/Skills/Expertise
Thomas D. Miller, MA, CHCA Lead Auditor	Lead auditor, Certified HEDIS Compliance Auditor (CHCA), multiple years of auditing experience, HEDIS and performance measure knowledge, and statistics and analysis background.
Tammy GianFrancisco, CHCA Project Manager, DSAA	Project Manager—Daily management of audit operations, including audit deliverables and timelines.
Advanced Analytics	Analytic Team—Provides analytic support, including source code review.

Table 3—Validation Team

Technical Methods of Data Collection and Analysis

The CMS performance measure validation protocol identifies key types of data that should be reviewed as part of the validation process. The following list describes the type of data collected and how HSAG conducted an analysis of these data:

- **MY 2020 ISCAT**: Amerigroup 360° completed and submitted the required and relevant portions of its -ISCAT for HSAG's review. HSAG used responses from the ISCAT to complete the pre-audit assessment of information systems.
- **Medical record documentation:** Amerigroup 360° completed the medical record section within the ISCAT. In addition, Amerigroup 360° submitted the following documentation for review: medical record hybrid tools and instructions, training materials for medical record review (MRR) staff members, and policies and procedures outlining the processes for monitoring the accuracy of the reviews performed by the review staff members.
- Source code (programming language) for performance measures: Amerigroup 360° was required to submit the source code used to calculate the performance measures under review by HSAG. HSAG reviewed the source code and performance measure generation process to ensure compliance with the measure specifications required by DCH.



- **Supporting documentation:** HSAG requested documentation that would provide reviewers with additional information to complete the validation process, including policies and procedures, file layouts, system flow diagrams, system log files, and data collection process descriptions. HSAG reviewed all supporting documentation, identifying issues or areas needing clarification for further follow-up.
- **Rate review:** Upon receiving the calculated rates from Amerigroup 360°, HSAG conducted a review on the reasonableness and integrity of the rates. The review included trending with prior year's rates and comparison of rates across all CMOs.

Virtual Review Activities

HSAG conducted a virtual audit review with Amerigroup 360° on March 23–24, 2021. HSAG collected information using several methods, including interviews, system demonstrations, review of data output files, primary source verification, observation of data processing, and review of data reports. The virtual site visit activities are described as follows:

- **Opening meeting:** The opening meeting included an introduction of the validation team and key Amerigroup 360° staff members involved in the performance measure validation activities. The review purpose, the required documentation, basic meeting logistics, and queries to be performed were discussed.
- Evaluation of system compliance: The evaluation included a review of the information systems, focusing on the processing of claims and encounter data, provider data, patient data, and inpatient data. Additionally, the review evaluated the processes used to collect and calculate the performance measure rates, including accurate numerator and denominator identification and algorithmic compliance (which evaluated whether rate calculations were performed correctly, all data were combined appropriately, and numerator events were counted accurately).
- **Review of ISCAT and supporting documentation:** The review included processes used for collecting, storing, validating, and reporting performance measure rates. This session was designed to be interactive with key Amerigroup 360° staff members so that HSAG could obtain a complete picture of all the steps taken to generate the performance measure rates. The goal of the session was to obtain a confidence level as to the degree of compliance with written documentation compared to actual processes. HSAG conducted interviews to confirm findings from the documentation review, expand or clarify outstanding issues, and ascertain that written policies and procedures were used and followed in daily practice.
- **Overview of data integration and control procedures:** The overview included discussion and observation of source code logic, a review of how all data sources were combined, and a review of how the analytic file was produced for the reporting of selected performance measure rates. HSAG performed primary source verification to further validate the output files, reviewed backup documentation on data integration, and addressed data control and security procedures. HSAG also reviewed preliminary rates during this session, if available.
- **Closing conference:** The closing conference included a summation of preliminary findings based on the review of the ISCAT and the virtual audit review, and revisited the documentation requirements for any post-audit review activities.



HSAG conducted several interviews with key Amerigroup 360° staff members who were involved with performance measure reporting.

Table 4 displays a list of key Amerigroup 360° interviewees:

Name	Title
Andy Katona	Business Information Consultant, Government Business Division (GBD) HEDIS
Angela Evans	Program Consultant, HEDIS
Ben Johnson	Program Management, Vendor Management
Brian Behnke	Business Consultant Senior, HEDIS MRR Team
Chandrashekara Mallappa	Business Information Consultant, Senior
Chris Watson	Vendor Management Consultant, Senior
Cybil Fry	Director Performance Measures (PM), Clinical Quality
David Reeves	Business Information Consultant, GBD HEDIS, Georgia
Debbie Murphy	Clinical Quality Program Manager
Derrica Butler	Reporting Analyst, Georgia Medicaid
Derrick Beneby	Claims Operations
Dorothy De Los Santos	Business Change Director
Ellena Weaver, Director Pursuit	Director Pursuit, Clinical Quality
Erikka Smith	Director Provider Data Management, APDO GBD
Gail Brown	Program Consultant, HEDIS
Graham Lukens	Vendor Management (Front End)
Greggory Cannavale	Staff Vice President (VP), QM Data Management
Haley Van Broekhoven	PM, Vendor Management, Reveleer Tool
Harwanda Hancock-Rowel	Director RNA, Clinical Quality
Heather Dyke	Regulatory Oversight Manager, Georgia
Heather Taylor	HEDIS Lead, GA Medicaid QM
Holly Conk	VP, Clinical Quality
James Magner	Director Performance Enhancement/QA
Jamie Giron	Medicaid (GA BA - File Processing/Technical)
Jason Isberto	Vendor Rx
Jennifer Camarro	Director, Clinical Information & Reporting
Jodi Searing	Director Pursuit, Clinical Quality

Table 4—List of Amerigroup 360° Interviewees



Name	Title
Joe Powers	Business Change Director, GBD HEDIS
John Kuehn	Vendor Dental/Vision
Jonathon Kinzel	Business Information Consultant Senior, GBD HEDIS
Joyce LeTourneau	Medicaid (Operations Manager & Front-End Demo, South Markets)
Judy Jusinski	Director Training, Clinical Quality
Karla Enrequez	Director Credentialing
Kathleen King	Vendor Management; Contracts
Kathleen Layman	Business Consultant Senior, Clinical Quality Management
Kelly Lanier	Claims Operations
Keyia Coleman	Administrative Assistant, Georgia Medicaid QM
Kori Magallanez	Director, Program Management
Kristina Mooney	Kristina Mooney, Business Info Consultant, Enterprise HEDIS
Kristy Kelly	Business Change Manager, Clinical Quality Management
Lakshmi Ramanujan	Business Information Consultant, Enterprise HEDIS
Latisha Adams	Latisha Adams, Manager. Business Information, GBD HEDIS
Leigh Ann Cole	Manager, Clinical Delegate Oversight
Leslie Langslow	Claims Operations MCD/MCR
Leticia Mayfield	MCD Compliance Director-Plan, Georgia
Lisa Hanshue	Business Information Consultant, GBD HEDIS
Melissa Turransky	Credentialing Manager, Credentialing
Mindy Albrecht	Business Information Consultant, GBD HEDIS
Nancy Sare	Cost Containment (Reversals)
Neal T. Maron	Systems Analyst Senior Advisor
Newk Newcomb	Staff VP, Provider Data Management
Patrick Sturgeon	Director Business Information, Enterprise HEDIS
Patty Boston	Director Clinical Quality Management, Clinical Quality Management
Peter Cheng	Business Information Consultant Senior, GBD HEDIS
Rebekah Hensley-Martin	Manager II, Credentialing
Samantha Young	Claims Operations, MCD
Sheila Cason	Business Information Consultant, GBD HEDIS—PSV
Tiarra Kelly	Systems Analyst Data Management



Name	Title
Tiffany Schuler	Business Analyst III, GBD Claims Ops Support (Front End Processes)
Wanda Lee	Director RNA, Clinical Quality
Yvette Harris	Director I GBD QM—Plan, Georgia



Data Integration, Data Control, and Performance Measure Documentation

There are several aspects crucial to the calculation of performance measure rates. These include data integration, data control, and documentation of performance measure rate calculations. Each of the following sections describes the validation processes used and the validation findings. For more detailed information, see Appendix A of this report.

Data Integration

Accurate data integration is essential for calculating valid performance measure rates. The steps used to combine various data sources (including claims/encounter data, eligibility data, and other administrative data) must be carefully controlled and validated. HSAG validated the data integration process used by Amerigroup 360°, which included a review of file consolidations or extracts, a comparison of source data to warehouse files, data integration documentation, source code, production activity logs, and linking mechanisms. Overall, HSAG determined that the data integration processes in place at Amerigroup 360° were:

\boxtimes	Acceptable
\square	Not acceptable

Data Control

Amerigroup 360°'s organizational infrastructure must support all necessary information systems; and its quality assurance practices and backup procedures must be sound to ensure timely and accurate processing of data, and to provide data protection in the event of a disaster. HSAG validated the data control processes Amerigroup 360° used which included a review of disaster recovery procedures, data backup protocols, and related policies and procedures. Overall, HSAG determined that the data control processes in place at Amerigroup 360° were:

Acceptable

Performance Measure Documentation

Sufficient, complete documentation is necessary to support validation activities. While interviews and system demonstrations provided supplementary information, the majority of the validation review findings were based on documentation provided by Amerigroup 360°. HSAG reviewed all related documentation, which included the completed ISCAT, job logs, computer programming code, output files, workflow diagrams, narrative descriptions of performance measure calculations, and other related documentation. Overall, HSAG determined that the documentation of performance measure rate calculations by Amerigroup 360° was:

Acceptable

] Not acceptable



Validation Results

HSAG evaluated Amerigroup 360°'s data systems for the processing of each data type used for reporting DCH performance measure rates. General findings are indicated below.

Medical Service Data (Claims and Encounters)

There were no concerns with Amerigroup 360°'s claims and encounter system or processes. Amerigroup 360°'s transactional systems, Facets, had sufficient edits in place during pre-, concurrent, and post-processing of claims and encounters. Additionally, there were no system changes or conversions implemented by the CMO in 2020.

Overall, approximately 3 percent of the claims in 2020 were submitted on paper with the majority of claims being received electronically via electronic data interchange (EDI) files . Paper claims were received through the document management system and scanned using an optical character recognition (OCR) process into the system. Paper claims that failed the process were routed to claims examiners trained on multiple markets for data entry into the system. Electronic EDI claims were submitted to and processed by three clearinghouses (i.e., Change Healthcare, Smart Data Solutions, and Availity) prior to intake and loading into Facets. During the virtual audit review, Amerigroup 360° noted that it is transitioning toward exclusive use of Availity in the future. Claims and encounters were validated for compliance against the national standards and each passed claim was matched to enrollment data in Facets. The pre-processing edits ensured the claims contained valid codes, member, and provider information. Market-specific business rules were applied to claims, as applicable. Claims that failed compliance checks were returned via a 277 claims acknowledgement file. All claims were tracked from the point of receipt until they were loaded into Facets; with Amerigroup 360° conducting daily and weekly audits to ensure claims were processed accurately.

Amerigroup 360° also captured ancillary service data from external vendors including pharmacy, dental, vision, and laboratory services to support performance measure reporting. Vendors submitted data to Amerigroup 360° regularly, and was tracked and trended to ensure files were complete and accurate. The CMO established detailed service level agreements (SLAs) with each vendor to define oversight requirements, data submission performance standards (i.e., timeliness and quality), and formal audit procedures. Encounters were received electronically and underwent front-end edits to assess accuracy of incoming files and monitor the completeness of data. A series of bi-weekly and monthly reports were generated to track data loads, file rejections, and reconciliation with cash disbursement. Additionally, the CMO conducted monthly and quarterly meetings with vendors as well as performing an annual audit. Amerigroup 360°'s oversight of this process ensured that all relevant data were captured prior to measure production.

Amerigroup 360° noted that all encounters, both paid and denied, were submitted to the State regularly; only claims rejected back to providers were withheld from encounter submission since they did not have a final disposition. Amerigroup 360° sent all required medical, dental, vision, and pharmacy encounters to Gainwell Technologies (Gainwell) in alignment with DCH encounter reporting requirements.



Based on its review of ISCAT responses, audit interviews, and a virtual demonstration, HSAG confirmed that core information systems captured appropriate, standard coding schemes as required for reporting. Amerigroup 360° only used standard claim forms for each service type (i.e., dental, professional, institutional, and pharmacy).

Enrollment Data

There were no concerns with Amerigroup 360°'s membership and enrollment data systems or processes. Amerigroup 360°'s transactional system, Facets, was used as the system of record for enrollment and eligibility information. No system changes or conversions were implemented by the MCO in 2020. Amerigroup 360° experienced an increase in both its Georgia Families Medicaid population (25 percent) and PeachCare for Kids[®] population (36 percent) between January and December. Membership trends were reviewed and discussed during the virtual audit review and were consistent with membership changes in other markets.

The daily 834 enrollment files were received electronically from the State's enrollment broker, Gainwell, separated into six regional files, as well as a full monthly reconciliation file. The files included member additions, deletions, and modifications. The CMO checked the files for compliance and reconciliation reports were produced to compare file counts received from the State versus loaded into the system. Facets continued to maintain all enrollment data for HEDIS MY 2020. Any identified errors were researched by the Enrollment Analyst and corrections were made through the Facets editing tool. Members with duplicate identifiers were merged into a single record based on the State's most recent identification number. There was no backlog in processing enrollment data during 2020. Using the aid codes provided on the enrollment files, Amerigroup 360° was able to identify and separate the GF 360° population from the GF population when reporting on each measure.

Amerigroup 360° assigned a unique member identification (ID) number by market and product line. During the virtual audit review, Amerigroup 360° confirmed that Medicaid members were evaluated in MY 2020 within markets and product lines, and that no mapping to commercial or Medicare was conducted. Further, Amerigroup confirmed that within the Medicaid designation, members retain the same Facets Subscriber ID. Once processed in Facets, Anthem transmitted enrollment data to downstream vendors and delegated entities on a timely basis to support member services. Amerigroup 360°'s Facets system captured all relevant fields from the State's enrollment files and continued to monitor daily file updates, cancelations, and renewals.

Amerigroup 360° demonstrated the Facets enrollment module during the virtual audit review and HSAG verified that Facets accurately captured each member's enrollment history and relevant data elements required for performance measure reporting.

Provider Data

There were no concerns with Amerigroup 360°'s provider data systems or processes. Amerigroup 360°'s credentialing system, Cactus, managed provider enrollment and contracting processes, including



the capture of key provider data elements—i.e., board certification and specialties, demographics, and contract details. Provider information was extracted from Cactus and loaded to Facets through scheduled Extract, Transform, and Load (ETL) processes nightly. The CMO had a systematic process to capture, review, and update provider credentialing and specialty data in both systems. The two systems were linked using Facets' common practitioner identifiers, and used to feed changes to provider data based on individual market requirements. Amerigroup 360° implemented daily, weekly, and monthly edit checks on provider data submitted via claims. Additionally, the CMO's audit team reviewed 25 percent of all completed records for accuracy and completeness each month. Amerigroup 360°'s oversight of its delegates contracted for credentialing and recredentialing activities also met industry standards.

Amerigroup 360° demonstrated the Facets and Cactus provider systems during the virtual audit review and HSAG verified that both systems accurately captured key provider characteristics, including specialty. HSAG found Amerigroup 360° to be compliant with the credentialing and assignment of individual provider specialties in both systems.

Medical Record Review Validation (MRRV)

There were no concerns with Amerigroup 360°'s MRR policies and procedures. Amerigroup 360° had well-established MRR processes and qualified internal staff performing MRR abstraction under experienced supervision. HSAG notified Amerigroup 360° on February 15, 2021, that convenience sample validation was required for the *Developmental Screening in the First Three Months of Life* hybrid measure. All selected records met validation requirements; no issues were identified.

HSAG confirmed that Amerigroup 360° sampled according to CMS Core Set sampling guidelines. Provider chase logic was reviewed and determined to be appropriate for the hybrid measure under review. MRR policies and procedures indicated that clinical quality staff and MRR abstractors underwent annual training and abstractions were regularly overread by experienced nurses.

Similar to past years, the CMO contracted with Ciox and ShareCare to support chase and procurement activities while internal staff abstracted, data entered, and conducted quality assurance oversight during MY 2020. All qualified staff members were trained in the *Developmental Screening in the First Three Months of Life* CMS Core Set specifications and in the use of Inovalon's abstraction tool (i.e., Quality Spectrum Hybrid Reporter [QSHR]) to manage and accurately conduct MRRs. HSAG's clinical team reviewed Inovalon's hybrid tool and participated in a live demonstration of the MRR application to determine compliance with HEDIS audit standards. HSAG approved the tool for use in MY 2020.

Amerigroup 360° completed MRR and submitted final counts on May 6, 2021. Amerigroup 360° passed the final MRRV for the DEV measure; individual results are presented in Table 5.

Performance Measure	Sample Size	Status	Final Results
Developmental Screening in the First Three Years of Life	5	Pass	No critical errors were confirmed.

Table 5—MRRV Results for Amerigroup 360°



Supplemental Data

Supplemental data validation was not under the scope of the PMV audit. However, processes to incorporate vendor data were identified and reported in the Medical Service Data section.

Data Integration

There were no concerns with Amerigroup 360°'s data pre-production, data integration, and reporting processes. Amerigroup 360° described its processes thoroughly and confirmed that there were no significant changes to its systems and protocols since the prior year.

Facets continued to serve as the source of data for measure production and reporting. Amerigroup 360° used a checklist process to validate record counts and load reports were produced to ensure that data were accurately transferred into the corporate HEDIS data warehouse. In case of any issues in the loading process, notifications were sent to the responsible business users for examination. Also, Amerigroup 360° had a robust quality control process in place to track the data load process for all sources. Data were mapped appropriately according to the measure specifications. Amerigroup 360° provided a thorough explanation of the data flow process within its systems.

Amerigroup 360° continued to contract with Inovalon to support the calculation of the non-HEDIS, CMS Core Set measures within the scope of HSAG's audit. Inovalon was responsible for maintaining all aspects of the Quality Spectrum Insight XL (QSI-XL) application. Amerigroup 360° loaded its data and monitored the status via the iPORT platform hosted by Inovalon. In coordination with Amerigroup 360° and Inovalon, HSAG coordinated a virtual review of all source code used to generate the performance measures. HSAG evaluated the code to ensure compliance with the measure specifications required by the State; all source code was approved.

During the virtual audit review, HSAG performed primary source verification (PSV) on the *Screening for Depression and Follow-Up Plan* measure. HSAG reviewed members' source data to confirm the eligibility, provider specialty, and services performed for each selected measure. Additional follow-up was required after the virtual audit review and Amerigroup 360° uploaded additional documentation to support the inclusion of selected PSV cases. All documentation and screenshots demonstrated compliance.

Amerigroup 360° submitted final rates in May which were benchmarked, trended, and reviewed. Follow-up was conducted and questions were successfully resolved. All measure rates were designated reportable.



Performance Measure Specific Findings

Based on all validation activities, HSAG determined validation results for each performance measure rate. HSAG provided an audit result for each performance measure as defined in Table 6.

Reportable (R)	Measure data were compliant with the specifications required by the state.
Do Not Report (DNR)	Measure data were materially biased.

Table 6—Audit Results and Definitions for Performance Measures

According to the CMS protocol, the audit result for each performance measure rate is determined by the magnitude of the errors detected for the audit elements, not by the number of audit elements determined to be noncompliant based on the review findings. Consequently, an error for a single audit element may result in a designation of "DNR" because the impact of the error associated with that element biased the reported performance measure rate by more than 5 percentage points. Conversely, it is also possible that several audit element errors may have little impact on the reported rate, leading to an audit result of "R."

Table 7 displays the key review findings and final audit results for Amerigroup 360° for each performance measure rate. For additional information regarding performance measure rates, see Appendix C of this report.

	Performance Measures	Key Review Findings	Audit Results
1	Developmental Screening in the First Three Years of Life	No concerns.	R
2	Percentage of Eligibles Who Received Dental Services	No concerns.	R
3	Screening for Depression and Follow-Up Plan: Ages 12—17	No concerns.	R
4	Screening for Depression and Follow-Up Plan: Ages 18 and Older	No concerns.	R
5	Use of Multiple Concurrent Antipsychotics in Children and Adolescent	No concerns.	R

Table 7—Key Review Findings and Audit Results for Amerigroup 360°



Appendix A. Data Integration and Control Findings

Documentation Worksheet

CMO Name:	Amerigroup Community Care for Georgia Families 360°				
Virtual Audit Review Date:	March 23–24, 2021				
Reviewer(s):	Thomas D. Miller, MA, CHCA				

Table A-1—Data Integration and Control Findings for Amerigroup 360°

Data Integration and Control Element	Met	Not Met	N/A	Comments				
Accuracy of data transfers to assigned performance measure data repository.								
The CMO accurately and completely processes transfer data from the transaction files (e.g., membership, provider, encounter/claims) into the performance measure data repository used to keep the data until the calculations of the performance measure rates have been completed and validated.				Data used to calculate performance measures were captured and stored in Amerigroup 360°'s core system, Facets. Production data were copied into Amerigroup 360°'s corporate HEDIS database reporting database prior to transferring data to the QSI-XL measure platform.				
Samples of data from the performance measure data repository are complete and accurate.	\square			Compliant; no issues or concerns.				
Accuracy of file consolidations, extracts, and deri	vations.							
The CMO's processes to consolidate diversified files and to extract required information from the performance measure data repository are appropriate.				Compliant; no issues or concerns.				
Actual results of file consolidations or extracts are consistent with those that should have resulted according to documented algorithms or specifications.				Source code was approved; no issues or concerns.				
Procedures for coordinating the activities of multiple subcontractors ensure the accurate, timely, and complete integration of data into the performance measure database.				Compliant; no issues or concerns.				



Data Integration and Control Element	Met	Not Met	N/A	Comments
Computer program reports or documentation reflect vendor coordination activities, and no data necessary for performance measure reporting are lost or inappropriately modified during transfer.				Compliant; no issues or concerns.
If the CMO uses a performance measure data rep programming necessary to calculate and report re				
The performance measure data repository's design, program flow charts, and source codes enable analyses and reports.	\boxtimes			Compliant; no issues or concerns.
Proper linkage mechanisms are employed to join data from all necessary sources (e.g., identifying a member with a given disease/condition).	\boxtimes			Source code was approved; no issues or concerns.
Assurance of effective management of report prod	duction a	nd of the	e report	ing software.
Documentation governing the production process, including CMO production activity logs and the CMO staff review of report runs, is adequate.	\boxtimes			Compliant; no issues or concerns.
Prescribed data cutoff dates are followed.	\boxtimes			Compliant; no issues or concerns.
The CMO retains copies of files or databases used for performance measure reporting in case results need to be reproduced.				Compliant; no issues or concerns.
The reporting software program is properly documented with respect to every aspect of the performance measure data repository, including building, maintaining, managing, testing, and report production.				Compliant; no issues or concerns.
The CMO's processes and documentation comply with the CMO standards associated with reporting program specifications, code review, and testing.				Compliant; no issues or concerns.



Appendix B. Denominator and Numerator Validation Findings

Reviewer Worksheets

CMO Name:	Amerigroup Community Care for Georgia Families 360°				
Virtual Site Visit Date: March 23–24, 2021					
Reviewers:	Thomas D. Miller, MA, CHCA				

Table B-1—Denominator Validation Findings for Amerigroup 360°

Audit Element	Met	Not Met	N/A	Comments
For each of the performance measures, all members of the relevant populations identified in the performance measure specifications are included in the population from which the denominator is produced.				Source code was approved; no issues were identified.
Adequate programming logic or source code exists to appropriately identify all relevant members of the specified denominator population for each of the performance measures.				Source code was approved; no issues were identified.
The CMO correctly calculates member months and member years if applicable to the performance measure.			\boxtimes	Member month calculations were not applicable to the audit scope.
The CMO properly evaluates the completeness and accuracy of any codes used to identify medical events, such as diagnoses, procedures, or prescriptions, and these codes are appropriately identified and applied as specified in each performance measure.				Source code was approved; no issues were identified.
If any time parameters are required by the specifications of the performance measure, they are followed (e.g., cutoff dates for data collection, counting 30 calendar days after discharge from a hospital).				Source code was approved; no issues were identified.
Exclusion criteria included in the performance measure specifications are followed.				Source code was approved; no issues were identified.
Systems or methods used by the CMO to estimate populations when they cannot be accurately or completely counted (e.g., newborns) are valid.	\square			Source code was approved; no issues were identified.



Audit Element	Met	Not Met	N/A	Comments
The CMO uses the appropriate data, including linked data from separate data sets, to identify the entire at-risk population.	\boxtimes			Source code was approved; no issues were identified.
Qualifying medical events (such as diagnoses, procedures, prescriptions, etc.) are properly identified and confirmed for inclusion in terms of time and services.				Source code was approved; no issues were identified.
The CMO avoids or eliminates all double-counted members or numerator events.				Source code was approved; no issues were identified.
Any nonstandard codes used in determining the numerator are mapped to a standard coding scheme in a manner that is consistent, complete, and reproducible, as evidenced by a review of the programming logic or a demonstration of the program.				Source code was approved; no issues were identified.
If any time parameters are required by the specifications of the performance measure, they are followed (i.e., the measured event occurred during the time period specified or defined in the performance measure).				Source code was approved; no issues were identified.

Table B-2—Numerator Validation Findings for Amerigroup 360°



Appendix C. Performance Measure Rate Submission File

Appendix C contains Amerigroup 360°'s final audited performance measure rate submission file.

Amerigroup Community Care Performance Measure Data Submission for State Fiscal Year (SFY) 2021 Reporting/Measurement Period: Calendar Year 2020						
Georgia Families 360° (GF 360°) Population						
Date Submitted: (Please enter the date each time a new version is submitted)	06.01.2021					
CMO Name:	Amerigroup Community Care—GF 360°					
Contact Name and Title:	Heather Taylor, Clinical Quality Program Admin					
Contact Phone Number:	470-707-3985					
Contact Email Address:	heather.taylor@amerigroup.com					
Comments:	APM measure should be titled APC					

	Audit Review Table—To Be Completed by Auditor							
	Performance Measure	Acronym	Audit Designation	Comments				
1	Developmental Screening in the First Three Years of Life	DEV		6/11/21 - All follow-up questions address; no concerns. Data collection, integration, and reporting processes are sufficient to produce valid results.				
2	Percentage of Eligibles Who Received Preventive Dental Services	PDENT		6/11/21 - All follow-up questions address; no concerns. Data collection, integration, and reporting processes are sufficient to produce valid results.				
3	Screening for Depression and Follow-Up Plan	CDF		6/11/21 - All follow-up questions address; no concerns. Data collection, integration, and reporting processes are sufficient to produce valid results.				
4	Use of Multiple Concurrent Antipsychotics in Children and Adolescents	APC		6/11/21 - All follow-up questions address; no concerns. Data collection, integration, and reporting processes are sufficient to produce valid results.				

Developmental Screening in the First Three Years of Life (DEV) <i>for</i> GF 360° Population							
Data Element	General Measure Data	Age 1	Age 2	Age 3	Total		
Measurement Year	2020						
Data Collection Methodology:	Hybrid						
Eligible Population		481	781	854	2116		
Number of Numerator Events by Administrative Data in Eligible Population (Before Exclusions)		293	396	513	1202		
Current Year's Administrative Rate (Before Exclusions)		60.91%	50.70%	60.07%	56.81%		
Minimum Required Sample Size (MRSS) Per Age Band					0		
Oversampling Rate					0.00		
Number of Oversample Records		0	0	0	0		
Number of Numerator Events by Administrative Data in MRSS					0		
Administrative Rate on MRSS		#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!		
Denominator		137	137	137	411		
Numerator Events by Administrative Data		92	92	93	277		
Numerator Events by Medical Records		8	16	14	38		
Reported Rate		72.99%	78.83%	78.10%	76.64%		

Percentage of Eligibles Who Received Preventive Dental Services (PDENT) <i>for</i> GF 360° Population					
Data Element	General Measure Data				
Measurement Year	2020				
Data Collection Methodology (Administrative)	А				
Eligible Population	28,130				
Number of Exclusions	0				
Denominator	28,130				
Numerator Events by Administrative Data	16,470				
Reported Rate	58.55%				

Screening for Depression and Follow-Up Plan (CDF) <i>for</i> GF 360° Population							
Data Element	General Measure Data	12–17 Years	18–64 Years	65+ Years			
Measurement Year	2020						
Data Collection Methodology (Administrative)	А						
Eligible Population		9,204	2,548	0			
Number of Exclusions		1,728	465	0			
Number of Exceptions		8	5	0			
Denominator		7,468	2,078	0			
Number of Members With a Positive Screen for Depression During an Outpatient Visit Using a Standardized Tool With a Follow-Up Plan Documented		20	9	0			
Number of Members With a Negative Screen for Depression During an Outpatient Visit Using a Standardized Tool		248	54	0			
Reported Rate		3.59%	3.03%	#DIV/0!			

Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APM) for GF 360° Population						
Data Element General Measure Data General Measure Data Ages 1-5 Ages 6-11 Ages 12-17						
Measurement Year	2020					
Data Collection Methodology (Administrative)	А					
Eligible Population		23	512	982	1,517	
Numerator		0	7	37	44	
Reported Rate		0.00%	1.37%	3.77%	2.90%	



Appendix D. HEDIS Interactive Data Submission System Data

Appendix D contains Amerigroup 360°'s reported IDSS data from its NCQA HEDIS Compliance Audit.

Number: None) Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - BMI percentile (Total)		86.13%	R	Reported	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Nutrition (Total)		83.7%	R	Reported	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity (Total)		81.02%	R	Reported	
Childhood Immunization Status (CIS)					
Childhood Immunization Status - DTaP		89.78%	R	Reported	
Childhood Immunization Status - IPV		97.57%	R	Reported	
Childhood Immunization Status - MMR		98.05%	R	Reported	
Childhood Immunization Status - HiB		94.89%	R	Reported	
Childhood Immunization Status - Hepatitis B		96.84%	R	Reported	
Childhood Immunization Status - VZV		97.57%	R	Reported	
Childhood Immunization Status - Pneumococcal Conjugate		88.56%	R	Reported	
Childhood Immunization Status - Hepatitis A		97.57%	R	Reported	
Childhood Immunization Status - Rotavirus		70.8%	R	Reported	
Childhood Immunization Status - Influenza		53.04%	R	Reported	
Childhood Immunization Status - Combo 2		88.81%	R	Reported	
Childhood Immunization Status - Combo 3		85.16%	R	Reported	
Childhood Immunization Status - Combo 4		85.16%	R	Reported	
Childhood Immunization Status - Combo 5		67.88%	R	Reported	
Childhood Immunization Status - Combo 6		47.93%	R	Reported	
Childhood Immunization Status - Combo 7		67.88%	R	Reported	
Childhood Immunization Status - Combo 8		47.93%	R	Reported	
Childhood Immunization Status - Combo 9		39.66%	R	Reported	
Childhood Immunization Status - Combo 10		39.66%	R	Reported	
Immunizations for Adolescents (IMA)					
Immunizations for Adolescents - Meningococcal		87.1%	R	Reported	

Audit Review Table

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Spec Area: Georgia, Spec Proj: GA 360, Contract Number: None)

Audit Designation

R

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock Measure/Data Element Benefit Offered Rate Immunizations for Adolescents - Tdap 86.37% Immunizations for Adolescents - HPV 42.09% Immunizations for Adolescents - Combination 1 85.4% Immunizations for Adolescents - Combination 2 41.12% Lead Screening in Children (LSC) Description of Children Description of Children

Immunizations for Adolescents - HPV		42.09%	R	Reported
Immunizations for Adolescents - Combination 1		85.4%	R	Reported
Immunizations for Adolescents - Combination 2		41.12%	R	Reported
Lead Screening in Children (LSC)				
Lead Screening in Children		86.62%	R	Reported
Breast Cancer Screening (BCS)				
Breast Cancer Screening			NA	Small Denominator
Cervical Cancer Screening (CCS)				
Cervical Cancer Screening		75%	R	Reported
Chlamydia Screening in Women (CHL)				
Chlamydia Screening in Women (16-20)		66%	R	Reported
Chlamydia Screening in Women (21-24)		63.27%	R	Reported
Chlamydia Screening in Women (Total)		65.63%	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y			
Appropriate Testing for Pharyngitis (3-17)		83.77%	R	Reported
Appropriate Testing for Pharyngitis (18-64)		71.71%	R	Reported
Appropriate Testing for Pharyngitis (65+)			NA	Small Denominator
Appropriate Testing for Pharyngitis (Total)		83.04%	R	Reported
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)				
Use of Spirometry Testing in the Assessment and Diagnosis of COPD			NA	Small Denominator
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y			
Pharmacotherapy Management of COPD Exacerbation - Systemic Corticosteroid			NA	Small Denominator
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator			NA	Small Denominator
Asthma Medication Ratio (AMR)	Y			
Asthma Medication Ratio (5-11)		91.53%	R	Reported
Asthma Medication Ratio (12-18)		78.54%	R	Reported
Asthma Medication Ratio (19-50)		50%	NA	Small Denominator

Comment

Reported

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Asthma Medication Ratio (51-64)			NA	Small Denominator	
Asthma Medication Ratio (Total)		82.49%	R	Reported	
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		50%	R	Reported	
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (M 21-75)			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (M 21-75)			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (F 40-75)			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (F 40-75)			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease - Received Statin Therapy (Total)			NA	Small Denominator	
Statin Therapy for Patients With Cardiovascular Disease - Statin Adherence 80% (Total)			NA	Small Denominator	
Cardiac Rehabilitation (CRE)					
Cardiac Rehabilitation - Initiation (18-64)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement1 (18-64)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement2 (18-64)			NA	Small Denominator	
Cardiac Rehabilitation - Achievement (18-64)			NA	Small Denominator	
Cardiac Rehabilitation - Initiation (65+)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement1 (65+)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement2 (65+)			NA	Small Denominator	
Cardiac Rehabilitation - Achievement (65+)			NA	Small Denominator	
Cardiac Rehabilitation - Initiation (Total)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement1 (Total)			NA	Small Denominator	
Cardiac Rehabilitation - Engagement2 (Total)			NA	Small Denominator	
Cardiac Rehabilitation - Achievement (Total)			NA	Small Denominator	

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Comprehensive Diabetes Care (CDC)					
Comprehensive Diabetes Care - HbA1c Testing		82.67%	R	Reported	
Comprehensive Diabetes Care - Poor HbA1c Control		60%	R	Reported	
Comprehensive Diabetes Care - HbA1c Control (<8%)		30.67%	R	Reported	
Comprehensive Diabetes Care - Eye Exams		30.67%	R	Reported	
Comprehensive Diabetes Care - Blood Pressure Control (<140/90)		76%	R	Reported	
Kidney Health Evaluation for Patients With Diabetes (KED)					
Kidney Health Evaluation for Patients With Diabetes (18-64)		15.79%	R	Reported	
Kidney Health Evaluation for Patients With Diabetes (65-74)			NA	Small Denominator	
Kidney Health Evaluation for Patients With Diabetes (75-85)			NA	Small Denominator	
Kidney Health Evaluation for Patients With Diabetes (Total)		15.79%	R	Reported	
Statin Therapy for Patients With Diabetes (SPD)	Y				
Statin Therapy for Patients With Diabetes - Received Statin Therapy			NA	Small Denominator	
Statin Therapy for Patients With Diabetes - Statin Adherence 80%			NA	Small Denominator	
Antidepressant Medication Management (AMM)	Y				
Antidepressant Medication Management - Effective Acute Phase Treatment		46.56%	R	Reported	
Antidepressant Medication Management - Effective Continuation Phase Treatment		25.19%	R	Reported	
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase		55.51%	R	Reported	
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase		67.47%	R	Reported	
Follow-up After Hospitalization for Mental Illness (FUH)	Y				
Follow-Up After Hospitalization For Mental Illness - 30 days (6-17)		79.74%	R	Reported	
Follow-Up After Hospitalization For Mental Illness - 7 days (6-17)		57.81%	R	Reported	
Follow-Up After Hospitalization For Mental Illness - 30 days (18-64)		50%	R	Reported	

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Follow-Up After Hospitalization For Mental Illness - 7 days (18-64)		35.45%	R	Reported	
Follow-Up After Hospitalization For Mental Illness - 30 days (65+)			NA	Small Denominator	
Follow-Up After Hospitalization For Mental Illness - 7 days (65+)			NA	Small Denominator	
Follow-Up After Hospitalization For Mental Illness - 30 days (Total)		74.69%	R	Reported	
Follow-Up After Hospitalization For Mental Illness - 7 days (Total)		54.01%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (6-17)		81.34%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (6-17)		61.19%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (18-64)		48.57%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (18-64)		32.38%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (65+)			NA	Small Denominator	
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (65+)			NA	Small Denominator	
Follow-Up After Emergency Department Visit for Mental Illness - 30 days (Total)		72.12%	R	Reported	
Follow-Up After Emergency Department Visit for Mental Illness - 7 days (Total)		53.08%	R	Reported	
Follow-Up After High-Intensity Care for Substance Use Disorder FUI)	Y				
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (13-17)		0%	NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (13-17)		0%	NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (18-64)		12.5%	NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (18-64)		0%	NA	Small Denominator	

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (65+)			NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (65+)			NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)		11.11%	NA	Small Denominator	
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)		0%	NA	Small Denominator	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)	Y				
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (13-17)		8.7%	NA	Small Denominator	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (13-17)		8.7%	NA	Small Denominator	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (18+)		10.81%	R	Reported	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (18+)		8.11%	R	Reported	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 30 days (Total)		10%	R	Reported	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence - 7 days (Total)		8.33%	R	Reported	
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
Pharmacotherapy for Opioid Use Disorder (16-64)		0%	NA	Small Denominator	
Pharmacotherapy for Opioid Use Disorder (65+)			NA	Small Denominator	
Pharmacotherapy for Opioid Use Disorder (Total)		0%	NA	Small Denominator	
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Med (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		77.65%	R	Reported	
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia		44.44%	NA	Small Denominator	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia			NA	Small Denominator	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		58.73%	R	Reported	
Netabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	Y				
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (1-11)		42.36%	R	Reported	
- Metabolic Monitoring for Children and Adolescents on Antipsychotics Cholesterol Testing (1-11)		32.32%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (1-11)		27.39%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose Testing (12-17)		65.8%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (12-17)		56.38%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (12-17)		53.46%	R	Reported	
- Metabolic Monitoring for Children and Adolescents on Antipsychotics Blood Glucose Testing (Total)		57.74%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Cholesterol Testing (Total)		48.11%	R	Reported	
Metabolic Monitoring for Children and Adolescents on Antipsychotics - Blood Glucose and Cholesterol Testing (Total)		44.5%	R	Reported	
Ion-Recommended Cervical Cancer Screening in Adolescent Females (NCS)					
Non-Recommended Cervical Cancer Screening in Adolescent Females		0.74%	R	Reported	
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
Appropriate Treatment for Upper Respiratory Infection (3 Months-17 Years)		87.92%	R	Reported	
Appropriate Treatment for Upper Respiratory Infection (18-64)		82.95%	R	Reported	
Appropriate Treatment for Upper Respiratory Infection (65+)			NA	Small Denominator	
Appropriate Treatment for Upper Respiratory Infection (Total)		87.74%	R	Reported	

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM This submission is on the stage: PlanLock					
Avoidance of Antibiotic Treatment for Acute	Y				
Bronchitis/Bronchiolitis (AAB)	·				
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (3 Months-17 Years)		56.54%	R	Reported	
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (18-64)		42.11%	R	Reported	
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (65+)			NA	Small Denominator	
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (Total)		55.87%	R	Reported	
Use of Imaging Studies for Low Back Pain (LBP)					
Use of Imaging Studies for Low Back Pain		84.44%	R	Reported	
Use of Opioids at High Dosage (HDO)	Y				
Use of Opioids at High Dosage		0%	NA	Small Denominator	
Use of Opioids From Multiple Providers (UOP)	Y				
Use of Opioids From Multiple Providers - Multiple Prescribers		37.5%	NA	Small Denominator	
Use of Opioids From Multiple Providers - Multiple Pharmacies		12.5%	NA	Small Denominator	
Use of Opioids From Multiple Providers - Multiple Prescribers and Multiple Pharmacies		12.5%	NA	Small Denominator	
Risk of Continued Opioid Use (COU)	Y				
Risk of Continued Opioid Use - >=15 Days (18-64)		0.48%	R	Reported	
Risk of Continued Opioid Use - >=31 Days (18-64)		0%	R	Reported	
Risk of Continued Opioid Use - >=15 Days (65+)			NA	Small Denominator	
Risk of Continued Opioid Use - >=31 Days (65+)			NA	Small Denominator	
Risk of Continued Opioid Use - >=15 Days (Total)		0.48%	R	Reported	
Risk of Continued Opioid Use - >=31 Days (Total)		0%	R	Reported	
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
Adults' Access to Preventive/Ambulatory Health Services (20-44)		63.05%	R	Reported	
Adults' Access to Preventive/Ambulatory Health Services (45-64)			NA	Small Denominator	
Adults' Access to Preventive/Ambulatory Health Services (65+)			NA	Small Denominator	
Adults' Access to Preventive/Ambulatory Health Services (Total)		63.05%	R	Reported	

Audit Review Table

Number: None)				
Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM				
	This submission is on the	e stage: PlanLock		
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Annual Dental Visit (ADV)	Y			
Annual Dental Visit (2-3)		65.42%	R	Reported
Annual Dental Visit (4-6)		73.36%	R	Reported
Annual Dental Visit (7-10)		71.35%	R	Reported
Annual Dental Visit (11-14)		66.73%	R	Reported
Annual Dental Visit (15-18)		57.95%	R	Reported
Annual Dental Visit (19-20)		29.74%	R	Reported
Annual Dental Visit (Total)		63.64%	R	Reported
nitiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Y			
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (13-17)		54.55%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (13-17)		3.03%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (13-17)		66.67%	NA	Small Denominator
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (13-17)		11.11%	NA	Small Denominator
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (13-17)		60.37%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (13-17)		20.28%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (13-17)		59.75%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (13-17)		19.07%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or		50%	R	Reported

Dependence (18+)

leasurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM									
This submission is on the stage: PlanLock									
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (18+)		7.89%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (18+)		83.33%	NA	Small Denominator					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (18+)		16.67%	NA	Small Denominator					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (18+)		51.7%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (18+)		10.88%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (18+)		49.41%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (18+)		10%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or Dependence (Total)		52.11%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (Total)		5.63%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (Total)		73.33%	NA	Small Denominator					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Opioid Abuse or Dependence (Total)		13.33%	NA	Small Denominator					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or Dependence (Total)		56.87%	R	Reported					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (Total)		16.48%	R	Reported					

Number: None)				
Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM				
7	This submission is on the	stage: PlanLock		
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Total (Total)		55.42%	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (Total)		15.27%	R	Reported
Prenatal and Postpartum Care (PPC)				
Prenatal and Postpartum Care - Timeliness of Prenatal Care		80.25%	R	Reported
Prenatal and Postpartum Care - Postpartum Care		67.9%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y			
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (1-11)		81.42%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (12-17)		82.52%	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (Total)		82.03%	R	Reported
Utilization				
Well-Child Visits in the First 30 Months of Life (W30)				
Well-Child Visits in the First 30 Months of Life (First 15 Months)		56.23%	R	Reported
Well-Child Visits in the First 30 Months of Life (15 Months-30 Months)		90.97%	R	Reported
Child and Adolescent Well-Care Visits (WCV)				
Child and Adolescent Well-Care Visits (3-11)		70.39%	R	Reported
Child and Adolescent Well-Care Visits (12-17)		60.84%	R	Reported
Child and Adolescent Well-Care Visits (18-21)		32.5%	R	Reported
Child and Adolescent Well-Care Visits (Total)		60.99%	R	Reported
Frequency of Selected Procedures (FSP)			R	Reported
Ambulatory Care (AMBa)			R	Reported
Ambulatory Care (AMBb)			NR	Not Reported
Ambulatory Care (AMBc)			NR	Not Reported
Ambulatory Care (AMBd)			NR	Not Reported
Inpatient Utilization - General Hospital/Acute Care (IPUa)			R	Reported
Inpatient Utilization - General Hospital/Acute Care (IPUb)			NR	Not Reported
Inpatient Utilization - General Hospital/Acute Care (IPUc)			NR	Not Reported

Number: None)	-			
Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM				
	This submission is on the	-		
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Inpatient Utilization - General Hospital/Acute Care (IPUd)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADa)	Y		R	Reported
Identification of Alcohol and other Drug Services (IADb)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADc)			NR	Not Reported
Identification of Alcohol and other Drug Services (IADd)			NR	Not Reported
Mental Health Utilization (MPTa)	Y		R	Reported
Mental Health Utilization (MPTb)			NR	Not Reported
Mental Health Utilization (MPTc)			NR	Not Reported
Mental Health Utilization (MPTd)			NR	Not Reported
Antibiotic Utilization (ABXa)	Y		R	Reported
Antibiotic Utilization (ABXb)			NR	Not Reported
Antibiotic Utilization (ABXc)			NR	Not Reported
Antibiotic Utilization (ABXd)			NR	Not Reported
Risk Adjusted Utilization				
Plan All-Cause Readmissions (PCR)			R	Reported
Health Plan Descriptive Information				
Enrollment by Product Line (ENPa)			R	Reported
Enrollment by Product Line (ENPb)			NR	Not Reported
Enrollment by Product Line (ENPc)			NR	Not Reported
Enrollment by Product Line (ENPd)			NR	Not Reported
Enrollment by State (EBS)			R	Reported
Language Diversity of Membership (LDM)			R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	Reported
Total Membership (TLM)			R	Reported
Electronic Clinical Data Systems				
Breast Cancer Screening (BCS-E)				
Breast Cancer Screening	y		NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD- E)				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase			NR	Not Reported

leasurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM					
	This submission is on the	stage: PlanLock			
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment	
Follow-Up Care for Children Prescribed ADHD Medication -			NR	Not Reported	
Continuation and Maintenance Phase				Not Reported	
Depression Screening and Follow-Up for Adolescents and Adults DSF-E)					
Depression Screening and Follow-Up for Adolescents and Adults -			NR	Not Donortod	
Depression Screening (Total)			NR	Not Reported	
Depression Screening and Follow-Up for Adolescents and Adults -			NR	Not Reported	
Follow-up on Positive Screen (Total)			NIX	Not Reported	
Itilization of the PHQ-9 to Monitor Depression Symptoms for					
dolescents and Adults (DMS-E)					
Utilization of the PHQ-9 to Monitor Depression Symptoms for			NR	Not Reported	
Adolescents and Adults - Utilization of PHQ-9-Period1 (Total)					
Utilization of the PHQ-9 to Monitor Depression Symptoms for			NR	Not Reported	
Adolescents and Adults - Utilization of PHQ-9-Period2 (Total)				Heritopolioa	
Utilization of the PHQ-9 to Monitor Depression Symptoms for			NR	Not Reported	
Adolescents and Adults - Utilization of PHQ-9-Period3 (Total)					
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)			NR	Not Reported	
Depression Remission or Response for Adolescents and Adults					
DRR-E)					
Depression Remission or Response for Adolescents and Adults -			NR	Not Reported	
Follow-up PHQ-9 (Total)			INK	Not Reported	
Depression Remission or Response for Adolescents and Adults -			NR	Not Reported	
Depression Remission (Total)			NIX	Not Reported	
Depression Remission or Response for Adolescents and Adults -			NR	Not Reported	
Depression Response (Total)			NIX	Not Reported	
Inhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol			ND	Not Deported	
Use Screening (Total)			NR	Not Reported	
Unhealthy Alcohol Use Screening and Follow-Up - Alcohol			NR	Not Departed	
Counseling or Other Follow-Up Care (Total)				Not Reported	
Adult Immunization Status (AIS-E)					
Adult Immunization Status - Influenza			NR	Not Reported	
Adult Immunization Status - Td/Tdap			NR	Not Reported	
Adult Immunization Status - Zoster			NR	Not Reported	

Audit Review Table

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Spec Area: Georgia, Spec Proj: GA 360, Contract Number: None)

Measurement Year - 2020; Date & Timestamp - 05/11/2021 2:01 PM

	This submission is on the	e stage: PlanLock		
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Prenatal Immunization Status - Influenza			NR	Not Reported
Prenatal Immunization Status - Tdap			NR	Not Reported
Prenatal Immunization Status - Combination			NR	Not Reported
Prenatal Depression Screening and Follow-Up (PND-E)				
Prenatal Depression Screening and Follow-Up - Depression Screening			NR	Not Reported
Prenatal Depression Screening and Follow-Up - Follow-Up on Positive Screen			NR	Not Reported
Postpartum Depression Screening and Follow-Up (PDS-E)				
Postpartum Depression Screening and Follow-Up - Depression Screening			NR	Not Reported
Postpartum Depression Screening and Follow-Up - Follow-Up on Positive Screen			NR	Not Reported

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	CollectionMethod	EligiblePopulation	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate
202501_20	BMI percentile (3-11)	3-11	Н	8571	6295	73.45	411	0.05
202500_20	BMI percentile (12-17)	12-17	Н	6696	4559	68.09	411	0.05
202502_20	BMI percentile (Total)	Total	Н	15267	10854	71.09	411	0.05
202504_20	Counseling for Nutrition (3-11)	3-11	Н	8571	5909	68.94	411	0.05
202503_20	Counseling for Nutrition (12-17)	12-17	Н	6696	4202	62.75	411	0.05
202505_20	Counseling for Nutrition (Total)	Total	Н	15267	10111	66.23	411	0.05
202507_20	Counseling for Physical Activity (3-11)	3-11	Н	8571	5214	60.83	411	0.05
202506_20	Counseling for Physical Activity (12-17)	12-17	Н	6696	3807	56.85	411	0.05
202508_20	Counseling for Physical Activity (Total)	Total	Н	15267	9021	59.09	411	0.05

OversampleRecordsNumber	ExclusionValidDataErrors	ExclusionAdminOptional	ExclusionMedRecsOptional	ExclusionEmployeeOrDep
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0
21	0	0	0	0

OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	244	178	35	0	87.30	R	R
0	167	109	30	2	84.43	R	R
0	411	287	65	2	86.13	R	R
0	244	170	39	1	86.07	R	R
0	167	101	32	1	80.24	R	R
0	411	271	71	2	83.70	R	R
0	244	145	57	0	82.79	R	R
0	167	99	32	0	78.44	R	R
0	411	244	89	0	81.02	R	R

MeasurementYear:	2020									
IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate	OversampleRecordsNumber	ExclusionValidDataErrors	ExclusionAdminOptional
200725_20	DTaP	н	781	629	80.54	411	0.05	21	0	0
200729_20	IPV	н	781	691	88.48	411	0.05	21	0	0
200731_20	MMR	н	781	750	96.03	411	0.05	21	0	0
200726_20	HiB	н	781	675	86.43	411	0.05	21	0	0
200728_20	Hepatitis B	н	781	669	85.66	411	0.05	21	0	0
200733_20	VZV	н	781	750	96.03	411	0.05	21	0	0
200715_20	Pneumococcal Conjugate	н	781	621	79.51	411	0.05	21	0	0
200727_20	Hepatitis A	н	781	760	97.31	411	0.05	21	0	0
200732_20	Rotavirus	н	781	497	63.64	411	0.05	21	0	0
200730_20	Influenza	н	781	393	50.32	411	0.05	21	0	0
200717_20	Combo 2	н	781	589	75.42	411	0.05	21	0	0
200718_20	Combo 3	н	781	562	71.96	411	0.05	21	0	0
200719_20	Combo 4	н	781	560	71.70	411	0.05	21	0	0
200720_20	Combo 5	н	781	443	56.72	411	0.05	21	0	0
200721_20	Combo 6	н	781	308	39.44	411	0.05	21	0	0
200722_20	Combo 7	н	781	443	56.72	411	0.05	21	0	0
200723_20	Combo 8	н	781	307	39.31	411	0.05	21	0	0
200724_20	Combo 9	н	781	258	33.03	411	0.05	21	0	0
200716_20	Combo 10	н	781	258	33.03	411	0.05	21	0	0

ExclusionMedRecsOptional	ExclusionEmployeeOrDep	OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	0	0	411	184	31	154	89.78	R	R
0	0	0	411	207	33	161	97.57	R	R
0	0	0	411	378	8	17	98.05	R	R
0	0	0	411	237	50	103	94.89	R	R
0	0	0	411	121	39	238	96.84	R	R
0	0	0	411	377	6	18	97.57	R	R
0	0	0	411	179	31	154	88.56	R	R
0	0	0	411	391	1	9	97.57	R	R
0	0	0	411	147	23	121	70.80	R	R
0	0	0	411	185	11	22	53.04	R	R
0	0	0	411	105	35	225	88.81	R	R
0	0	0	411	100	34	216	85.16	R	R
0	0	0	411	100	34	216	85.16	R	R
0	0	0	411	74	27	178	67.88	R	R
0	0	0	411	53	23	121	47.93	R	R
0	0	0	411	74	27	178	67.88	R	R
0	0	0	411	53	23	121	47.93	R	R
0	0	0	411	42	17	104	39.66	R	R
0	0	0	411	42	17	104	39.66	R	R

MeasurementYear:	AeasurementYear: 2020											
IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate	OversampleRecordsNumber	ExclusionValidDataErrors	ExclusionAdminOptional		
201710_20	Meningococcal	н	1310	1121	85.57	411	0.05	21	0	0		
201711_20	Tdap	н	1310	1112	84.89	411	0.05	21	0	0		
201709_20	HPV	н	1310	506	38.63	411	0.05	21	0	0		
	Combination 1	н	1310	1095	83.59	411	0.05	21	0	0		
201708_20	Combination 2	н	1310	493	37.63	411	0.05	21	0	0		

ExclusionMedRecsOptional	ExclusionEmployeeOrDep	OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	0	0	411	289	9	60	87.10	R	R
0	0	0	411	287	10	58	86.37	R	R
0	0	0	411	124	7	42	42.09	R	R
0	0	0	411	280	9	62	85.40	R	R
0	0	0	411	119	7	43	41.12	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate
201858_20	Lead Screening in Children	н	781	640	81.95	411	0.05

OversampleRecordsNumber	ExclusionValidDataErrors	ExclusionAdminOptional	ExclusionMedRecsOptional	ExclusionEmployeeOrDep
21	0	0	0	0

OversampleRecsAdde	d Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	411	339	11	6	86.62	R	R

MeasurementYear:	2020

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	ExclusionAdminOptional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
200694_20	Breast Cancer Screening	0	0	0	0	0		NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
200701_20	Cervical Cancer Screening	A	72	0	51	3	75.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminOptional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
200712_20	(16-20)	16-20	1753	60	1112	45	66.00	R	R
200713_20	(21-24)	21-24	275	21	169	5	63.27	R	R
200714_20	(Total)	Total	2028	81	1281	50	65.63	R	R

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210013_10	(3-17)	3-17	2348	1966	1	83.77	R	R
210012_10	(18-64)	18-64	152	109	0	71.71	R	R
210014_10	(65+)	65+	0	0	0		NA	NA
210015_10	(Total)	Total	2500	2075	1	83.04	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202457_20	Use of Spirometry Testing in the Assessment and Diagnosis of COPD	0	0	0		NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
201964_20	Systemic Corticosteroid	0	0	0		NA	NA
201963_20	Bronchodilator	0	0	0		NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2	MeasurementYear: 2020											
IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status			
200663_20	(5-11)	5-11	189	14	173	0	91.53	R	R			
200661_20	(12-18)	12-18	219	22	172	0	78.54	R	R			
200662_20	(19-50)	19-50	26	5	13	0	50.00	NA	NA			
200664_20	(51-64)	51-64	0	0	0	0		NA	NA			
200667_20	(Total)	Total	434	41	358	0	82.49	R	R			

MY 2020 Validation of Performance Measures

MeasurementYear:	2020									
IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate	OversampleRecordsNumber	ExclusionValidDataErrors
200700_20	Controlling High Blood Pressure	н	39	0	8	20.51	36	0	0	0

ExclusionAdminOption	ExclusionMedRecsOptional	ExclusionEmployeeOrDep	OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	0	0	0	36	2	15	1	50.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminOptional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
201962_20	Persistence of Beta-Blocker Treatment After a Heart Attack	0	0	0	0		NA	NA

Measurement Year: 2020												
IndicatorKey	IndicatorName	Gender	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status			
202449_20	Received Statin Therapy (M 21-75)	м	0	0	0	0		NA	NA			
202452_20	Statin Adherence 80% (M 21-75)	м	0		0	0		NA	NA			
202450_20	Received Statin Therapy (F 40-75)	F	0	0	0	0		NA	NA			
202453_20	Statin Adherence 80% (F 40-75)	F	0		0	0		NA	NA			
202451_20	Received Statin Therapy (Total)	F,M	0	0	0	0		NA	NA			
202454_20	Statin Adherence 80% (Total)	F,M	0		0	0		NA	NA			

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210081_10	Initiation (18-64)	18-64	0	0	0	0		NA	NA
210075_10	Engagement1 (18-64)	18-64	0	0	0	0		NA	NA
210078_10	Engagement2 (18-64)	18-64	0	0	0	0		NA	NA
210072_10	Achievement (18-64)	18-64	0	0	0	0		NA	NA
210082_10	Initiation (65+)	65+	0	0	0	0		NA	NA
210076_10	Engagement1 (65+)	65+	0	0	0	0		NA	NA
210079_10	Engagement2 (65+)	65+	0	0	0	0		NA	NA
210073_10	Achievement (65+)	65+	0	0	0	0		NA	NA
210083_10	Initiation (Total)	Total	0	0	0	0		NA	NA
210077_10	Engagement1 (Total)	Total	0	0	0	0		NA	NA
210080_10	Engagement2 (Total)	Total	0	0	0	0		NA	NA
210074_10	Achievement (Total)	Total	0	0	0	0		NA	NA

MeasurementYear: 2020												
IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate	OversampleRecordsNumber	ExclusionValidDataErrors		
200708_20	HbA1c Testing	н	78	0	61	78.21	75	0	0	1		
200711_20	Poor HbA1c Control	н	78	0	59	75.64	75	0	0	1		
200707_20	HbA1c Control (<8%)	н	78	0	16	20.51	75	0	0	1		
200705_20	Eye Exams	н	78	0	18	23.08	75	0	0	1		
200704_20	Blood Pressure Control (<140/90)	н	78	0	8	10.26	75	0	0	1		

ExclusionAdminOptional	ExclusionMedRecsOptional	ExclusionEmployeeOrDep	OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	NumeratorBySupplemental	Rate	AuditDesignation	Status
0	0	0	0	75	57	2	3	82.67	R	R
0	0	0	0	75	30	12	3	60.00	R	R
0	0	0	0	75	0	9	14	30.67	R	R
0	0	0	0	75	18	5	0	30.67	R	R
0	0	0	0	75	1	53	3	76.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminRequired	ExclusionAdminOptional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210084_10	(18-64)	18-64	76	1	1	3	9	15.79	R	R
210085_10	(65-74)	65-74	0	0	0	0	0		NA	NA
210086_10	(75-85)	75-85	0	0	0	0	0		NA	NA
210087_10	(Total)	Total	76	1	1	3	9	15.79	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202455_20	Received Statin Therapy	0	0	0	0		NA	NA
202456_20	Statin Adherence 80%	0		0	0		NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
200659_20	Effective Acute Phase Treatment	131	150	61	0	46.56	R	R
200660_20	Effective Continuation Phase Treatment	131	150	33	0	25.19	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	Exclusion Admin Optional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
200631_20	Initiation Phase	980	0	544	0	55.51	R	R
200630_20	Continuation and Maintenance Phase	332	0	224	0	67.47	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
203481_10	30 days (6-17)	6-17	1076	858	0	79.74	R	R
203484_10	7 days (6-17)	6-17	1076	622	0	57.81	R	R
203479_10	30 days (18-64)	18-64	220	110	0	50.00	R	R
203482_10	7 days (18-64)	18-64	220	78	0	35.45	R	R
203480_10	30 days (65+)	65+	0	0	0		NA	NA
203483_10	7 days (65+)	65+	0	0	0		NA	NA
201179_20	30 days (Total)	Total	1296	968	0	74.69	R	R
201180_20	7 days (Total)	Total	1296	700	0	54.01	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
203487_10	30 days (6-17)	6-17	268	217	1	81.34	R	R
203490_10	7 days (6-17)	6-17	268	164	0	61.19	R	R
203485_10	30 days (18-64)	18-64	105	50	1	48.57	R	R
203488_10	7 days (18-64)	18-64	105	34	0	32.38	R	R
203486_10	30 days (65+)	65+	0	0	0		NA	NA
203489_10	7 days (65+)	65+	0	0	0		NA	NA
201181_20	30 days (Total)	Total	373	267	2	72.12	R	R
201182_20	7 days (Total)	Total	373	198	0	53.08	R	R

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210017_10	30 days (13-17)	13-17	1	0	0	0.00	NA	NA
210021_10	7 Days (13-17)	13-17	1	0	0	0.00	NA	NA
210018_10	30 days (18-64)	18-64	8	1	0	12.50	NA	NA
210022_10	7 Days (18-64)	18-64	8	0	0	0.00	NA	NA
210019_10	30 days (65+)	65+	0	0	0		NA	NA
210023_10	7 Days (65+)	65+	0	0	0		NA	NA
210016_10	30 days (Total)	Total	9	1	0	11.11	NA	NA
210020_10	7 Days (Total)	Total	9	0	0	0.00	NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
201173_20	30 days (13-17)	13-17	23	2	0	8.70	NA	NA
201178_20	7 days (13-17)	13-17	23	2	0	8.70	NA	NA
201174_20	30 days (18+)	18+	37	4	0	10.81	R	R
201176_20	7 days (18+)	18+	37	3	0	8.11	R	R
201175_20	30 days (Total)	Total	60	6	0	10.00	R	R
201177_20	7 days (Total)	Total	60	5	0	8.33	R	R

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210065_10	(16-64)	16-64	1	0	0	0.00	NA	NA
210066_10	(65+)	65+	0	0	0		NA	NA
210067_10	(Total)	Total	1	0	0	0.00	NA	NA

MeasurementYear:	: 2020							
IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202458_20	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	264	148	202	3	77.65	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminOptional	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202448_20	Diabetes Monitoring for People With Diabetes and Schizophrenia	9	0	3	1	44.44	NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202447_20	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia	0	0	0		NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202446_20	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	63	25	37	0	58.73	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210005_10	Blood Glucose Testing (1-11)	1-11	628	256	10	42.36	R	R
210009_10	Cholesterol Testing (1-11)	1-11	628	198	5	32.32	R	R
210007_10	Blood Glucose and Cholesterol Testing (1-11)	1-11	628	163	9	27.39	R	R
210006_10	Blood Glucose Testing (12-17)	12-17	1199	764	25	65.80	R	R
210010_10	Cholesterol Testing (12-17)	12-17	1199	643	33	56.38	R	R
200674_20	Blood Glucose and Cholesterol Testing (12-17)	12-17	1199	603	38	53.46	R	R
210004_10	Blood Glucose Testing (Total)	Total	1827	1020	35	57.74	R	R
210008_10	Cholesterol Testing (Total)	Total	1827	841	38	48.11	R	R
200676_20	Blood Glucose and Cholesterol Testing (Total)	Total	1827	766	47	44.50	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	Rate	AuditDesignation	Status
201957_20	Non-Recommended Cervical Cancer Screening in Adolescent Females	2954	27	22	0.74	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
210070_10	(3 Months-17 Years)	3m-17	3484	421	87.92	R	R
210069_10	(18-64)	18-64	129	22	82.95	R	R
210071_10	(65+)	65+	0	0		NA	NA
210068_10	(Total)	Total	3613	443	87.74	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
210002_10	(3 Months-17 Years)	3m-17	780	339	56.54	R	R
210001_10	(18-64)	18-64	38	22	42.11	R	R
210003_10	(65+)	65+	0	0		NA	NA
210000_10	(Total)	Total	818	361	55.87	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	Rate	AuditDesignation	Status
201818_20	Use of Imaging Studies for Low Back Pain	45	10	7	84.44	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	Rate	AuditDesignation	Status
202527_10	Use of Opioids at High Dosage	8	0	0	0.00	NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
202529_10	Multiple Prescribers	8	3	37.50	NA	NA
202528_10	Multiple Pharmacies	8	1	12.50	NA	NA
202530_10	Multiple Prescribers and Multiple Pharmacies	8	1	12.50	NA	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	Rate	AuditDesignation	Status
203434_10	>=15 Days (18-64)	18-64	210	2	1	0.48	R	R
203437_10	>=31 Days (18-64)	18-64	210	2	0	0.00	R	R
203435_10	>=15 Days (65+)	65+	0	0	0		NA	NA
203438_10	>=31 Days (65+)	65+	0	0	0		NA	NA
203436_10	>=15 Days (Total)	Total	210	2	1	0.48	R	R
203439_10	>=31 Days (Total)	Total	210	2	0	0.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
200001_20	(20-44)	20-44	1421	896	63.05	R	R
200002_20	(45-64)	45-64	0	0		NA	NA
200003_20	(65+)	65+	0	0		NA	NA
200004_20	(Total)	Total	1421	896	63.05	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
200635_20	(2-3)	2-3	1718	1124	65.42	R	R
200636_20	(4-6)	4-6	3333	2445	73.36	R	R
200637_20	(7-10)	7-10	4652	3319	71.35	R	R
200632_20	(11-14)	11-14	5384	3593	66.73	R	R
200633_20	(15-18)	15-18	5727	3319	57.95	R	R
200634_20	(19-20)	19-20	1634	486	29.74	R	R
200638_20	(Total)	Total	22448	14286	63.64	R	R

MeasurementYear:	2020						
IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	Rate	AuditDesignation	Status
203288_10	Initiation of AOD - Alcohol Abuse or Dependence (13-17)	13-17	33	18	54.55	R	R
203279_10	Engagement of AOD - Alcohol Abuse or Dependence (13-17)	13-17	33	1	3.03	R	R
203289_10	Initiation of AOD - Opioid Abuse or Dependence (13-17)	13-17	9	6	66.67	NA	NA
203280_10	Engagement of AOD - Opioid Abuse or Dependence (13-17)	13-17	9	1	11.11	NA	NA
203290_10	Initiation of AOD - Other Drug Abuse or Dependence (13-17)	13-17	217	131	60.37	R	R
203281_10	Engagement of AOD - Other Drug Abuse or Dependence (13-17)	13-17	217	44	20.28	R	R
201452_20	Initiation of AOD - Total (13-17)	13-17	236	141	59.75	R	R
201449_20	Engagement of AOD - Total (13-17)	13-17	236	45	19.07	R	R
203291_10	Initiation of AOD - Alcohol Abuse or Dependence (18+)	18+	38	19	50.00	R	R
203282_10	Engagement of AOD - Alcohol Abuse or Dependence (18+)	18+	38	3	7.89	R	R
203292_10	Initiation of AOD - Opioid Abuse or Dependence (18+)	18+	6	5	83.33	NA	NA
203283_10	Engagement of AOD - Opioid Abuse or Dependence (18+)	18+	6	1	16.67	NA	NA
203293_10	Initiation of AOD - Other Drug Abuse or Dependence (18+)	18+	147	76	51.70	R	R
203284_10	Engagement of AOD - Other Drug Abuse or Dependence (18+)	18+	147	16	10.88	R	R
201453_20	Initiation of AOD - Total (18+)	18+	170	84	49.41	R	R
201450_20	Engagement of AOD - Total (18+)	18+	170	17	10.00	R	R
203294_10	Initiation of AOD - Alcohol Abuse or Dependence (Total)	Total	71	37	52.11	R	R
203285_10	Engagement of AOD - Alcohol Abuse or Dependence (Total)	Total	71	4	5.63	R	R
203295_10	Initiation of AOD - Opioid Abuse or Dependence (Total)	Total	15	11	73.33	NA	NA
203286_10	Engagement of AOD - Opioid Abuse or Dependence (Total)	Total	15	2	13.33	NA	NA
203296_10	Initiation of AOD - Other Drug Abuse or Dependence (Total)	Total	364	207	56.87	R	R
203287_10	Engagement of AOD - Other Drug Abuse or Dependence (Total)	Total	364	60	16.48	R	R
201454_20	Initiation of AOD - Total (Total)	Total	406	225	55.42	R	R
201451_20	Engagement of AOD - Total (Total)	Total	406	62	15.27	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	CollectionMethod	EligiblePopulation	NumeratorByAdminElig	CYAR	MinReqSampleSize	OversampleRate	OversampleRecordsNumber
202142_20	Timeliness of Prenatal Care	н	163	105	64.42	162	0	0
202141_20	Postpartum Care	н	163	83	50.92	162	0	0

ExclusionValidDataError	s ExclusionEmployeeOrDep	OversampleRecsAdded	Denominator	NumeratorByAdmin	NumeratorByMedicalRecords	Rate	AuditDesignation	Status
1	0	0	162	104	26	80.25	R	R
1	0	0	162	83	27	67.90	R	R

MeasurementYear: 2	MeasurementYear: 2020										
IndicatorKey	IndicatorName	Age	EligiblePopulation	ExclusionAdminRequired	NumeratorByAdmin	Rate	AuditDesignation	Status			
210011_10	(1-11)	1-11	226	75	184	81.42	R	R			
200678_20	(12-17)	12-17	286	206	236	82.52	R	R			
200680_20	(Total)	Total	512	281	420	82.03	R	R			

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
202498_20	(First 15 Months)	530	231	67	56.23	R	R
210089_10	(15 Months-30 Months)	742	669	6	90.97	R	R

incusurement curves	2020							
IndicatorKey	IndicatorName	Age	EligiblePopulation	NumeratorByAdmin	NumeratorBySupplemental	Rate	AuditDesignation	Status
210093_10	(3-11)	3-11	10124	7118	8	70.39	R	R
210091_10	(12-17)	12-17	8598	5223	8	60.84	R	R
210092_10	(18-21)	18-21	3292	1069	1	32.50	R	R
210094_10	(Total)	Total	22014	13410	17	60.99	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	ProcedureCount	Rate	AuditDesignation	Status
BariatricWeightLossSurgery	201043_20	Bariatric weight loss surgery (M 0-19)	0-19	М	167826	0	0.00	R	R
BariatricWeightLossSurgery	201035_20	Bariatric weight loss surgery (F 0-19)	0-19	F	155946	1	0.01	R	R
BariatricWeightLossSurgery	201044_20	Bariatric weight loss surgery (M 20-44)	20-44	м	6001	0	0.00	R	R
BariatricWeightLossSurgery	201036_20	Bariatric weight loss surgery (F 20-44)	20-44	F	8491	1	0.12	R	R
BariatricWeightLossSurgery	201045_20	Bariatric weight loss surgery (M 45-64)	45-64	м	0	0		R	NA
BariatricWeightLossSurgery	201037_20	Bariatric weight loss surgery (F 45-64)	45-64	F	0	0		R	NA
Tonsillectomy	201155_20	Tonsillectomy (M/F 0-9)	0-9	M+F	146753	109	0.74	R	R
Tonsillectomy	201156_20	Tonsillectomy (M/F 10-19)	10-19	M+F	177033	46	0.26	R	R
HysterectomyAbdominal	201113_20	Hysterectomy Abdominal (15-44)	15-44	F	51174	0	0.00	R	R
HysterectomyAbdominal	201114_20	Hysterectomy Abdominal (45-64)	45-64	F	0	0		R	NA
HysterectomyVaginal	201120_20	Hysterectomy Vaginal (15-44)	15-44	F	51174	0	0.00	R	R
HysterectomyVaginal	201121_20	Hysterectomy Vaginal (45-64)	45-64	F	0	0		R	NA
CholecystectomyOpen	201083_20	Cholecystectomy Open (F 15-44)	15-44	F	51174	0	0.00	R	R
CholecystectomyOpen	201090_20	Cholecystectomy Open (M 30-64)	30-64	М	0	0		R	NA
CholecystectomyOpen	201084_20	Cholecystectomy Open (F 45-64)	45-64	F	0	0		R	NA
CholecystectomyLaparoscopic	201096_20	Cholecystectomy Laparoscopic (F 15-44)	15-44	F	51174	14	0.27	R	R
CholecystectomyLaparoscopic	201103_20	Cholecystectomy Laparoscopic (M 30-64)	30-64	М	0	0		R	NA
CholecystectomyLaparoscopic	201097_20	Cholecystectomy Laparoscopic (F 45-64)	45-64	F	0	0		R	NA
BackSurgery	201028_20	Back Surgery (M 20-44)	20-44	М	6001	0	0.00	R	R
BackSurgery	201021_20	Back Surgery (F 20-44)	20-44	F	8491	1	0.12	R	R
BackSurgery	201029_20	Back Surgery (M 45-64)	45-64	м	0	0		R	NA
BackSurgery	201022_20	Back Surgery (F 45-64)	45-64	F	0	0		R	NA
Mastectomy	201130_20	Mastectomy (F 15-44)	15-44	F	51174	0	0.00	R	R
Mastectomy	201131_20	Mastectomy (F 45-64)	45-64	F	0	0		R	NA
Lumpectomy	201123_20	Lumpectomy (F 15-44)	15-44	F	51174	5	0.10	R	R
Lumpectomy	201124_20	Lumpectomy (F 45-64)	45-64	F	0	0		R	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	MemberMonths	ServiceCount	Rate	AuditDesignation	Status
Outpatient	200657_20	Outpatient Visits/1000 MM (<1)	0-1	7436	6847	920.79	R	R
ED	200648_20	Emergency Dept Visits/1000 MM (<1)	0-1	7436	289	38.86	R	R
Outpatient	200650_20	Outpatient Visits/1000 MM (1-9)	1-9	139317	41180	295.58	R	R
ED	200641_20	Emergency Dept Visits/1000 MM (1-9)	1-9	139317	2521	18.10	R	R
Outpatient	200651_20	Outpatient Visits/1000 MM (10-19)	10-19	177033	36384	205.52	R	R
ED	200642_20	Emergency Dept Visits/1000 MM (10-19)	10-19	177033	5326	30.08	R	R
Outpatient	200652_20	Outpatient Visits/1000 MM (20-44)	20-44	14492	2839	195.90	R	R
ED	200643_20	Emergency Dept Visits/1000 MM (20-44)	20-44	14492	1301	89.77	R	R
Outpatient	200653_20	Outpatient Visits/1000 MM (45-64)	45-64	0	0		R	NA
ED	200644_20	Emergency Dept Visits/1000 MM (45-64)	45-64	0	0		R	NA
Outpatient	200654_20	Outpatient Visits/1000 MM (65-74)	65-74	0	0		R	NA
ED	200645_20	Emergency Dept Visits/1000 MM (65-74)	65-74	0	0		R	NA
Outpatient	200655_20	Outpatient Visits/1000 MM (75-84)	75-84	0	0		R	NA
ED	200646_20	Emergency Dept Visits/1000 MM (75-84)	75-84	0	0		R	NA
Outpatient	200656_20	Outpatient Visits/1000 MM (85+)	85+	0	0		R	NA
ED	200647_20	Emergency Dept Visits/1000 MM (85+)	85+	0	0		R	NA
Outpatient	200640_20	Outpatient Visits/1000 MM (Unknown)	Unknown	0	0		R	NA
ED	200639_20	Emergency Dept Visits/1000 MM (Unknown)	Unknown	0	0		R	NA
Outpatient	200658_20	Outpatient Visits/1000 MM (Total)	Total	338278	87250	257.92	R	R
ED	200649_20	Emergency Dept Visits/1000 MM (Total)	Total	338278	9437	27.90	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

Measurement	tYear: 2020								
Category	IndicatorKey	IndicatorName	Age	Days	Discharges	MemberMonths	Rate	AuditDesignation	Status
Total	201811_20	Total Inpatient Discharges/1000 MM (<1)	0-1		55	7436	7.40	R	R
Total	201810_20	Total Inpatient Days/1000 MM (<1)	0-1	481		7436	64.69	R	R
Total	201809_20	Total Inpatient ALOS (<1)	0-1	481	55		8.75	R	R
Total	201790_20	Total Inpatient Discharges/1000 MM (1-9)	1-9		96	139317	0.69	R	R
Total	201789_20	Total Inpatient Days/1000 MM (1-9)	1-9	435		139317	3.12	R	R
Total	201788_20	Total Inpatient ALOS (1-9)	1-9	435	96		4.53	R	R
Total	201793_20	Total Inpatient Discharges/1000 MM (10-19)	10-19		348	177033	1.97	R	R
Total	201792_20	Total Inpatient Days/1000 MM (10-19)	10-19	1521		177033	8.59	R	R
Total	201791_20	Total Inpatient ALOS (10-19)	10-19	1521	348		4.37	R	R
Total	201796_20	Total Inpatient Discharges/1000 MM (20-44)	20-44		140	14492	9.66	R	R
Total	201795_20	Total Inpatient Days/1000 MM (20-44)	20-44	430		14492	29.67	R	R
Total	201794 20	Total Inpatient ALOS (20-44)	20-44	430	140		3.07	R	R
Total	201799 20	Total Inpatient Discharges/1000 MM (45-64)	45-64		0	0		R	NA
Total	201798 20	Total Inpatient Days/1000 MM (45-64)	45-64	0		0		R	NA
Total	201797 20	Total Inpatient ALOS (45-64)	45-64	0	0			R	NA
Total	201802 20	Total Inpatient Discharges/1000 MM (65-74)	65-74	-	0	0		R	NA
Total	201801 20	Total Inpatient Days/1000 MM (65-74)	65-74	0	-	0		R	NA
Total	201800 20	Total Inpatient ALOS (65-74)	65-74	0	0			R	NA
Total	201805 20	Total Inpatient Discharges/1000 MM (75-84)	75-84	-	0	0		R	NA
Total	201804 20	Total Inpatient Days/1000 MM (75-84)	75-84	0	-	0		R	NA
Total	201803 20	Total Inpatient ALOS (75-84)	75-84	0	0			R	NA
Total	201808 20	Total Inpatient Discharges/1000 MM (85+)	85+	-	0	0		R	NA
Total	201807 20	Total Inpatient Days/1000 MM (85+)	85+	0	-	0		R	NA
Total	201806 20	Total Inpatient ALOS (85+)	85+	0	0			R	NA
Total	201812 20	Total Inpatient Discharges/1000 MM (Unknown)	Unknown	0	0	0		R	NA
Total	201813 20	Total Inpatient Days/1000 MM (Unknown)	Unknown	0	0	0		R	NA
Total	201817 20	Total Inpatient ALOS (Unknown)	Unknown	0	0			R	NA
Total	201816 20	Total Inpatient Discharges/1000 MM (Total)	Total	0	639	338278	1.89	R	R
Total	201815_20	Total Inpatient Days/1000 MM (Total)	Total	2867		338278	8.48	R	R
Total	201814 20	Total Inpatient ALOS (Total)	Total	2867	639	000270	4.49	R	R
Maternity	201715 20	Maternity Discharges/1000 MM (10-19)	10-19	2007	112	177033	0.63	R	R
Maternity	201714 20	Maternity Days/1000 MM (10-19)	10-19	310		177033	1.75	R	R
Maternity	201713 20	Maternity ALOS (10-19)	10-19	310	112	177033	2.77	R	R
Maternity	201724 20	Maternity Discharges/1000 MM (Total)	Total	510	210	191525	1.10	R	R
Maternity	201723 20	Maternity Discharges 1000 MM (Total)	Total	586		191525	3.06	R	R
Maternity	201722_20	Maternity ALOS (Total)	Total	586	210	191929	2.79	R	R
Maternity	201722_20	Maternity ALOS (1001) Maternity Discharges/1000 MM (20-44)	20-44	200	98	14492	6.76	R	R
Maternity	201718_20	Maternity Discharges/1000 MM (20-44) Maternity Days/1000 MM (20-44)	20-44	276	50	14492	19.04	R	R
Maternity	201716 20	Maternity ALOS (20-44)	20-44	276	98	17772	2.82	R	P
	201716_20		45-64	270	0	0	2.02	P	NA
Maternity		Maternity Discharges/1000 MM (45-64)		0	0	0		D	NA
Maternity	201720_20	Maternity Days/1000 MM (45-64)	45-64	U		V		N	NA

Measuremen	tYear: 2020								
Category	IndicatorKey	IndicatorName	Age	Days	Discharges	MemberMonths	Rate	AuditDesignation	Status
Maternity	201719_20	Maternity ALOS (45-64)	45-64	0	0			R	NA
Maternity	201727_20	Maternity Discharges/1000 MM (Unknown)	Unknown		0	0		R	NA
Maternity	201726_20	Maternity Days/1000 MM (Unknown)	Unknown	0		0		R	NA
Maternity	201725_20	Maternity ALOS (Unknown)	Unknown	0	0			R	NA
Surgery	201781_20	Surgery Discharges/1000 MM (<1)	0-1		0	7436	0.00	R	R
Surgery	201780_20	Surgery Days/1000 MM (<1)	0-1	0		7436	0.00	R	R
Surgery	201779_20	Surgery ALOS (<1)	0-1	0	0			R	NA
Surgery	201760_20	Surgery Discharges/1000 MM (1-9)	1-9		0	139317	0.00	R	R
Surgery	201759_20	Surgery Days/1000 MM (1-9)	1-9	0		139317	0.00	R	R
Surgery	201758_20	Surgery ALOS (1-9)	1-9	0	0			R	NA
Surgery	201763_20	Surgery Discharges/1000 MM (10-19)	10-19		0	177033	0.00	R	R
Surgery	201762_20	Surgery Days/1000 MM (10-19)	10-19	0		177033	0.00	R	R
Surgery	201761_20	Surgery ALOS (10-19)	10-19	0	0			R	NA
Surgery	201766_20	Surgery Discharges/1000 MM (20-44)	20-44		0	14492	0.00	R	R
Surgery	201765_20	Surgery Days/1000 MM (20-44)	20-44	0		14492	0.00	R	R
Surgery	201764_20	Surgery ALOS (20-44)	20-44	0	0			R	NA
Surgery	201769_20	Surgery Discharges/1000 MM (45-64)	45-64		0	0		R	NA
Surgery	201768_20	Surgery Days/1000 MM (45-64)	45-64	0		0		R	NA
Surgery	201767_20	Surgery ALOS (45-64)	45-64	0	0			R	NA
Surgery	201772_20	Surgery Discharges/1000 MM (65-74)	65-74		0	0		R	NA
Surgery	201771_20	Surgery Days/1000 MM (65-74)	65-74	0		0		R	NA
Surgery	201770 20	Surgery ALOS (65-74)	65-74	0	0			R	NA
Surgery	201775_20	Surgery Discharges/1000 MM (75-84)	75-84		0	0		R	NA
Surgery	201774_20	Surgery Days/1000 MM (75-84)	75-84	0		0		R	NA
Surgery	201773_20	Surgery ALOS (75-84)	75-84	0	0			R	NA
Surgery	201778_20	Surgery Discharges/1000 MM (85+)	85+		0	0		R	NA
Surgery	201777_20	Surgery Days/1000 MM (85+)	85+	0		0		R	NA
Surgery	201776_20	Surgery ALOS (85+)	85+	0	0			R	NA
Surgery	201787_20	Surgery Discharges/1000 MM (Unknown)	Unknown		0	0		R	NA
Surgery	201786_20	Surgery Days/1000 MM (Unknown)	Unknown	0		0		R	NA
Surgery	201785_20	Surgery ALOS (Unknown)	Unknown	0	0			R	NA
Surgery	201784_20	Surgery Discharges/1000 MM (Total)	Total		0	338278	0.00	R	R
Surgery	201783_20	Surgery Days/1000 MM (Total)	Total	0		338278	0.00	R	R
Surgery	201782_20	Surgery ALOS (Total)	Total	0	0			R	NA
Medicine	201751_20	Medicine Discharges/1000 MM (<1)	0-1		55	7436	7.40	R	R
Medicine	201750_20	Medicine Days/1000 MM (<1)	0-1	481		7436	64.69	R	R
Medicine	201749_20	Medicine ALOS (<1)	0-1	481	55		8.75	R	R
Medicine	201730_20	Medicine Discharges/1000 MM (1-9)	1-9		96	139317	0.69	R	R
Medicine	201729_20	Medicine Days/1000 MM (1-9)	1-9	435		139317	3.12	R	R
Medicine	201728_20	Medicine ALOS (1-9)	1-9	435	96		4.53	R	R
Medicine	201733_20	Medicine Discharges/1000 MM (10-19)	10-19		236	177033	1.33	R	R

Measurement	Year: 2020								
Category	IndicatorKey	IndicatorName	Age	Days	Discharges	MemberMonths	Rate	AuditDesignation	Status
Medicine	201732_20	Medicine Days/1000 MM (10-19)	10-19	1211		177033	6.84	R	R
Medicine	201731_20	Medicine ALOS (10-19)	10-19	1211	236		5.13	R	R
Medicine	201736_20	Medicine Discharges/1000 MM (20-44)	20-44		42	14492	2.90	R	R
Medicine	201735_20	Medicine Days/1000 MM (20-44)	20-44	154		14492	10.63	R	R
Medicine	201734_20	Medicine ALOS (20-44)	20-44	154	42		3.67	R	R
Medicine	201739_20	Medicine Discharges/1000 MM (45-64)	45-64		0	0		R	NA
Medicine	201738_20	Medicine Days/1000 MM (45-64)	45-64	0		0		R	NA
Medicine	201737_20	Medicine ALOS (45-64)	45-64	0	0			R	NA
Medicine	201742_20	Medicine Discharges/1000 MM (65-74)	65-74		0	0		R	NA
Medicine	201741_20	Medicine Days/1000 MM (65-74)	65-74	0		0		R	NA
Medicine	201740_20	Medicine ALOS (65-74)	65-74	0	0			R	NA
Medicine	201745_20	Medicine Discharges/1000 MM (75-84)	75-84		0	0		R	NA
Medicine	201744_20	Medicine Days/1000 MM (75-84)	75-84	0		0		R	NA
Medicine	201743_20	Medicine ALOS (75-84)	75-84	0	0			R	NA
Medicine	201748_20	Medicine Discharges/1000 MM (85+)	85+		0	0		R	NA
Medicine	201747_20	Medicine Days/1000 MM (85+)	85+	0		0		R	NA
Medicine	201746_20	Medicine ALOS (85+)	85+	0	0			R	NA
Medicine	201757_20	Medicine Discharges/1000 MM (Unknown)	Unknown		0	0		R	NA
Medicine	201756_20	Medicine Days/1000 MM (Unknown)	Unknown	0		0		R	NA
Medicine	201755_20	Medicine ALOS (Unknown)	Unknown	0	0			R	NA
Medicine	201754_20	Medicine Discharges/1000 MM (Total)	Total		429	338278	1.27	R	R
Medicine	201753_20	Medicine Days/1000 MM (Total)	Total	2281		338278	6.74	R	R
Medicine	201752_20	Medicine ALOS (Total)	Total	2281	429		5.32	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care

(Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
						wiennbercount		AuditDesignation	Status
Any	202755_10	Alcohol Any Service (M 0-12)	0-12	M	103936	6	0.07	R	R
Any	202751_10	Alcohol Any Service (F 0-12)	0-12	F	94829	3	0.04	R	R
Any	202759_10	Alcohol Any Service (Total 0-12)	0-12	F,M	198765	9	0.05	R	R
Inpatient	202946_10	Alcohol Inpatient (M 0-12)	0-12	M	103936	3	0.03	R	R
Inpatient	202943_10	Alcohol Inpatient (F 0-12)	0-12	F	94829	2	0.03	R	R
Inpatient	202949_10	Alcohol Inpatient (Total 0-12)	0-12	F,M	198765	5	0.03	R	R
Intensive	203018_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 0-12)	0-12	M	103936	0	0.00	R	R
Intensive	203015_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 0-12)	0-12	F	94829	0	0.00	R	R
Intensive	203021_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
ED	202851_10	Alcohol Emergency Department (M 0-12)	0-12	M	103936	0	0.00	R	R
ED	202847_10	Alcohol Emergency Department (F 0-12)	0-12	F	94829	0	0.00	R	R
ED	202855_10	Alcohol Emergency Department (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
Outpatient	203091_10	Alcohol Outpatient or Medication Treatment (M 0-12)	0-12	M	103936	3	0.03	R	R
Outpatient	203087_10	Alcohol Outpatient or Medication Treatment (F 0-12)	0-12	F	94829	1	0.01	R	R
Outpatient	203095_10	Alcohol Outpatient or Medication Treatment (Total 0-12)	0-12	F,M	198765	4	0.02	R	R
Telehealth	203187_10	Alcohol Telehealth (M 0-12)	0-12	М	103936	0	0.00	R	R
Telehealth	203183_10	Alcohol Telehealth (F 0-12)	0-12	F	94829	0	0.00	R	R
Telehealth	203191_10	Alcohol Telehealth (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
Any	202767_10	Alcohol Any Service (M 13-17)	13-17	М	51051	46	1.08	R	R
Any	202763_10	Alcohol Any Service (F 13-17)	13-17	F	48307	52	1.29	R	R
Any	202771_10	Alcohol Any Service (Total 13-17)	13-17	F,M	99358	98	1.18	R	R
Inpatient	202955_10	Alcohol Inpatient (M 13-17)	13-17	Μ	51051	17	0.40	R	R
Inpatient	202952_10	Alcohol Inpatient (F 13-17)	13-17	F	48307	23	0.57	R	R
Inpatient	202958_10	Alcohol Inpatient (Total 13-17)	13-17	F,M	99358	40	0.48	R	R
Intensive	203027_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 13-17)	13-17	Μ	51051	2	0.05	R	R
Intensive	203024_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 13-17)	13-17	F	48307	0	0.00	R	R
Intensive	203030_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 13-17)	13-17	F,M	99358	2	0.02	R	R
ED	202863_10	Alcohol Emergency Department (M 13-17)	13-17	М	51051	12	0.28	R	R
ED	202859_10	Alcohol Emergency Department (F 13-17)	13-17	F	48307	1	0.02	R	R
ED	202867_10	Alcohol Emergency Department (Total 13-17)	13-17	F,M	99358	13	0.16	R	R
Outpatient	203103_10	Alcohol Outpatient or Medication Treatment (M 13-17)	13-17	м	51051	14	0.33	R	R
Outpatient	203099_10	Alcohol Outpatient or Medication Treatment (F 13-17)	13-17	F	48307	28	0.70	R	R
Outpatient	203107_10	Alcohol Outpatient or Medication Treatment (Total 13-17)	13-17	F,M	99358	42	0.51	R	R
Telehealth	203199_10	Alcohol Telehealth (M 13-17)	13-17	М	51051	12	0.28	R	R
Telehealth	203195_10	Alcohol Telehealth (F 13-17)	13-17	F	48307	13	0.32	R	R
Telehealth	203203_10	Alcohol Telehealth (Total 13-17)	13-17	F,M	99358	25	0.30	R	R
Any	202779_10	Alcohol Any Service (M 18-24)	18-24	М	18701	22	1.41	R	R
Any	202775_10	Alcohol Any Service (F 18-24)	18-24	F	21014	22	1.26	R	R
Any	202783_10	Alcohol Any Service (Total 18-24)	18-24	F,M	39715	44	1.33	R	R
Inpatient	202964_10	Alcohol Inpatient (M 18-24)	18-24	М	18701	8	0.51	R	R
Inpatient	202961_10	Alcohol Inpatient (F 18-24)	18-24	F	21014	4	0.23	R	R
Inpatient	202967_10	Alcohol Inpatient (Total 18-24)	18-24	F,M	39715	12	0.36	R	R
Intensive	203036_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 18-24)	18-24	М	18701	0	0.00	R	R
Intensive	203033_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 18-24)	18-24	F	21014	4	0.23	R	R
Intensive	203039_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 18-24)	18-24	F,M	39715	4	0.12	R	R
ED	202875_10	Alcohol Emergency Department (M 18-24)	18-24	М	18701	12	0.77	R	R
ED	202871_10	Alcohol Emergency Department (F 18-24)	18-24	F	21014	10	0.57	R	R
ED	202879_10	Alcohol Emergency Department (Total 18-24)	18-24	F,M	39715	22	0.66	R	R
Outpatient	203115_10	Alcohol Outpatient or Medication Treatment (M 18-24)	18-24	М	18701	5	0.32	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Outpatient	203111_10	Alcohol Outpatient or Medication Treatment (F 18-24)	18-24	F	21014	6	0.34	R	R
Outpatient	203119 10	Alcohol Outpatient or Medication Treatment (Total 18-24)	18-24	F,M	39715	11	0.33	R	R
Telehealth	203211_10	Alcohol Telehealth (M 18-24)	18-24	М	18701	1	0.06	R	R
Telehealth	203207_10	Alcohol Telehealth (F 18-24)	18-24	F	21014	1	0.06	R	R
Telehealth	203215_10	Alcohol Telehealth (Total 18-24)	18-24	F,M	39715	2	0.06	R	R
Any	202791_10	Alcohol Any Service (M 25-34)	25-34	М	139	1	8.63	R	NA
Any	202787_10	Alcohol Any Service (F 25-34)	25-34	F	287	0	0.00	R	NA
Any	202795_10	Alcohol Any Service (Total 25-34)	25-34	F,M	426	1	2.82	R	R
Inpatient	202973_10	Alcohol Inpatient (M 25-34)	25-34	м	139	1	8.63	R	NA
Inpatient	202970_10	Alcohol Inpatient (F 25-34)	25-34	F	287	0	0.00	R	NA
Inpatient	202976_10	Alcohol Inpatient (Total 25-34)	25-34	F,M	426	1	2.82	R	R
Intensive	203045_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 25-34)	25-34	М	139	0	0.00	R	NA
Intensive	203042_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 25-34)	25-34	F	287	0	0.00	R	NA
Intensive	203048_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 25-34)	25-34	F,M	426	0	0.00	R	R
ED	202887_10	Alcohol Emergency Department (M 25-34)	25-34	М	139	0	0.00	R	NA
ED	202883_10	Alcohol Emergency Department (F 25-34)	25-34	F	287	0	0.00	R	NA
ED	202891_10	Alcohol Emergency Department (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Outpatient	203127_10	Alcohol Outpatient or Medication Treatment (M 25-34)	25-34	М	139	0	0.00	R	NA
Outpatient	203123_10	Alcohol Outpatient or Medication Treatment (F 25-34)	25-34	F	287	0	0.00	R	NA
Outpatient	203131_10	Alcohol Outpatient or Medication Treatment (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Telehealth	203223_10	Alcohol Telehealth (M 25-34)	25-34	М	139	0	0.00	R	NA
Telehealth	203219_10	Alcohol Telehealth (F 25-34)	25-34	F	287	0	0.00	R	NA
Telehealth	203227_10	Alcohol Telehealth (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Any	202803_10	Alcohol Any Service (M 35-64)	35-64	м	0	0		R	NA
Any	202799_10	Alcohol Any Service (F 35-64)	35-64	F	0	0		R	NA
Any	202807_10	Alcohol Any Service (Total 35-64)	35-64	F,M	0	0		R	NA
Inpatient	202982_10	Alcohol Inpatient (M 35-64)	35-64	М	0	0		R	NA
Inpatient	202979_10	Alcohol Inpatient (F 35-64)	35-64	F	0	0		R	NA
Inpatient	202985_10	Alcohol Inpatient (Total 35-64)	35-64	F,M	0	0		R	NA
Intensive	203054_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 35-64)	35-64	М	0	0		R	NA
Intensive	203051_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 35-64)	35-64	F	0	0		R	NA
Intensive	203057_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 35-64)	35-64	F,M	0	0		R	NA
ED	202899_10	Alcohol Emergency Department (M 35-64)	35-64	М	0	0		R	NA
ED	202895_10	Alcohol Emergency Department (F 35-64)	35-64	F	0	0		R	NA
ED	202903_10	Alcohol Emergency Department (Total 35-64)	35-64	F,M	0	0		R	NA
Outpatient	203139_10	Alcohol Outpatient or Medication Treatment (M 35-64)	35-64	М	0	0		R	NA
Outpatient	203135_10	Alcohol Outpatient or Medication Treatment (F 35-64)	35-64	F	0	0		R	NA
Outpatient	203143_10	Alcohol Outpatient or Medication Treatment (Total 35-64)	35-64	F,M	0	0		R	NA
Telehealth	203235_10	Alcohol Telehealth (M 35-64)	35-64	М	0	0		R	NA
Telehealth	203231_10	Alcohol Telehealth (F 35-64)	35-64	F	0	0		R	NA
Telehealth	203239_10	Alcohol Telehealth (Total 35-64)	35-64	F,M	0	0		R	NA
Any	202815_10	Alcohol Any Service (M 65+)	65+	М	0	0		R	NA
Any	202811_10	Alcohol Any Service (F 65+)	65+	F	0	0		R	NA
Any	202819_10	Alcohol Any Service (Total 65+)	65+	F,M	0	0		R	NA
Inpatient	202991_10	Alcohol Inpatient (M 65+)	65+	М	0	0		R	NA
Inpatient	202988_10	Alcohol Inpatient (F 65+)	65+	F	0	0		R	NA
Inpatient	202994_10	Alcohol Inpatient (Total 65+)	65+	F,M	0	0		R	NA
Intensive	203063_10	Alcohol Intensive Outpatient or Partial Hospitalization (M 65+)	65+	м	0	0		R	NA
Intensive	203060_10	Alcohol Intensive Outpatient or Partial Hospitalization (F 65+)	65+	F	0	0		R	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Cotogory		IndicatorNama	100	Condor	MomborMonths	MomborCount	Pata	AuditDesignation	Status
• •	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Intensive	203066_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total 65+)	65+	F,M	0	0		R	NA
ED	202911_10	Alcohol Emergency Department (M 65+)	65+	M	0	0		R	NA
ED	202907_10	Alcohol Emergency Department (F 65+)	65+	F	0	0		R	NA
ED	202915_10	Alcohol Emergency Department (Total 65+)	65+	F,M	0	0		R	NA
Outpatient	203151_10	Alcohol Outpatient or Medication Treatment (M 65+)	65+	М	-	0		R	NA
Outpatient	203147_10	Alcohol Outpatient or Medication Treatment (F 65+)	65+	F	0	0		R	NA
Outpatient	203155_10	Alcohol Outpatient or Medication Treatment (Total 65+)	65+	F,M	-	0		R	NA
Telehealth	203247_10	Alcohol Telehealth (M 65+)	65+	м	0	0		R	NA
Telehealth	203243_10	Alcohol Telehealth (F 65+)	65+	F	0	0		R	NA
Telehealth	203251_10	Alcohol Telehealth (Total 65+)	65+	F,M	0	0		R	NA
Any	202839_10	Alcohol Any Service (M Unknown)	Unknown	М	0	0		R	NA
Any	202835_10	Alcohol Any Service (F Unknown)	Unknown	F	0	0		R	NA
Any	202843_10	Alcohol Any Service (Total Unknown)	Unknown	F,M	0	0		R	NA
Inpatient	203009_10	Alcohol Inpatient (M Unknown)	Unknown	М	0	0		R	NA
Inpatient	203006_10	Alcohol Inpatient (F Unknown)	Unknown	F	0	0		R	NA
Inpatient	203012_10	Alcohol Inpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Intensive	203081_10	Alcohol Intensive Outpatient or Partial Hospitalization (M Unknown)	Unknown	м	0	0		R	NA
Intensive	203078_10	Alcohol Intensive Outpatient or Partial Hospitalization (F Unknown)	Unknown	F	0	0		R	NA
Intensive	203084_10	Alcohol Intensive Outpatient or Partial Hospitalization (Total Unknown)	Unknown	F,M	0	0		R	NA
ED	202935_10	Alcohol Emergency Department (M Unknown)	Unknown	М	0	0		R	NA
ED	202931_10	Alcohol Emergency Department (F Unknown)	Unknown	F	0	0		R	NA
ED	202939_10	Alcohol Emergency Department (Total Unknown)	Unknown	F,M	0	0		R	NA
Outpatient	203175_10	Alcohol Outpatient or Medication Treatment (M Unknown)	Unknown	м	0	0		R	NA
Outpatient	203171_10	Alcohol Outpatient or Medication Treatment (F Unknown)	Unknown	F	0	0		R	NA
Outpatient	203179_10	Alcohol Outpatient or Medication Treatment (Total Unknown)	Unknown	F,M	0	0		R	NA
Telehealth	203271_10	Alcohol Telehealth (M Unknown)	Unknown	м	0	0		R	NA
Telehealth	203267_10	Alcohol Telehealth (F Unknown)	Unknown	F	0	0		R	NA
Telehealth	203275_10	Alcohol Telehealth (Total Unknown)	Unknown	F,M	0	0		R	NA
Any	202827_10	Alcohol Any Service (M Total)	Total	М	173827	75	0.52	R	R
Any	202823_10	Alcohol Any Service (F Total)	Total	F	164437	77	0.56	R	R
Any	202831 10	Alcohol Any Service (Total)	Total	F,M	338264	152	0.54	R	R
Inpatient	203000 10	Alcohol Inpatient (M Total)	Total	м	173827	29	0.20	R	R
Inpatient	202997 10	Alcohol Inpatient (F Total)	Total	F	164437	29	0.21	R	R
Inpatient	203003 10	Alcohol Inpatient (Total)	Total	F,M	338264	58	0.21	R	R
Intensive	203072 10	Alcohol Intensive Outpatient or Partial Hospitalization (M Total)	Total	M	173827	2	0.01	R	R
Intensive	203069 10	Alcohol Intensive Outpatient or Partial Hospitalization (F Total)	Total	F	164437	4	0.03	R	R
Intensive	203075 10	Alcohol Intensive Outpatient or Partial Hospitalization (Total)	Total	F,M	338264	6	0.02	R	R
ED	202923 10	Alcohol Emergency Department (M Total)	Total	M		24	0.17	R	R
ED	202919 10	Alcohol Emergency Department (F Total)	Total	F	164437	11	0.08	R	R
ED	202927 10	Alcohol Emergency Department (Total)	Total	F,M	338264	35	0.12	R	R
Outpatient	203163 10	Alcohol Outpatient or Medication Treatment (M Total)	Total	M	173827	22	0.15	R	R
Outpatient	203159_10	Alcohol Outpatient or Medication Treatment (F Total)	Total	F		35	0.26	B	R
Outpatient	203167 10	Alcohol Outpatient or Medication Treatment (Total)	Total	F,M	338264	57	0.20	R	R
Telehealth	203259 10	Alcohol Telehealth (M Total)	Total	M	173827	13	0.09	R	R
Telehealth	203255_10	Alcohol Telehealth (F Total)	Total	F	164437	14	0.10	R	R
Telehealth	203263 10	Alcohol Telehealth (Total)	Total	F,M	338264	27	0.10	R	R
Any	202756 10	Opioid Any Service (M 0-12)	0-12	M	103936	5	0.06	R	R
Any	202752 10	Opioid Any Service (F 0-12)	0-12	F	94829	1	0.01	R	R
	1	Opioid Any Service (Total 0-12)	0-12	F.M	198765	6	0.04		

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Inpatient	202947 10	Opioid Inpatient (M 0-12)	0-12	м	103936	0	0.00	R	R
Inpatient	202944 10	Opioid Inpatient (F 0-12)	0-12	F	94829	0	0.00	R	R
Inpatient	202950 10	Opioid Inpatient (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
Intensive	203019 10	Opioid Intensive Outpatient or Partial Hospitalization (M 0-12)	0-12	М	103936	0	0.00	R	R
Intensive	203016_10	Opioid Intensive Outpatient or Partial Hospitalization (F 0-12)	0-12	F	94829	0	0.00	R	R
Intensive	203022_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
ED	202852 10	Opioid Emergency Department (M 0-12)	0-12	М	103936	1	0.01	R	R
ED	202848_10	Opioid Emergency Department (F 0-12)	0-12	F	94829	0	0.00	R	R
ED	202856_10	Opioid Emergency Department (Total 0-12)	0-12	F,M	198765	1	0.01	R	R
Outpatient	203092_10	Opioid Outpatient or Medication Treatment (M 0-12)	0-12	м	103936	4	0.05	R	R
Outpatient	203088_10	Opioid Outpatient or Medication Treatment (F 0-12)	0-12	F	94829	1	0.01	R	R
Outpatient	203096_10	Opioid Outpatient or Medication Treatment (Total 0-12)	0-12	F,M	198765	5	0.03	R	R
Telehealth	203188_10	Opioid Telehealth (M 0-12)	0-12	м	103936	0	0.00	R	R
Telehealth	203184_10	Opioid Telehealth (F 0-12)	0-12	F	94829	0	0.00	R	R
Telehealth	203192_10	Opioid Telehealth (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
Any	202768_10	Opioid Any Service (M 13-17)	13-17	М	51051	16	0.38	R	R
Any	202764_10	Opioid Any Service (F 13-17)	13-17	F	48307	27	0.67	R	R
Any	202772_10	Opioid Any Service (Total 13-17)	13-17	F,M	99358	43	0.52	R	R
Inpatient	202956_10	Opioid Inpatient (M 13-17)	13-17	М	51051	5	0.12	R	R
Inpatient	202953_10	Opioid Inpatient (F 13-17)	13-17	F	48307	3	0.07	R	R
Inpatient	202959_10	Opioid Inpatient (Total 13-17)	13-17	F,M	99358	8	0.10	R	R
Intensive	203028_10	Opioid Intensive Outpatient or Partial Hospitalization (M 13-17)	13-17	М	51051	0	0.00	R	R
Intensive	203025_10	Opioid Intensive Outpatient or Partial Hospitalization (F 13-17)	13-17	F	48307	0	0.00	R	R
Intensive	203031_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 13-17)	13-17	F,M	99358	0	0.00	R	R
ED	202864_10	Opioid Emergency Department (M 13-17)	13-17	М	51051	1	0.02	R	R
ED	202860_10	Opioid Emergency Department (F 13-17)	13-17	F	48307	3	0.07	R	R
ED	202868_10	Opioid Emergency Department (Total 13-17)	13-17	F,M	99358	4	0.05	R	R
Outpatient	203104_10	Opioid Outpatient or Medication Treatment (M 13-17)	13-17	М	51051	9	0.21	R	R
Outpatient	203100_10	Opioid Outpatient or Medication Treatment (F 13-17)	13-17	F	48307	20	0.50	R	R
Outpatient	203108_10	Opioid Outpatient or Medication Treatment (Total 13-17)	13-17	F,M	99358	29	0.35	R	R
Telehealth	203200_10	Opioid Telehealth (M 13-17)	13-17	М	51051	5	0.12	R	R
Telehealth	203196_10	Opioid Telehealth (F 13-17)	13-17	F	48307	2	0.05	R	R
Telehealth	203204_10	Opioid Telehealth (Total 13-17)	13-17	F,M	99358	7	0.08	R	R
Any	202780_10	Opioid Any Service (M 18-24)	18-24	М	18701	5	0.32	R	R
Any	202776_10	Opioid Any Service (F 18-24)	18-24	F	21014	8	0.46	R	R
Any	202784_10	Opioid Any Service (Total 18-24)	18-24	F,M	39715	13	0.39	R	R
Inpatient	202965_10	Opioid Inpatient (M 18-24)	18-24	м	18701	2	0.13	R	R
Inpatient	202962_10	Opioid Inpatient (F 18-24)	18-24	F	21014	3	0.17	R	R
Inpatient	202968_10	Opioid Inpatient (Total 18-24)	18-24	F,M	39715	5	0.15	R	R
Intensive	203037_10	Opioid Intensive Outpatient or Partial Hospitalization (M 18-24)	18-24	м	18701	0	0.00	R	R
Intensive	203034_10	Opioid Intensive Outpatient or Partial Hospitalization (F 18-24)	18-24	F	21014	1	0.06	R	R
Intensive	203040_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 18-24)	18-24	F,M	39715	1	0.03	R	R
ED	202876_10	Opioid Emergency Department (M 18-24)	18-24	М	18701	1	0.06	R	R
ED	202872_10	Opioid Emergency Department (F 18-24)	18-24	F	21014	2	0.11	R	R
ED	202880_10	Opioid Emergency Department (Total 18-24)	18-24	F,M	39715	3	0.09	R	R
Outpatient	203116_10	Opioid Outpatient or Medication Treatment (M 18-24)	18-24	М	18701	2	0.13	R	R
Outpatient	203112_10	Opioid Outpatient or Medication Treatment (F 18-24)	18-24	F	21014	3	0.17	R	R
Outpatient	203120_10	Opioid Outpatient or Medication Treatment (Total 18-24)	18-24	F,M	39715	5	0.15	R	R
Telehealth	203212_10	Opioid Telehealth (M 18-24)	18-24	м	18701	0	0.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Telehealth	203208 10	Opioid Telehealth (F 18-24)	18-24	F	21014	0	0.00	R	R
Telehealth	203216_10	Opioid Telehealth (Total 18-24)	18-24	F,M	39715	0	0.00	R	R
Any	202792 10	Opioid Any Service (M 25-34)	25-34	M	139	0	0.00	R	NA
Any	202788 10	Opioid Any Service (F 25-34)	25-34	F	287	0	0.00	R	NA
Any	202796_10	Opioid Any Service (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Inpatient	202974 10	Opioid Inpatient (M 25-34)	25-34	M	139	0	0.00	R	NA
Inpatient	202971 10	Opioid Inpatient (F 25-34)	25-34	F	287	0	0.00	R	NA
Inpatient	202977_10	Opioid Inpatient (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Intensive	203046 10	Opioid Intensive Outpatient or Partial Hospitalization (M 25-34)	25-34	М	139	0	0.00	R	NA
Intensive	203043 10	Opioid Intensive Outpatient or Partial Hospitalization (F 25-34)	25-34	F	287	0	0.00	R	NA
Intensive	203049_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 25-34)	25-34	F,M	426	0	0.00	R	R
ED	202888 10	Opioid Emergency Department (M 25-34)	25-34	М	139	0	0.00	R	NA
ED	202884_10	Opioid Emergency Department (F 25-34)	25-34	F	287	0	0.00	R	NA
ED	202892 10	Opioid Emergency Department (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Outpatient	203128 10	Opioid Outpatient or Medication Treatment (M 25-34)	25-34	М	139	0	0.00	R	NA
Outpatient	203124_10	Opioid Outpatient or Medication Treatment (F 25-34)	25-34	F	287	1	4.18	R	NA
Outpatient	203132 10	Opioid Outpatient or Medication Treatment (Total 25-34)	25-34	F,M	426	1	2.82	R	R
Telehealth	203224 10	Opioid Telehealth (M 25-34)	25-34	М	139	0	0.00	R	NA
Telehealth	203220 10	Opioid Telehealth (F 25-34)	25-34	F	287	0	0.00	R	NA
Telehealth	203228 10	Opioid Telehealth (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Any	202804 10	Opioid Any Service (M 35-64)	35-64	М	0	0		R	NA
Any	202800 10	Opioid Any Service (F 35-64)	35-64	F	0	0		R	NA
Any	202808 10	Opioid Any Service (Total 35-64)	35-64	F,M	0	0		R	NA
Inpatient	202983_10	Opioid Inpatient (M 35-64)	35-64	М	0	0		R	NA
Inpatient	202980_10	Opioid Inpatient (F 35-64)	35-64	F	0	0		R	NA
Inpatient	202986_10	Opioid Inpatient (Total 35-64)	35-64	F,M	0	0		R	NA
Intensive	203055_10	Opioid Intensive Outpatient or Partial Hospitalization (M 35-64)	35-64	М	0	0		R	NA
Intensive	203052_10	Opioid Intensive Outpatient or Partial Hospitalization (F 35-64)	35-64	F	0	0		R	NA
Intensive	203058_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 35-64)	35-64	F,M	0	0		R	NA
ED	202900_10	Opioid Emergency Department (M 35-64)	35-64	М	0	0		R	NA
ED	202896_10	Opioid Emergency Department (F 35-64)	35-64	F	0	0		R	NA
ED	202904_10	Opioid Emergency Department (Total 35-64)	35-64	F,M	0	0		R	NA
Outpatient	203140_10	Opioid Outpatient or Medication Treatment (M 35-64)	35-64	М	0	0		R	NA
Outpatient	203136_10	Opioid Outpatient or Medication Treatment (F 35-64)	35-64	F	0	0		R	NA
Outpatient	203144_10	Opioid Outpatient or Medication Treatment (Total 35-64)	35-64	F,M	0	0		R	NA
Telehealth	203236_10	Opioid Telehealth (M 35-64)	35-64	М	0	0		R	NA
Telehealth	203232_10	Opioid Telehealth (F 35-64)	35-64	F	0	0		R	NA
Telehealth	203240_10	Opioid Telehealth (Total 35-64)	35-64	F,M	0	0		R	NA
Any	202816_10	Opioid Any Service (M 65+)	65+	М	0	0		R	NA
Any	202812_10	Opioid Any Service (F 65+)	65+	F	0	0		R	NA
Any	202820_10	Opioid Any Service (Total 65+)	65+	F,M	0	0		R	NA
Inpatient	202992_10	Opioid Inpatient (M 65+)	65+	м	0	0		R	NA
Inpatient	202989_10	Opioid Inpatient (F 65+)	65+	F	0	0		R	NA
Inpatient	202995_10	Opioid Inpatient (Total 65+)	65+	F,M	0	0		R	NA
Intensive	203064_10	Opioid Intensive Outpatient or Partial Hospitalization (M 65+)	65+	м	0	0		R	NA
Intensive	203061_10	Opioid Intensive Outpatient or Partial Hospitalization (F 65+)	65+	F	0	0		R	NA
Intensive	203067_10	Opioid Intensive Outpatient or Partial Hospitalization (Total 65+)	65+	F,M	0	0		R	NA
ED	202912_10	Opioid Emergency Department (M 65+)	65+	м	0	0		R	NA
ED	202908_10	Opioid Emergency Department (F 65+)	65+	F	0	0		R	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Ago	Gender	MemberMonths	MemberCount	Pato	AuditDesignation	Status
			Age		IVIEITIDELIVIOITUIS	weinbercount	nate	AuditDesignation	_
ED	202916_10	Opioid Emergency Department (Total 65+)	65+	F,M	0	0		R	NA
Outpatient	203152_10	Opioid Outpatient or Medication Treatment (M 65+)	65+	M	0	0		R	NA
Outpatient	203148_10	Opioid Outpatient or Medication Treatment (F 65+)	65+	F	0	0		R	NA
Outpatient	203156_10	Opioid Outpatient or Medication Treatment (Total 65+)	65+	F,M	0	0		R	NA
Telehealth	203248_10	Opioid Telehealth (M 65+)	65+	M	0	0		R	NA
Telehealth	203244_10	Opioid Telehealth (F 65+)	65+	F	0	0		R	NA
Telehealth	203252_10	Opioid Telehealth (Total 65+)	65+	F,M	0	0		R	NA
Any	202840_10	Opioid Any Service (M Unknown)	Unknown	M	0	0		R	NA
Any	202836_10	Opioid Any Service (F Unknown)	Unknown	F	0	0		R	NA
Any	202844_10	Opioid Any Service (Total Unknown)	Unknown	F,M	0	0		R	NA
Inpatient	203010_10	Opioid Inpatient (M Unknown)	Unknown	M	0	0		R	NA
Inpatient	203007_10	Opioid Inpatient (F Unknown)	Unknown	F	0	0		R	NA
Inpatient	203013_10	Opioid Inpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Intensive	203082_10	Opioid Intensive Outpatient or Partial Hospitalization (M Unknown)	Unknown	M	0	0		R	NA
Intensive	203079_10	Opioid Intensive Outpatient or Partial Hospitalization (F Unknown)	Unknown	F	0	0		R	NA
Intensive	203085_10	Opioid Intensive Outpatient or Partial Hospitalization (Total Unknown)	Unknown	F,M	0	0		R	NA
ED	202936_10	Opioid Emergency Department (M Unknown)	Unknown	M	0	0		R	NA
ED	202932_10	Opioid Emergency Department (F Unknown)	Unknown	F	0	0		R	NA
ED	202940_10	Opioid Emergency Department (Total Unknown)	Unknown	F,M	0	0		R	NA
Outpatient	203176_10	Opioid Outpatient or Medication Treatment (M Unknown)	Unknown	М	0	0		R	NA
Outpatient	203172_10	Opioid Outpatient or Medication Treatment (F Unknown)	Unknown	F	0	0		R	NA
Outpatient	203180_10	Opioid Outpatient or Medication Treatment (Total Unknown)	Unknown	F,M	0	0		R	NA
Telehealth	203272_10	Opioid Telehealth (M Unknown)	Unknown	м	0	0		R	NA
Telehealth	203268_10	Opioid Telehealth (F Unknown)	Unknown	F	0	0		R	NA
Telehealth	203276_10	Opioid Telehealth (Total Unknown)	Unknown	F,M	0	0		R	NA
Any	202828_10	Opioid Any Service (M Total)	Total	М	173827	26	0.18	R	R
Any	202824_10	Opioid Any Service (F Total)	Total	F	164437	36	0.26	R	R
Any	202832_10	Opioid Any Service (Total)	Total	F,M	338264	62	0.22	R	R
Inpatient	203001_10	Opioid Inpatient (M Total)	Total	М	173827	7	0.05	R	R
Inpatient	202998_10	Opioid Inpatient (F Total)	Total	F	164437	6	0.04	R	R
Inpatient	203004_10	Opioid Inpatient (Total)	Total	F,M	338264	13	0.05	R	R
Intensive	203073_10	Opioid Intensive Outpatient or Partial Hospitalization (M Total)	Total	М	173827	0	0.00	R	R
Intensive	203070_10	Opioid Intensive Outpatient or Partial Hospitalization (F Total)	Total	F	164437	1	0.01	R	R
Intensive	203076_10	Opioid Intensive Outpatient or Partial Hospitalization (Total)	Total	F,M	338264	1	0.00	R	R
ED	202924_10	Opioid Emergency Department (M Total)	Total	М	173827	3	0.02	R	R
ED	202920_10	Opioid Emergency Department (F Total)	Total	F	164437	5	0.04	R	R
ED	202928_10	Opioid Emergency Department (Total)	Total	F,M	338264	8	0.03	R	R
Outpatient	203164_10	Opioid Outpatient or Medication Treatment (M Total)	Total	М	173827	15	0.10	R	R
Outpatient	203160_10	Opioid Outpatient or Medication Treatment (F Total)	Total	F	164437	25	0.18	R	R
Outpatient	203168_10	Opioid Outpatient or Medication Treatment (Total)	Total	F,M	338264	40	0.14	R	R
Telehealth	203260_10	Opioid Telehealth (M Total)	Total	М	173827	5	0.03	R	R
Telehealth	203256_10	Opioid Telehealth (F Total)	Total	F	164437	2	0.01	R	R
Telehealth	203264_10	Opioid Telehealth (Total)	Total	F,M	338264	7	0.02	R	R
Any	202757_10	Other Any Service (M 0-12)	0-12	М	103936	43	0.50	R	R
Any	202753_10	Other Any Service (F 0-12)	0-12	F	94829	23	0.29	R	R
Any	202761_10	Other Any Service (Total 0-12)	0-12	F,M	198765	66	0.40	R	R
Inpatient	202948_10	Other Inpatient (M 0-12)	0-12	М	103936	2	0.02	R	R
Inpatient	202945_10	Other Inpatient (F 0-12)	0-12	F	94829	4	0.05	R	R
Inpatient	202951_10	Other Inpatient (Total 0-12)	0-12	F,M	198765	6	0.04	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey	IndicatorName	Age	Gender					
		-		MemberMonths	MemberCount		AuditDesignation	Status
-	Other Intensive Outpatient or Partial Hospitalization (M 0-12)	0-12	М	103936	0	0.00	R	R
203017_10	Other Intensive Outpatient or Partial Hospitalization (F 0-12)	0-12	F	94829	0	0.00	R	R
203023_10	Other Intensive Outpatient or Partial Hospitalization (Total 0-12)	0-12	F,M	198765	0	0.00	R	R
-			М		2		R	R
-			F		3		R	R
-		-			5		R	R
203093_10		-	М		*.		R	R
203089_10		-	F				R	R
203097_10	Other Outpatient or Medication Treatment (Total 0-12)	-	F,M	198765	-		R	R
203189_10	Other Telehealth (M 0-12)	0-12	М	103936	10	-	R	R
203185_10	Other Telehealth (F 0-12)	0-12	F	94829	3	0.04	R	R
203193_10	Other Telehealth (Total 0-12)	0-12	F,M	198765	-	0.08	R	R
202769_10	Other Any Service (M 13-17)	13-17	м	51051	347	8.16	R	R
202765_10	Other Any Service (F 13-17)	13-17	F	48307	229	5.69	R	R
202773_10	Other Any Service (Total 13-17)	13-17	F,M	99358	576	6.96	R	R
202957_10	Other Inpatient (M 13-17)	13-17	М	51051	61	1.43	R	R
202954_10	Other Inpatient (F 13-17)	13-17	F	48307	79	1.96	R	R
202960_10	Other Inpatient (Total 13-17)	13-17	F,M	99358	140	1.69	R	R
203029_10	Other Intensive Outpatient or Partial Hospitalization (M 13-17)	13-17	М	51051	4	0.09	R	R
203026_10	Other Intensive Outpatient or Partial Hospitalization (F 13-17)	13-17	F	48307	3	0.07	R	R
203032_10	Other Intensive Outpatient or Partial Hospitalization (Total 13-17)	13-17	F,M	99358	7	0.08	R	R
202865_10	Other Emergency Department (M 13-17)	13-17	М	51051	45	1.06	R	R
202861 10	Other Emergency Department (F 13-17)	13-17	F	48307	44	1.09	R	R
202869_10	Other Emergency Department (Total 13-17)	13-17	F,M	99358	89	1.07	R	R
203105 10	Other Outpatient or Medication Treatment (M 13-17)	13-17	М	51051	241	5.66	R	R
203101 10	Other Outpatient or Medication Treatment (F 13-17)	13-17	F	48307	114	2.83	R	R
203109 10	Other Outpatient or Medication Treatment (Total 13-17)	13-17	F,M	99358	355	4.29	R	R
203201 10	Other Telehealth (M 13-17)	13-17	M	51051	119	2.80	R	R
203197 10		13-17	F	48307	65	1.61	R	R
203205_10	Other Telehealth (Total 13-17)	13-17	F,M	99358	184	2.22	R	R
		18-24	M		104	6.67	R	R
—		-	F				R	R
-		-	F.M		-	-	B	R
-		-	M		44	2.82	R	R
—			F				B	R
-			F.M				R	R
-		-	M		7		B	R
-			F		4		R	R
-			F M		11		B	R
-		-	,				B	R
-		-	F				B	R
-			E M				R	R
-			,				R	R
		-	F				R	R
-		-	E M				R	R
-		-					P	D
-							P	D
-		-	F M			-	D	D
203217_10 202793 10	Other Any Service (M 25-34)	25-34	F,M M	139	23	0.88 25.90	n D	NA
	02853_10 02853_10 02849_10 03093_10 03097_10 03189_10 03189_10 03189_10 03189_10 03189_10 03189_10 03189_10 03189_10 03197_10 02765_10 02773_10 02957_10 02957_10 0329_10 03029_10 03026_10 03029_10 03026_10 0332_10 02861_10 02869_10 03105_10 03101_10 03102_10 03101_10 03101_10 03101_10 03101_10	22853_10 Other Emergency Department (M 0-12) 02849_10 Other Emergency Department (F 0-12) 02857_10 Other Compartment (Total 0-12) 03093_10 Other Outpatient or Medication Treatment (M 0-12) 03089_10 Other Outpatient or Medication Treatment (Total 0-12) 03189_10 Other Outpatient or Medication Treatment (Total 0-12) 03189_10 Other Telehealth (F 0-12) 03185_10 Other Telehealth (F 0-12) 03185_10 Other Telehealth (F 0-12) 03185_10 Other Any Service (N 13-17) 02765_10 Other Any Service (Total 13-17) 02773_10 Other Inpatient (M 13-17) 02960_10 Other Intensive Outpatient or Partial Hospitalization (M 13-17) 03029_10 Other Intensive Outpatient or Partial Hospitalization (M 13-17) 03026_10 Other Intensive Outpatient or Partial Hospitalization (Total 13-17) 03026_10 Other Emergency Department (M 13-17) 02861_10 Other Emergency Department (Total 13-17) 02861_10 Other Emergency Department (Total 13-17) 03026_10 Other Emergency Department (Total 13-17) 02861_10 Other Emergency Department (Total 13-1	0 Other Emergency Department (M 0-12) 0-12 02859_10 Other Emergency Department (F 0-12) 0-12 02857_10 Other Emergency Department (F 0-12) 0-12 03093_10 Other Outpatient or Medication Treatment (M 0-12) 0-12 03097_10 Other Outpatient or Medication Treatment (F 0-12) 0-12 03097_10 Other Outpatient or Medication Treatment (Total 0-12) 0-12 03189_10 Other Telehealth (M 0-12) 0-12 03189_10 Other Any Service (H 13-17) 13-17 02769_10 Other Any Service (G 13-17) 13-17 02757_10 Other Inpatient (F 13-17) 13-17 03029_10 Other Inpatient (F 0-13) 13-17 03020_10 Other Intensive Outpatient or Partial Hospitalization (M 13-17) 13-17 030210 Other Intensive Outpatient or Partial Hospitalization (Total 13-17) 13-17 03025_10 Other Emergency Department (M 13-17) <	02853_10 Other Emergency Department (M 0-12) 0-12 M 02845_10 Other Emergency Department (F 0-12) 0-12 F,M 03093_10 Other Outpatient or Medication Treatment (M 0-12) 0-12 F,M 03093_10 Other Outpatient or Medication Treatment (F 0-12) 0-12 F,M 03097_10 Other Outpatient or Medication Treatment (F 0-12) 0-12 F,M 03185_10 Other Telehealth (M 0-12) 0-12 F,M 03193_10 Other Telehealth (M 0-12) 0-12 F,M 02765_10 Other Any Service (F 0-12) 0-12 F,M 02775_10 Other Any Service (F 13-17) 13-17 F,M 02954_10 Other Inpatient (M 13-17) 13-17 F,M 03026_10 Other Inpatient (Total 13-17) 13-17 F,M 03026_10 Other Intensive Outpatient or Partial Hospitalization (M 13-17) 13-17 F,M 03032_10 Other Intensive Outpatient or Partial Hospitalization (F 13-17) 13-17 F,M 03026_10 Other Intensive Outpatient or Partial Hospitalization (F 13-17) 13-17 F,M	02855_10 Other Emergency Department (M 0-12) 0-12 M 103936 02849_10 Other Emergency Department (F0-12) 0-12 F. M 198765 03093_10 Other Outpatient or Medication Treatment (N 0-12) 0-12 F. M 198765 03093_10 Other Outpatient or Medication Treatment (F0-12) 0-12 F. M 198765 03093_10 Other Outpatient or Medication Treatment (Total 0-12) 0-12 F. M 198765 03189_10 Other Telehealth (M 0-12) 0-12 F. M 198765 03191_10 Other Telehealth (M 0-12) 0-12 F. M 198765 03191_10 Other Telehealth (M 0-12) 0-12 F. M 198765 03191_10 Other Any Service (F13-17) 13-17 F. M 48307 02765_10 Other Any Service (F13-17) 13-17 F. M 48307 02854_10 Other Inpatient (F13-17) 13-17 F. M 48307 02854_10 Other Intensive Outpatient or Partial Hospitalization (F13-17) 13-17 F. M 49315 03025_10	2283.10 Other Emergency Department (M 0.12) 0.12 M 193393 2 22849.10 Other Emergency Department (Total 0-12) 0.12 F.M 198765 5 20287.10 Other Margency Department (Total 0-12) 0.12 F.M 198765 5 20287.10 Other Outpattent or Medication Treatment (Total 0-12) 0.12 F. 9429 15 20309.10 Other Outpattent or Medication Treatment (Total 0-12) 0.12 F. 9429 15 20309.10 Other Telebealth (Fo.12) 0.12 F. 9429 3 20318.10 Other Telebealth (Fo.12) 0.12 F. 9429 3 20276.10 Other Any Service (M 3.17) 13.17 M 51051 347 20276.10 Other Any Service (M 3.17) 13.17 F.M 9308 160 20276.10 Other Any Service (M 3.17) 13.17 F.M 9308 161 20276.10 Other Interstve Outpattent or Partial Hospitalization (M 13.17) 13.17 F.M 9307 44	Diff Other framsgrov Department [V 01-2] D12 M 19196. 2 0.04 D2849.10 Other Framsgrov, Department [V 01-2] D12 F.M 198765. S D03 D2857.10 Other Construct or Medication Treatment (M 0-2) D-12 F.M 198765. S D03 D3089.10 Other Construct or Medication Treatment (F 0-12) D-12 F.M 198755. S.2 D.31 D3089.10 Other Construct or Medication Treatment (F 0-12) D-12 F.M 198755. S.2 D.32 D3089.10 Other Teibehalth (F 0-12) D-12 F.M 198755. D.32 D.32 D3389.10 Other Ary Service (Total 0-12) D-12 F.M 198755. D.33 D.04 D2759.10 Other Ary Service (Total 1-317) D-12 F.M 198755. D.30 D.42 F.M 9358. S.76 6.66 D2759.10 Other Ary Service (Total 1-317) D.317 F.M 9358. D.40 D.40 D.40 D.40 D.40 D.40<	Dists incomengency Department (PO-12)PO-12PAPAH2

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Any	202789 10	Other Any Service (F 25-34)	25-34	F	287	1	4.18	R	NA
Any	202797 10	Other Any Service (Total 25-34)	25-34	F,M	426	4	11.27	B	R
Inpatient	202975 10	Other Inpatient (M 25-34)	25-34	M	139	1	8.63	R	NA
Inpatient	202972 10	Other Inpatient (F 25-34)	25-34	F	287	0	0.00	R	NA
Inpatient	202978_10	Other Inpatient (Total 25-34)	25-34	F,M	426	1	2.82	R	R
Intensive	203047 10	Other Intensive Outpatient or Partial Hospitalization (M 25-34)	25-34	M	139	0	0.00	B	NA
Intensive	203044 10	Other Intensive Outpatient or Partial Hospitalization (F 25-34)	25-34	F	287	0	0.00	R	NA
Intensive	203050 10	Other Intensive Outpatient or Partial Hospitalization (Total 25-34)	25-34	F,M	426	0	0.00	R	R
ED	202889 10	Other Emergency Department (M 25-34)	25-34	M	139	1	8.63	R	NA
ED	202885 10	Other Emergency Department (F 25-34)	25-34	F	287	1	4.18	B	NA
ED	202893 10	Other Emergency Department (Total 25-34)	25-34	F,M	426	2	5.63	R	R
Outpatient	203129 10	Other Outpatient or Medication Treatment (M 25-34)	25-34	M	139	1	8.63	R	NA
Outpatient	203125 10	Other Outpatient or Medication Treatment (F 25-34)	25-34	F	287	1	4.18	R	NA
Outpatient	203133 10	Other Outpatient or Medication Treatment (Total 25-34)	25-34	F,M	426	2	5.63	R	R
Telehealth	203225 10	Other Telehealth (M 25-34)	25-34	M	139	0	0.00	R	NA
Telehealth	203221 10	Other Telehealth (F 25-34)	25-34	F	287	0	0.00	R	NA
Telehealth	203229 10	Other Telehealth (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Any	202805 10	Other Any Service (M 35-64)	35-64	M	0	0		R	NA
Any	202801 10	Other Any Service (F 35-64)	35-64	F	0	0		R	NA
Any	202809 10	Other Any Service (Total 35-64)	35-64	F.M	0	0		B	NA
Inpatient	202984 10	Other Inpatient (M 35-64)	35-64	M	0	0		R	NA
Inpatient	202981 10	Other Inpatient (F 35-64)	35-64	F	0	0		R	NA
Inpatient	202987 10	Other Inpatient (Total 35-64)	35-64	F,M	0	0		B	NA
Intensive	203056 10	Other Intensive Outpatient or Partial Hospitalization (M 35-64)	35-64	M	0	0		R	NA
Intensive	203053 10	Other Intensive Outpatient or Partial Hospitalization (F 35-64)	35-64	F	0	0		R	NA
Intensive	203059 10	Other Intensive Outpatient or Partial Hospitalization (Total 35-64)	35-64	F.M	0	0		R	NA
ED	202901 10	Other Emergency Department (M 35-64)	35-64	M	0	0		R	NA
ED	202897 10	Other Emergency Department (F 35-64)	35-64	F	0	0		R	NA
ED	202905 10	Other Emergency Department (Total 35-64)	35-64	F.M	0	0		R	NA
Outpatient	203141 10	Other Outpatient or Medication Treatment (M 35-64)	35-64	M	0	0		B	NA
Outpatient	203137 10	Other Outpatient or Medication Treatment (F 35-64)	35-64	F	0	0		R	NA
Outpatient	203145 10	Other Outpatient or Medication Treatment (Total 35-64)	35-64	F,M	0	0		R	NA
Telehealth	203237 10	Other Telehealth (M 35-64)	35-64	M	0	0		R	NA
Telehealth	203233_10	Other Telehealth (F 35-64)	35-64	F	0	0		B	NA
Telehealth	203241_10	Other Telehealth (Total 35-64)	35-64	F,M	0	0		R	NA
Any	202817 10	Other Any Service (M 65+)	65+	M	0	0		R	NA
Any	202813 10	Other Any Service (F 65+)	65+	F	0	0		R	NA
Any	202821 10	Other Any Service (Total 65+)	65+	F,M	0	0		R	NA
Inpatient	202993 10	Other Inpatient (M 65+)	65+	M	0	0		R	NA
Inpatient	202990 10	Other Inpatient (F 65+)	65+	F	0	0		B	NA
Inpatient	202996 10	Other Inpatient (Total 65+)	65+	F,M	0	0		R	NA
Intensive	203065 10	Other Intensive Outpatient or Partial Hospitalization (M 65+)	65+	M	0	0		R	NA
Intensive	203062 10	Other Intensive Outpatient or Partial Hospitalization (F 65+)	65+	F	0	0		R	NA
Intensive	203068 10	Other Intensive Outpatient of Partial Hospitalization (Fost)	65+	F,M	0	0		R	NA
ED	202913 10	Other Emergency Department (M 65+)	65+	M	0	0		R	NA
ED	202909 10	Other Emergency Department (F 65+)	65+	F	0	0		R	NA
ED	202917_10	Other Emergency Department (Total 65+)	65+	F,M	0	0		R	NA
Outpatient	203153 10	Other Outpatient or Medication Treatment (M 65+)	65+	M	0	0		R	NA
Outpatient	203149 10	Other Outpatient of Medication Treatment (N 657)	65+		0	0		P	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Catagory		IndicatorNama	100	Gender	MomborMonths	MomborCount	Pata	AuditDesignation	Status
	IndicatorKey	IndicatorName	Age		MemberMonths	MemberCount	nale	AuditDesignation	
Outpatient	203157_10	Other Outpatient or Medication Treatment (Total 65+)	65+	F,M	0	0		R	NA
Telehealth	203249_10	Other Telehealth (M 65+)	65+	M	0	0		R	NA
Telehealth	203245_10	Other Telehealth (F 65+)	65+	F	0	0		R	NA
Telehealth	203253_10	Other Telehealth (Total 65+)	65+	F,M	0	0		R	NA
Any	202841_10	Other Any Service (M Unknown)	Unknown	M	0	0		R	NA
Any	202837_10	Other Any Service (F Unknown)	Unknown	F	0	0		R	NA
Any	202845_10	Other Any Service (Total Unknown)	Unknown	F,M	0	0		R	NA
Inpatient	203011_10	Other Inpatient (M Unknown)	Unknown	M	0	0		R	NA
Inpatient	203008_10	Other Inpatient (F Unknown)	Unknown	F	0	0		R	NA
Inpatient	203014_10	Other Inpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Intensive	203083_10	Other Intensive Outpatient or Partial Hospitalization (M Unknown)	Unknown	M	0	0		R	NA
Intensive	203080_10	Other Intensive Outpatient or Partial Hospitalization (F Unknown)	Unknown	F	0	0		R	NA
Intensive	203086_10	Other Intensive Outpatient or Partial Hospitalization (Total Unknown)	Unknown	F,M	0	0		R	NA
ED	202937_10	Other Emergency Department (M Unknown)	Unknown	M	0	0		R	NA
ED	202933_10	Other Emergency Department (F Unknown)	Unknown	F	0	0		R	NA
ED	202941_10	Other Emergency Department (Total Unknown)	Unknown	F,M	0	0		R	NA
Outpatient	203177_10	Other Outpatient or Medication Treatment (M Unknown)	Unknown	м	0	0		R	NA
Outpatient	203173_10	Other Outpatient or Medication Treatment (F Unknown)	Unknown	F	0	0		R	NA
Outpatient	203181_10	Other Outpatient or Medication Treatment (Total Unknown)	Unknown	F,M	0	0		R	NA
Telehealth	203273_10	Other Telehealth (M Unknown)	Unknown	М	0	0		R	NA
Telehealth	203269_10	Other Telehealth (F Unknown)	Unknown	F	0	0		R	NA
Telehealth	203277_10	Other Telehealth (Total Unknown)	Unknown	F,M	0	0		R	NA
Any	202829_10	Other Any Service (M Total)	Total	Μ	173827	497	3.43	R	R
Any	202825_10	Other Any Service (F Total)	Total	F	164437	360	2.63	R	R
Any	202833_10	Other Any Service (Total)	Total	F,M	338264	857	3.04	R	R
Inpatient	203002_10	Other Inpatient (M Total)	Total	Μ	173827	108	0.75	R	R
Inpatient	202999_10	Other Inpatient (F Total)	Total	F	164437	115	0.84	R	R
Inpatient	203005_10	Other Inpatient (Total)	Total	F,M	338264	223	0.79	R	R
Intensive	203074_10	Other Intensive Outpatient or Partial Hospitalization (M Total)	Total	Μ	173827	11	0.08	R	R
Intensive	203071_10	Other Intensive Outpatient or Partial Hospitalization (F Total)	Total	F	164437	7	0.05	R	R
Intensive	203077_10	Other Intensive Outpatient or Partial Hospitalization (Total)	Total	F,M	338264	18	0.06	R	R
ED	202925_10	Other Emergency Department (M Total)	Total	Μ	173827	95	0.66	R	R
ED	202921_10	Other Emergency Department (F Total)	Total	F	164437	90	0.66	R	R
ED	202929_10	Other Emergency Department (Total)	Total	F,M	338264	185	0.66	R	R
Outpatient	203165_10	Other Outpatient or Medication Treatment (M Total)	Total	Μ	173827	309	2.13	R	R
Outpatient	203161_10	Other Outpatient or Medication Treatment (F Total)	Total	F	164437	174	1.27	R	R
Outpatient	203169_10	Other Outpatient or Medication Treatment (Total)	Total	F,M	338264	483	1.71	R	R
Telehealth	203261_10	Other Telehealth (M Total)	Total	м	173827	145	1.00	R	R
Telehealth	203257_10	Other Telehealth (F Total)	Total	F	164437	81	0.59	R	R
Telehealth	203265_10	Other Telehealth (Total)	Total	F,M	338264	226	0.80	R	R
Any	202758_10	Total Any Service (M 0-12)	0-12	м	103936	51	0.59	R	R
Any	202754_10	Total Any Service (F 0-12)	0-12	F	94829	26	0.33	R	R
Any	202762_10	Total Any Service (Total 0-12)	0-12	F,M	198765	77	0.46	R	R
Inpatient	201378_20	Total Inpatient (M 0-12)	0-12	М	103936	5	0.06	R	R
Inpatient	201377_20	Total Inpatient (F 0-12)	0-12	F	94829	6	0.08	R	R
Inpatient	201379_20	Total Inpatient (Total 0-12)	0-12	F,M	198765	11	0.07	R	R
Intensive	201402_20	Total Intensive Outpatient or Partial Hospitalization (M 0-12)	0-12	М	103936	0	0.00	R	R
Intensive	201401_20	Total Intensive Outpatient or Partial Hospitalization (F 0-12)	0-12	F	94829	0	0.00	R	R
Intensive	201403_20	Total Intensive Outpatient or Partial Hospitalization (Total 0-12)	0-12	F,M	198765	0	0.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
ED	202854 10	Total Emergency Department (M 0-12)	0-12	м	103936	3	0.03	R	R
ED	202850 10	Total Emergency Department (F 0-12)	0-12	F	94829	3	0.04	R	R
ED	202858 10	Total Emergency Department (Total 0-12)	0-12	F.M	198765	6	0.04	R	R
Outpatient	203094 10	Total Outpatient or Medication Treatment (M 0-12)	0-12	M	103936	41	0.47	R	R
Outpatient	203090 10	Total Outpatient or Medication Treatment (F 0-12)	0-12	F	94829	16	0.20	R	R
Outpatient	203098 10	Total Outpatient or Medication Treatment (Total 0-12)	0-12	F,M	198765	57	0.34	R	R
Telehealth	203190 10	Total Telehealth (M 0-12)	0-12	M	103936	10	0.12	R	R
Telehealth	203186 10	Total Telehealth (F 0-12)	0-12	F	94829	3	0.04	R	R
Telehealth	203194 10	Total Telehealth (Total 0-12)	0-12	F,M	198765	13	0.08	R	R
Any	202770 10	Total Any Service (M 13-17)	13-17	м	51051	360	8.46	R	R
Any	202766_10	Total Any Service (F 13-17)	13-17	F	48307	248	6.16	R	R
Any	202774_10	Total Any Service (Total 13-17)	13-17	F,M	99358	608	7.34	R	R
Inpatient	201381_20	Total Inpatient (M 13-17)	13-17	М	51051	64	1.50	R	R
Inpatient	201380_20	Total Inpatient (F 13-17)	13-17	F	48307	83	2.06	R	R
Inpatient	201382_20	Total Inpatient (Total 13-17)	13-17	F,M	99358	147	1.78	R	R
Intensive	201405_20	Total Intensive Outpatient or Partial Hospitalization (M 13-17)	13-17	м	51051	5	0.12	R	R
Intensive	201404_20	Total Intensive Outpatient or Partial Hospitalization (F 13-17)	13-17	F	48307	3	0.07	R	R
Intensive	201406_20	Total Intensive Outpatient or Partial Hospitalization (Total 13-17)	13-17	F,M	99358	8	0.10	R	R
ED	202866_10	Total Emergency Department (M 13-17)	13-17	м	51051	53	1.25	R	R
ED	202862_10	Total Emergency Department (F 13-17)	13-17	F	48307	46	1.14	R	R
ED	202870_10	Total Emergency Department (Total 13-17)	13-17	F,M	99358	99	1.20	R	R
Outpatient	203106_10	Total Outpatient or Medication Treatment (M 13-17)	13-17	м	51051	247	5.81	R	R
Outpatient	203102_10	Total Outpatient or Medication Treatment (F 13-17)	13-17	F	48307	134	3.33	R	R
Outpatient	203110_10	Total Outpatient or Medication Treatment (Total 13-17)	13-17	F,M	99358	381	4.60	R	R
Telehealth	203202_10	Total Telehealth (M 13-17)	13-17	М	51051	124	2.91	R	R
Telehealth	203198_10	Total Telehealth (F 13-17)	13-17	F	48307	68	1.69	R	R
Telehealth	203206_10	Total Telehealth (Total 13-17)	13-17	F,M	99358	192	2.32	R	R
Any	202782_10	Total Any Service (M 18-24)	18-24	М	18701	111	7.12	R	R
Any	202778_10	Total Any Service (F 18-24)	18-24	F	21014	121	6.91	R	R
Any	202786_10	Total Any Service (Total 18-24)	18-24	F,M	39715	232	7.01	R	R
Inpatient	201384_20	Total Inpatient (M 18-24)	18-24	М	18701	45	2.89	R	R
Inpatient	201383_20	Total Inpatient (F 18-24)	18-24	F	21014	35	2.00	R	R
Inpatient	201385_20	Total Inpatient (Total 18-24)	18-24	F,M	39715	80	2.42	R	R
Intensive	201408_20	Total Intensive Outpatient or Partial Hospitalization (M 18-24)	18-24	м	18701	7	0.45	R	R
Intensive	201407_20	Total Intensive Outpatient or Partial Hospitalization (F 18-24)	18-24	F	21014	5	0.29	R	R
Intensive	201409_20	Total Intensive Outpatient or Partial Hospitalization (Total 18-24)	18-24	F,M	39715	12	0.36	R	R
ED	202878_10	Total Emergency Department (M 18-24)	18-24	м	18701	57	3.66	R	R
ED	202874_10	Total Emergency Department (F 18-24)	18-24	F	21014	49	2.80	R	R
ED	202882_10	Total Emergency Department (Total 18-24)	18-24	F,M	39715	106	3.20	R	R
Outpatient	203118_10	Total Outpatient or Medication Treatment (M 18-24)	18-24	м	18701	34	2.18	R	R
Outpatient	203114_10	Total Outpatient or Medication Treatment (F 18-24)	18-24	F	21014	49	2.80	R	R
Outpatient	203122_10	Total Outpatient or Medication Treatment (Total 18-24)	18-24	F,M	39715	83	2.51	R	R
Telehealth	203214_10	Total Telehealth (M 18-24)	18-24	м	18701	16	1.03	R	R
Telehealth	203210_10	Total Telehealth (F 18-24)	18-24	F	21014	13	0.74	R	R
Telehealth	203218_10	Total Telehealth (Total 18-24)	18-24	F,M	39715	29	0.88	R	R
Any	202794_10	Total Any Service (M 25-34)	25-34	М	139	3	25.90	R	NA
Any	202790_10	Total Any Service (F 25-34)	25-34	F	287	1	4.18	R	NA
Any	202798_10	Total Any Service (Total 25-34)	25-34	F,M	426	4	11.27	R	R
Inpatient	201387_20	Total Inpatient (M 25-34)	25-34	М	139	1	8.63	R	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Inpatient	201386 20	Total Inpatient (F 25-34)	25-34	F	287	0	0.00	R	NA
Inpatient	201388 20	Total Inpatient (Total 25-34)	25-34	F,M	426	1	2.82	R	R
Intensive	201411 20	Total Intensive Outpatient or Partial Hospitalization (M 25-34)	25-34	M	139	0	0.00	R	NA
Intensive	201410 20	Total Intensive Outpatient or Partial Hospitalization (F 25-34)	25-34	F	287	0	0.00	R	NA
Intensive	201412_20	Total Intensive Outpatient or Partial Hospitalization (Total 25-34)	25-34	F,M	426	0	0.00	R	R
ED	202890 10	Total Emergency Department (M 25-34)	25-34	M	139	1	8.63	R	NA
ED	202886 10	Total Emergency Department (F 25-34)	25-34	F	287	1	4.18	R	NA
ED	202894_10	Total Emergency Department (Total 25-34)	25-34	F,M	426	2	5.63	R	R
Outpatient	203130_10	Total Outpatient or Medication Treatment (M 25-34)	25-34	м	139	1	8.63	R	NA
Outpatient	203126_10	Total Outpatient or Medication Treatment (F 25-34)	25-34	F	287	2	8.36	R	NA
Outpatient	203134_10	Total Outpatient or Medication Treatment (Total 25-34)	25-34	F,M	426	3	8.45	R	R
Telehealth	203226_10	Total Telehealth (M 25-34)	25-34	м	139	0	0.00	R	NA
Telehealth	203222_10	Total Telehealth (F 25-34)	25-34	F	287	0	0.00	R	NA
Telehealth	203230_10	Total Telehealth (Total 25-34)	25-34	F,M	426	0	0.00	R	R
Any	202806_10	Total Any Service (M 35-64)	35-64	м	0	0		R	NA
Any	202802_10	Total Any Service (F 35-64)	35-64	F	0	0		R	NA
Any	202810_10	Total Any Service (Total 35-64)	35-64	F,M	0	0		R	NA
Inpatient	201390_20	Total Inpatient (M 35-64)	35-64	м	0	0		R	NA
Inpatient	201389_20	Total Inpatient (F 35-64)	35-64	F	0	0		R	NA
Inpatient	201391_20	Total Inpatient (Total 35-64)	35-64	F,M	0	0		R	NA
Intensive	201414_20	Total Intensive Outpatient or Partial Hospitalization (M 35-64)	35-64	м	0	0		R	NA
Intensive	201413_20	Total Intensive Outpatient or Partial Hospitalization (F 35-64)	35-64	F	0	0		R	NA
Intensive	201415_20	Total Intensive Outpatient or Partial Hospitalization (Total 35-64)	35-64	F,M	0	0		R	NA
ED	202902_10	Total Emergency Department (M 35-64)	35-64	м	0	0		R	NA
ED	202898_10	Total Emergency Department (F 35-64)	35-64	F	0	0		R	NA
ED	202906_10	Total Emergency Department (Total 35-64)	35-64	F,M	0	0		R	NA
Outpatient	203142_10	Total Outpatient or Medication Treatment (M 35-64)	35-64	Μ	0	0		R	NA
Outpatient	203138_10	Total Outpatient or Medication Treatment (F 35-64)	35-64	F	0	0		R	NA
Outpatient	203146_10	Total Outpatient or Medication Treatment (Total 35-64)	35-64	F,M	0	0		R	NA
Telehealth	203238_10	Total Telehealth (M 35-64)	35-64	Μ	0	0		R	NA
Telehealth	203234_10	Total Telehealth (F 35-64)	35-64	F	0	0		R	NA
Telehealth	203242_10	Total Telehealth (Total 35-64)	35-64	F,M	0	0		R	NA
Any	202818_10	Total Any Service (M 65+)	65+	Μ	0	0		R	NA
Any	202814_10	Total Any Service (F 65+)	65+	F	0	0		R	NA
Any	202822_10	Total Any Service (Total 65+)	65+	F,M	0	0		R	NA
Inpatient	201393_20	Total Inpatient (M 65+)	65+	Μ	0	0		R	NA
Inpatient	201392_20	Total Inpatient (F 65+)	65+	F	0	0		R	NA
Inpatient	201394_20	Total Inpatient (Total 65+)	65+	F,M	0	0		R	NA
Intensive	201417_20	Total Intensive Outpatient or Partial Hospitalization (M 65+)	65+	М	0	0		R	NA
Intensive	201416_20	Total Intensive Outpatient or Partial Hospitalization (F 65+)	65+	F	0	0		R	NA
Intensive	201418_20	Total Intensive Outpatient or Partial Hospitalization (Total 65+)	65+	F,M	0	0		R	NA
ED	202914_10	Total Emergency Department (M 65+)	65+	М	0	0		R	NA
ED	202910_10	Total Emergency Department (F 65+)	65+	F	0	0		R	NA
ED	202918_10	Total Emergency Department (Total 65+)	65+	F,M	0	0		R	NA
Outpatient	203154_10	Total Outpatient or Medication Treatment (M 65+)	65+	М	0	0		R	NA
Outpatient	203150_10	Total Outpatient or Medication Treatment (F 65+)	65+	F	0	0		R	NA
Outpatient	203158_10	Total Outpatient or Medication Treatment (Total 65+)	65+	F,M	0	0		R	NA
Telehealth	203250_10	Total Telehealth (M 65+)	65+	М	0	0		R	NA
Telehealth	203246_10	Total Telehealth (F 65+)	65+	F	0	0		R	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

	IndicatorKev	IndicatorName	100	Gender	MemberMonths	MemberCount	Pata	AuditDesignation	Status
Category			Age		wemberwonuns	WemberCount	кате	AuditDesignation	
Telehealth	203254_10	Total Telehealth (Total 65+)	65+	F,M	0	0		R	NA
Any	202842_10	Total Any Service (M Unknown)	Unknown	М	0	0		R	NA
Any	202838_10	Total Any Service (F Unknown)	Unknown	F	0	0		R	NA
Any	202846_10	Total Any Service (Total Unknown)	Unknown	F,M	0	0		R	NA
Inpatient	201399_20	Total Inpatient (M Unknown)	Unknown	м	0	0		R	NA
Inpatient	201398_20	Total Inpatient (F Unknown)	Unknown	F	0	0		R	NA
Inpatient	201400_20	Total Inpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Intensive	201423_20	Total Intensive Outpatient or Partial Hospitalization (M Unknown)	Unknown	М	0	0		R	NA
Intensive	201422_20	Total Intensive Outpatient or Partial Hospitalization (F Unknown)	Unknown	F	0	0		R	NA
Intensive	201424_20	Total Intensive Outpatient or Partial Hospitalization (Total Unknown)	Unknown	F,M	0	0		R	NA
ED	202938_10	Total Emergency Department (M Unknown)	Unknown	М	0	0		R	NA
ED	202934_10	Total Emergency Department (F Unknown)	Unknown	F	0	0		R	NA
ED	202942_10	Total Emergency Department (Total Unknown)	Unknown	F,M	0	0		R	NA
Outpatient	203178_10	Total Outpatient or Medication Treatment (M Unknown)	Unknown	М	0	0		R	NA
Outpatient	203174_10	Total Outpatient or Medication Treatment (F Unknown)	Unknown	F	0	0		R	NA
Outpatient	203182_10	Total Outpatient or Medication Treatment (Total Unknown)	Unknown	F,M	0	0		R	NA
Telehealth	203274_10	Total Telehealth (M Unknown)	Unknown	М	0	0		R	NA
Telehealth	203270_10	Total Telehealth (F Unknown)	Unknown	F	0	0		R	NA
Telehealth	203278_10	Total Telehealth (Total Unknown)	Unknown	F,M	0	0		R	NA
Any	202830_10	Total Any Service (M Total)	Total	М	173827	525	3.62	R	R
Any	202826 10	Total Any Service (F Total)	Total	F	164437	396	2.89	R	R
Any	202834_10	Total Any Service (Total)	Total	F,M	338264	921	3.27	R	R
Inpatient	201396_20	Total Inpatient (M Total)	Total	М	173827	115	0.79	R	R
Inpatient	201395_20	Total Inpatient (F Total)	Total	F	164437	124	0.90	R	R
Inpatient	201397_20	Total Inpatient (Total)	Total	F,M	338264	239	0.85	R	R
Intensive	201420 20	Total Intensive Outpatient or Partial Hospitalization (M Total)	Total	М	173827	12	0.08	R	R
Intensive	201419_20	Total Intensive Outpatient or Partial Hospitalization (F Total)	Total	F	164437	8	0.06	R	R
Intensive	201421 20	Total Intensive Outpatient or Partial Hospitalization (Total)	Total	F,M	338264	20	0.07	R	R
ED	202926 10	Total Emergency Department (M Total)	Total	М	173827	114	0.79	R	R
ED	202922 10	Total Emergency Department (F Total)	Total	F	164437	99	0.72	R	R
ED	202930 10	Total Emergency Department (Total)	Total	F,M	338264	213	0.76	R	R
Outpatient	203166 10	Total Outpatient or Medication Treatment (M Total)	Total	M	173827	323	2.23	R	R
Outpatient	203162 10	Total Outpatient or Medication Treatment (F Total)	Total	F	164437	201	1.47	R	R
Outpatient	203170 10	Total Outpatient or Medication Treatment (Total)	Total	F,M	338264	524	1.86	R	R
Telehealth	203262 10	Total Telehealth (M Total)	Total	M	173827	150	1.04	R	R
Telehealth	203258 10	Total Telehealth (F Total)	Total	F	164437	84	0.61	R	R
Telehealth	203266 10	Total Telehealth (Total)	Total	F,M	338264	234	0.83	B	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Catagoria		to direct a shirt as a		Canalan	Manual autor autor	Manula and annual	Data		Chatter
Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount		AuditDesignation	Status
Any	201882_20	Any Service (M 0-12)	0-12	Μ	103936	4055	46.82	R	R
Any	201881_20	Any Service (F 0-12)	0-12	F	94829	3368	42.62	R	R
Any	201883_20	Any Service (Total 0-12)	0-12	F,M	198765	7423	44.81	R	R
Inpatient	201900_20	Inpatient (M 0-12)	0-12	М	103936	161	1.86	R	R
Inpatient	201899_20	Inpatient (F 0-12)	0-12	F	94829	129	1.63	R	R
Inpatient	201901_20	Inpatient (Total 0-12)	0-12	F,M	198765	290	1.75	R	R
Intensive	201918_20	Intensive Outpatient or Partial Hospitalization (M 0-12)	0-12	М	103936	24	0.28	R	R
Intensive	201917_20	Intensive Outpatient or Partial Hospitalization (F 0-12)	0-12	F	94829	10	0.13	R	R
Intensive	201919_20	Intensive Outpatient or Partial Hospitalization (Total 0-12)	0-12	F,M	198765	34	0.21	R	R
ED	203298_10	Emergency Department (M 0-12)	0-12	М	103936	1	0.01	R	R
ED	203297_10	Emergency Department (F 0-12)	0-12	F	94829	1	0.01	R	R
ED	203299_10	Emergency Department (Total 0-12)	0-12	F,M	198765	2	0.01	R	R
Outpatient	203316_10	Outpatient (M 0-12)	0-12	М	103936	3655	42.20	R	R
Outpatient	203315_10	Outpatient (F 0-12)	0-12	F	94829	3040	38.47	R	R
Outpatient	203317_10	Outpatient (Total 0-12)	0-12	F,M	198765	6695	40.42	R	R
Telehealth	203334_10	Telehealth (M 0-12)	0-12	М	103936	2653	30.63	R	R
Telehealth	203333_10	Telehealth (F 0-12)	0-12	F	94829	2179	27.57	R	R
Telehealth	203335_10	Telehealth (Total 0-12)	0-12	F,M	198765	4832	29.17	R	R
Any	201885_20	Any Service (M 13-17)	13-17	М	51051	2574	60.50	R	R
Any	201884_20	Any Service (F 13-17)	13-17	F	48307	2381	59.15	R	R
Any	201886_20	Any Service (Total 13-17)	13-17	F,M	99358	4955	59.84	R	R
Inpatient	201903_20	Inpatient (M 13-17)	13-17	М	51051	287	6.75	R	R
Inpatient	201902_20	Inpatient (F 13-17)	13-17	F	48307	436	10.83	R	R
Inpatient	201904_20	Inpatient (Total 13-17)	13-17	F,M	99358	723	8.73	R	R
Intensive	201921_20	Intensive Outpatient or Partial Hospitalization (M 13-17)	13-17	М	51051	24	0.56	R	R
Intensive	201920_20	Intensive Outpatient or Partial Hospitalization (F 13-17)	13-17	F	48307	54	1.34	R	R
Intensive	201922_20	Intensive Outpatient or Partial Hospitalization (Total 13-17)	13-17	F,M	99358	78	0.94	R	R
ED	203301_10	Emergency Department (M 13-17)	13-17	м	51051	2	0.05	R	R
ED	203300 10	Emergency Department (F 13-17)	13-17	F	48307	0	0.00	R	R
ED	203302 10	Emergency Department (Total 13-17)	13-17	F,M	99358	2	0.02	R	R
Outpatient	203319_10	Outpatient (M 13-17)	13-17	М	51051	2372	55.76	R	R
Outpatient	203318_10	Outpatient (F 13-17)	13-17	F	48307	2172	53.95	R	R
Outpatient	203320_10	Outpatient (Total 13-17)	13-17	F,M	99358	4544	54.88	R	R
Telehealth	203337_10	Telehealth (M 13-17)	13-17	М	51051	1787	42.01	R	R
Telehealth	203336_10	Telehealth (F 13-17)	13-17	F	48307	1717	42.65	R	R
Telehealth	203338 10	Telehealth (Total 13-17)	13-17	F,M	99358	3504	42.32	R	R
Any	201888 20	Any Service (M 18-64)	18-64	M	18840	442	28.15	R	R
Any	201887 20	Any Service (F 18-64)	18-64	F	21301	467	26.31	R	R
Any	201889 20	Any Service (Total 18-64)	18-64	F,M	40141	909	27.17	R	R
, Inpatient	201906 20	Inpatient (M 18-64)	18-64	M	18840	84	5.35	R	R
Inpatient	201905 20	Inpatient (F 18-64)	18-64	F	21301	76	4.28	R	R
Inpatient	201907 20	Inpatient (Total 18-64)	18-64	F,M	40141	160	4.78	R	R
Intensive	201924_20	Intensive Outpatient or Partial Hospitalization (M 18-64)	18-64	M	18840	17	1.08	R	R
Intensive	201923 20	Intensive Outpatient or Partial Hospitalization (H 10 0 1)	18-64	F	21301	15	0.85	R	R
Intensive	201925 20	Intensive Outpatient or Partial Hospitalization (Total 18-64)	18-64	F,M	40141	32	0.96	R	R
	203304 10	Emergency Department (M 18-64)	18-64	M	18840	10	0.64		

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
ED	203303 10	Emergency Department (F 18-64)	18-64	F	21301	8	0.45	R	R
ED	203305 10	Emergency Department (Total 18-64)	18-64	F,M	40141	18	0.54	R	R
Outpatient	203322 10	Outpatient (M 18-64)	18-64	M	18840	383	24.39	R	R
Outpatient	203321 10	Outpatient (F 18-64)	18-64	F	21301	375	21.13	R	R
Outpatient	203323 10	Outpatient (Total 18-64)	18-64	F,M	40141	758	22.66	R	R
Telehealth	203340 10	Telehealth (M 18-64)	18-64	M	18840	287	18.28	R	R
Telehealth	203339_10	Telehealth (F 18-64)	18-64	F	21301	302	17.01	R	R
Telehealth	203341 10	Telehealth (Total 18-64)	18-64	F,M	40141	589	17.61	R	R
Any	201891_20	Any Service (M 65+)	65+	M	0	0		R	NA
Any	201890 20	Any Service (F 65+)	65+	F	0	0		R	NA
Any	201892_20	Any Service (Total 65+)	65+	F,M	0	0		R	NA
Inpatient	201909 20	Inpatient (M 65+)	65+	M	0	0		R	NA
Inpatient	201908_20	Inpatient (F 65+)	65+	F	0	0		R	NA
Inpatient	201910_20	Inpatient (Total 65+)	65+	F,M	0	0		R	NA
Intensive	201927_20	Intensive Outpatient or Partial Hospitalization (M 65+)	65+	М	0	0		R	NA
Intensive	201926_20	Intensive Outpatient or Partial Hospitalization (F 65+)	65+	F	0	0		R	NA
Intensive	201928_20	Intensive Outpatient or Partial Hospitalization (Total 65+)	65+	F,M	0	0		R	NA
ED	203307_10	Emergency Department (M 65+)	65+	М	0	0		R	NA
ED	203306_10	Emergency Department (F 65+)	65+	F	0	0		R	NA
ED	203308_10	Emergency Department (Total 65+)	65+	F,M	0	0		R	NA
Outpatient	203325_10	Outpatient (M 65+)	65+	М	0	0		R	NA
Outpatient	203324_10	Outpatient (F 65+)	65+	F	0	0		R	NA
Outpatient	203326_10	Outpatient (Total 65+)	65+	F,M	0	0		R	NA
Telehealth	203343_10	Telehealth (M 65+)	65+	М	0	0		R	NA
Telehealth	203342_10	Telehealth (F 65+)	65+	F	0	0		R	NA
Telehealth	203344_10	Telehealth (Total 65+)	65+	F,M	0	0		R	NA
Any	201897_20	Any Service (M Unknown)	Unknown	М	0	0		R	NA
Any	201896_20	Any Service (F Unknown)	Unknown	F	0	0		R	NA
Any	201898_20	Any Service (Total Unknown)	Unknown	F,M	0	0		R	NA
Inpatient	201915_20	Inpatient (M Unknown)	Unknown	М	0	0		R	NA
Inpatient	201914_20	Inpatient (F Unknown)	Unknown	F	0	0		R	NA
Inpatient	201916_20	Inpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Intensive	201933_20	Intensive Outpatient or Partial Hospitalization (M Unknown)	Unknown	М	0	0		R	NA
Intensive	201932_20	Intensive Outpatient or Partial Hospitalization (F Unknown)	Unknown	F	0	0		R	NA
Intensive	201934_20	Intensive Outpatient or Partial Hospitalization (Total Unknown)	Unknown	F,M	0	0		R	NA
ED	203313_10	Emergency Department (M Unknown)	Unknown	М	0	0		R	NA
ED	203312_10	Emergency Department (F Unknown)	Unknown	F	0	0		R	NA
ED	203314_10	Emergency Department (Total Unknown)	Unknown	F,M	0	0		R	NA
Outpatient	203331_10	Outpatient (M Unknown)	Unknown	М	0	0		R	NA
Outpatient	203330_10	Outpatient (F Unknown)	Unknown	F	0	0		R	NA
Outpatient	203332_10	Outpatient (Total Unknown)	Unknown	F,M	0	0		R	NA
Telehealth	203349_10	Telehealth (M Unknown)	Unknown	М	0	0		R	NA
Telehealth	203348_10	Telehealth (F Unknown)	Unknown	F	0	0		R	NA
Telehealth	203350_10	Telehealth (Total Unknown)	Unknown	F,M	0	0		R	NA
Any	201894_20	Any Service (M Total)	Total	М	173827	7071	48.81	R	R
Any	201893_20	Any Service (F Total)	Total	F	164437	6216	45.36	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	MemberCount	Rate	AuditDesignation	Status
Any	201895_20	Any Service (Total)	Total	F,M	338264	13287	47.14	R	R
Inpatient	201912_20	Inpatient (M Total)	Total	М	173827	532	3.67	R	R
Inpatient	201911_20	Inpatient (F Total)	Total	F	164437	641	4.68	R	R
Inpatient	201913_20	Inpatient (Total)	Total	F,M	338264	1173	4.16	R	R
Intensive	201930_20	Intensive Outpatient or Partial Hospitalization (M Total)	Total	М	173827	65	0.45	R	R
Intensive	201929_20	Intensive Outpatient or Partial Hospitalization (F Total)	Total	F	164437	79	0.58	R	R
Intensive	201931_20	Intensive Outpatient or Partial Hospitalization (Total)	Total	F,M	338264	144	0.51	R	R
ED	203310_10	Emergency Department (M Total)	Total	М	173827	13	0.09	R	R
ED	203309_10	Emergency Department (F Total)	Total	F	164437	9	0.07	R	R
ED	203311_10	Emergency Department (Total)	Total	F,M	338264	22	0.08	R	R
Outpatient	203328_10	Outpatient (M Total)	Total	М	173827	6410	44.25	R	R
Outpatient	203327_10	Outpatient (F Total)	Total	F	164437	5587	40.77	R	R
Outpatient	203329_10	Outpatient (Total)	Total	F,M	338264	11997	42.56	R	R
Telehealth	203346_10	Telehealth (M Total)	Total	М	173827	4727	32.63	R	R
Telehealth	203345_10	Telehealth (F Total)	Total	F	164437	4198	30.64	R	R
Telehealth	203347_10	Telehealth (Total)	Total	F,M	338264	8925	31.66	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

MeasurementYear: 2020	

MeasurementYear: 20											
Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
AntibioticUtilization	200514_20	Average Scrips for Antibiotics PMPY (M) 0-9	0-9	м	76636		4353		0.68	R	R
AntibioticUtilization	200504_20	Average Scrips for Antibiotics PMPY (F) 0-9	0-9	F	70103		4593		0.79	R	R
AntibioticUtilization	200524_20	Average Scrips for Antibiotics PMPY (M/F) 0-9	0-9	F,M	146739		8946		0.73	R	R
AntibioticUtilization	200547_20	Average Days Supplied per Antibiotic Scrip (M) 0-9	0-9	м			4353	43857	10.08	R	R
AntibioticUtilization	200537_20	Average Days Supplied per Antibiotic Scrip (F) 0-9	0-9	F			4593	47735	10.39	R	R
AntibioticUtilization	200557_20	Average Days Supplied per Antibiotic Scrip (M/F) 0-9	0-9	F,M			8946	91592	10.24	R	R
AntibioticUtilization	200607_20	Average Scrips for Antibiotics of Concern PMPY (M) 0-9	0-9	м	76636	1831			0.29	R	R
AntibioticUtilization	200597_20	Average Scrips for Antibiotics of Concern PMPY (F) 0-9	0-9	F	70103	1900			0.33	R	R
AntibioticUtilization	200617_20	Average Scrips for Antibiotics of Concern PMPY (M/F) 0-9	0-9	F,M	146739	3731			0.31	R	R
AntibioticUtilization	200577_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 0-9	0-9	м		1831	4353		42.06	R	R
AntibioticUtilization	200567_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 0-9	0-9	F		1900	4593		41.37	R	R
AntibioticUtilization	200587 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 0-9	0-9	F,M		3731	8946		41.71	R	R
AntibioticUtilization	200515 20	Average Scrips for Antibiotics PMPY (M) 10-17	10-17	M	78351		2230		0.34	R	R
AntibioticUtilization	200505 20	Average Scrips for Antibiotics PMPY (F) 10-17	10-17	F	73033		3640		0.60	R	R
AntibioticUtilization	200525_20	Average Scrips for Antibiotics PMPY (M/F) 10-17	10-17	F,M	151384		5870		0.47	R	R
AntibioticUtilization	200548 20	Average Days Supplied per Antibiotic Scrip (M) 10-17	10-17	M			2230	26223	11.76	R	R
AntibioticUtilization	200538 20	Average Days Supplied per Antibiotic Scrip (F) 10-17	10-17	F			3640	36949	10.15	R	R
AntibioticUtilization	200558_20	Average Days Supplied per Antibiotic Scrip (M/F) 10-17	10-17	F.M			5870	63172	10.76	R	R
AntibioticUtilization	200608 20	Average Scrips for Antibiotics of Concern PMPY (M) 10-17	10-17	M	78351	782			0.12	R	R
AntibioticUtilization	200598_20	Average Scrips for Antibiotics of Concern PMPY (F) 10-17	10-17	F	73033	1201			0.20	R	R
AntibioticUtilization	200618 20	Average Scrips for Antibiotics of Concern PMPY (M/F) 10-17	10-17	F.M	151384	1983			0.16	R	R
AntibioticUtilization	200578 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 10-17	10-17	M		782	2230		35.07	R	R
AntibioticUtilization	200568_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 10-17	10-17	F		1201	3640		32.99	R	R
AntibioticUtilization	200588 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 10-17	10-17	F.M		1983	5870		33.78	R	R
AntibioticUtilization	200516_20	Average Scrips for Antibiotics PMPY (M) 18-34	18-34	M	18840	1505	573		0.36	R	R
AntibioticUtilization	200506 20	Average Scrips for Antibiotics PMPY (F) 18-34	18-34	F	21301		1898		1.07	R	R
AntibioticUtilization	200526_20	Average Scrips for Antibiotics PMPY (M/F) 18-34	18-34	F M	40141		2471		0.74	R	R
AntibioticUtilization	200549 20	Average Days Supplied per Antibiotic Scrip (M) 18-34	18-34	N4	-01-11		573	6263	10.02	P	P
AntibioticUtilization	200539_20	Average Days Supplied per Antibiotic Scrip (F) 18-34	18-34	c.			1898	14682	7.74	P	P
AntibioticUtilization	200559_20	Average Days Supplied per Antibiotic Scrip (N/F) 18-34	18-34	FM			2471	20945	8.48	R	P
AntibioticUtilization	200609 20	Average Scrips for Antibiotics of Concern PMPY (M) 18-34	18-34	N/	18840	255	24/1	20545	0.16	R	P
AntibioticUtilization	200599 20	Average Scrips for Antibiotics of Concern PMPY (F) 18-34	18-34	F	21301	617			0.35	R	R
AntibioticUtilization	200619_20	Average Scrips for Antibiotics of Concern PMPY (M/F) 18-34	18-34	F.M	40141	872			0.26	R	R
AntibioticUtilization	200579 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 18-34	18-34	M	-01-11	255	573		44.50	P	P
AntibioticUtilization	200569 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (W) 20-34 Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 18-34	18-34	E		617	1898		32.51	P	P
AntibioticUtilization	200589 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (N/18-34 Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 18-34	18-34	F.M		872	2471		35.29	P	P
AntibioticUtilization	200517 20	Average Scrips for Antibiotics PMPY (M) 35-49	35-49	NA NA	0	072	0		55.25	P	NA
AntibioticUtilization	200507_20	Average Scrips for Antibiotics PMPY (F) 35-49	35-49	E	0		0			P	NA
AntibioticUtilization	200527 20	Average Scrips for Antibiotics PMPY (M/F) 35-49	35-49	F.M	0		0			P	NA
AntibioticUtilization	200550 20	Average Days Supplied per Antibiotic Scrip (M) 35-49	35-49	1,101	0		0	8		0	NA
AntibioticUtilization	200530_20		35-49	E C			0	0		n.	NA
AntibioticUtilization	200540_20	Average Days Supplied per Antibiotic Scrip (F) 35-49 Average Days Supplied per Antibiotic Scrip (M/F) 35-49	35-49	F F.M			0	0		R	NA
AntibioticUtilization	200560_20	Average Days Supplied per Antibiotic Scrip (M/F) 35-49 Average Scrips for Antibiotics of Concern PMPY (M) 35-49	35-49	F,IVI	0	0	0	0		R	NA NA
AntibioticUtilization	200600 20	Average Scrips for Antibiotics of Concern PMPY (N) 53-49 Average Scrips for Antibiotics of Concern PMPY (F) 35-49	35-49	E C	0	0				n.	NA
AntibioticUtilization	200600_20	Average Scrips for Antibiotics of Concern PMPY (P) 35-49 Average Scrips for Antibiotics of Concern PMPY (M/F) 35-49	35-49	F F.M	0	0				R	NA
AntibioticUtilization	200520_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 35-49	35-49	F,IM M	0	0	0			R	NA
				IVI r		0	0			R	NA
AntibioticUtilization	200570_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 35-49	35-49 35-49	FM		0	0			R	NA NA
AntibioticUtilization AntibioticUtilization	200590_20 200518_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 35-49	35-49 50-64	F,M M		U	0			R	NA NA
		Average Scrips for Antibiotics PMPY (M) 50-64		M	0		0			R	NA
AntibioticUtilization	200508_20	Average Scrips for Antibiotics PMPY (F) 50-64	50-64	F	0		-			R	NA
AntibioticUtilization	200528_20	Average Scrips for Antibiotics PMPY (M/F) 50-64	50-64	F,M	0		0	-		R	NA
AntibioticUtilization	200551_20	Average Days Supplied per Antibiotic Scrip (M) 50-64	50-64	M			0	0		R	NA
AntibioticUtilization	200541_20	Average Days Supplied per Antibiotic Scrip (F) 50-64	50-64	F			0	0		R	NA
Antibioticutilization	200561_20	Average Days Supplied per Antibiotic Scrip (M/F) 50-64	50-64 50-64	r,M			U	U		R	NA
AntibioticUtilization	200611_20	Average Scrips for Antibiotics of Concern PMPY (M) 50-64	50.04	M	0	0				R	1473
AntibioticUtilization	200601_20	Average Scrips for Antibiotics of Concern PMPY (F) 50-64	50-64	r	0	U				ĸ	NA
AntibioticUtilization	200621_20	Average Scrips for Antibiotics of Concern PMPY (M/F) 50-64	50-64	F,M	0	0	•			R	NA
AntibioticUtilization	200581_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 50-64	50-64	M		0	U			R	NA
AntibioticUtilization	200571_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 50-64	50-64	F		0	0			R	NA
AntibioticUtilization	200591_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 50-64	50-64	F,M	-	0	0			R	NA
AntibioticUtilization	200519_20	Average Scrips for Antibiotics PMPY (M) 65-74	65-74	М	0		0			R	NA
AntibioticUtilization	200509_20	Average Scrips for Antibiotics PMPY (F) 65-74	65-74	F	0		0			R	NA
AntibioticUtilization	200529_20	Average Scrips for Antibiotics PMPY (M/F) 65-74	65-74	F,M	0		0			R	NA
AntibioticUtilization	200552_20	Average Days Supplied per Antibiotic Scrip (M) 65-74	65-74	М			0	0		R	NA
AntibioticUtilization	200542_20	Average Days Supplied per Antibiotic Scrip (F) 65-74	65-74	F			0	0		R	NA
AntibioticUtilization	200562_20	Average Days Supplied per Antibiotic Scrip (M/F) 65-74	65-74	F,M			0	0		R	NA
AntibioticUtilization	200612_20	Average Scrips for Antibiotics of Concern PMPY (M) 65-74	65-74	M	0	0				R	NA
AntibioticUtilization	200602_20	Average Scrips for Antibiotics of Concern PMPY (F) 65-74	65-74	F	0	0				R	NA
AntibioticUtilization	200622_20	Average Scrips for Antibiotics of Concern PMPY (M/F) 65-74	65-74	F,M	0	0				R	NA
AntibioticUtilization	200582_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 65-74	65-74	м		0	0			R	NA
AntibioticUtilization	200572_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 65-74	65-74	F		0	0			R	NA
AntibioticUtilization	200592_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 65-74	65-74	F,M		0	0			R	NA
AntibioticUtilization	200520_20	Average Scrips for Antibiotics PMPY (M) 75-84	75-84	M	0		0			R	NA
AntibioticUtilization	200510_20	Average Scrips for Antibiotics PMPY (F) 75-84	75-84	F	0		0			R	NA
AntibioticUtilization	200530_20	Average Scrips for Antibiotics PMPY (M/F) 75-84	75-84	F,M	0		0			R	NA
		• • • • • • • • • • • • • • • • • • • •				•					

MeasurementYear: 2020

Category											
	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
AntibioticUtilization	200553_20	Average Days Supplied per Antibiotic Scrip (M) 75-84	75-84	м			0	0		R	NA
AntibioticUtilization	200543_20	Average Days Supplied per Antibiotic Scrip (F) 75-84	75-84	F			0	0		R	NA
AntibioticUtilization	200563 20	Average Days Supplied per Antibiotic Scrip (M/F) 75-84	75-84	F,M			0	0		R	NA
AntibioticUtilization	200613 20	Average Scrips for Antibiotics of Concern PMPY (M) 75-84	75-84	м	0	0				R	NA
AntibioticUtilization	200603_20	Average Scrips for Antibiotics of Concern PMPY (F) 75-84	75-84	F	0	0				R	NA
AntibioticUtilization	200623 20	Average Scrips for Antibiotics of Concern PMPY (M/F) 75-84	75-84	F.M	0	0				R	NA
AntibioticUtilization	200583_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 75-84	75-84	M	0	0	0			R	NA
AntibioticUtilization	200573 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 75-84	75-84	c.		0	0			P	NA
AntibioticUtilization	200593 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (N/F) 75-84	75-84	F.M		0	0			R	NA
AntibioticUtilization	200595_20	Average Scrips for Antibiotics PMPY (M) 85+		r,ivi		0	0			n	INA
			85+	M	0		0			R	NA
AntibioticUtilization	200511_20	Average Scrips for Antibiotics PMPY (F) 85+	85+	F	0		0			R	NA
AntibioticUtilization	200531_20	Average Scrips for Antibiotics PMPY (M/F) 85+	85+	F,M	0		0			R	
AntibioticUtilization	200554_20	Average Days Supplied per Antibiotic Scrip (M) 85+	85+	м			0	0		0.	NA
AntibioticUtilization	200544_20	Average Days Supplied per Antibiotic Scrip (F) 85+	85+	F			0	0		R	NA
AntibioticUtilization	200564_20	Average Days Supplied per Antibiotic Scrip (M/F) 85+	85+	F,M			0	0		R	NA
AntibioticUtilization	200614_20	Average Scrips for Antibiotics of Concern PMPY (M) 85+	85+	м	0	0				R	NA
AntibioticUtilization	200604_20	Average Scrips for Antibiotics of Concern PMPY (F) 85+	85+	F	0	0				R	NA
AntibioticUtilization	200624 20	Average Scrips for Antibiotics of Concern PMPY (M/F) 85+	85+	F,M	0	0				R	NA
AntibioticUtilization	200584_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) 85+	85+	м		0	0			R	NA
AntibioticUtilization	200574 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) 85+	85+	F		0	0			R	NA
AntibioticUtilization	200594 20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) 85+	85+	E.M.		0	0			P	NA
AntibioticUtilization	200523 20	Average Scrips for Antibiotics PMPY (M) Unk	Unknown	1,101	0	0	0			R	NA
AntibioticUtilization	200523_20	Average Scrips for Antibiotics PMPY (M) Onk Average Scrips for Antibiotics PMPY (F) Unk		E .	0	1	0			R .	NA
			Unknown	F	0		U			ĸ	NA
AntibioticUtilization	200533_20	Average Scrips for Antibiotics PMPY (M/F) Unk	Unknown	F,M	U		U			ĸ	NA
AntibioticUtilization	200556_20	Average Days Supplied per Antibiotic Scrip (M) Unk	Unknown	М			0	0		R	NA
AntibioticUtilization	200546_20	Average Days Supplied per Antibiotic Scrip (F) Unk	Unknown	F			0	0		R	NA
AntibioticUtilization	200566_20	Average Days Supplied per Antibiotic Scrip (M/F) Unk	Unknown	F,M			0	0		R	NA
AntibioticUtilization	200616_20	Average Scrips for Antibiotics of Concern PMPY (M) Unk	Unknown	м	0	0				R	NA
AntibioticUtilization	200606_20	Average Scrips for Antibiotics of Concern PMPY (F) Unk	Unknown	F	0	0				R	NA
AntibioticUtilization	200626_20	Average Scrips for Antibiotics of Concern PMPY (M/F) Unk	Unknown	F,M	0	0				R	NA
AntibioticUtilization	200586_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Unk	Unknown	M		0	0			R	NA
AntibioticUtilization	200576_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Unk	Unknown	F		0	0			R	NA
AntibioticUtilization	200596_20	Percentage Antibiotics of Concern of All Antibiotic Scrips (I/) Onk	Unknown	E.M		0	0			R	NA
AntibioticUtilization	200530_20	Average Scrips for Antibiotics PMPY (M)	Total	1,101	173827	0	7156		0.49	R D	D D
AntibioticUtilization	200522_20	Average Scrips for Antibiotics PMPY (F)	Total	ivi	164437		10131		0.49	n	n.
				F					0.74	R	к
AntibioticUtilization	200532_20	Average Scrips for Antibiotics PMPY (M/F)	Total	F,M	338264		17287		0.61	R	R
AntibioticUtilization	200555_20	Average Days Supplied per Antibiotic Scrip (M)	Total	м			7156	76343	10.67	R	R
AntibioticUtilization	200545_20	Average Days Supplied per Antibiotic Scrip (F)	Total	F			10131	99366	9.81	R	R
AntibioticUtilization	200565_20	Average Days Supplied per Antibiotic Scrip (M/F)	Total	F,M			17287	175709	10.16	R	R
AntibioticUtilization	200615 20	Average Scrips for Antibiotics of Concern PMPY (M)	Total		173827						
			TULAI	IVI	1/302/	2868			0.20	к	R
AntibioticUtilization	200605_20	Average Scrips for Antibiotics of Concern PMPY (F)	Total	F	164437	2868 3718			0.20	R	R R
		Average Scrips for Antibiotics of Concern PMPY (F)	Total	F F,M	164437	2000			0.27	R R	R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization	200625_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F)		F F,M M		3718 6586	7156			R R R	R R R R
AntibioticUtilization AntibioticUtilization	200625_20 200585_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M)	Total Total Total	,	164437	3718 6586 2868	7156		0.27 0.23 40.08	K R R R	R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization	200625_20 200585_20 200575_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F)	Total Total Total Total	M F	164437	3718 6586 2868 3718	10131		0.27 0.23 40.08 36.70	R R R R R	R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization	200625_20 200585_20 200575_20 200595_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Oncern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F)	Total Total Total Total Total	M F F,M	164437 338264	3718 6586 2868	10131 17287		0.27 0.23 40.08 36.70 38.10	R R R R R	R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200595_20 200217_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotics Scrips (F). Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F	164437 338264 76636	3718 6586 2868 3718	10131		0.27 0.23 40.08 36.70 38.10 0.00	R R R R R R	R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200595_20 200217_20 200207_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (H) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9	Total Total Total Total Total	M F F,M M F	164437 338264 76636 70103	3718 6586 2868 3718	10131 17287 11 3		0.27 0.23 40.08 36.70 38.10	R R R R R R R R	R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200595_20 200217_20 200207_20 200227_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 0-9	Total Total Total Total Total 0-9	M F F,M	164437 338264 76636 70103 146739	3718 6586 2868 3718	10131 17287 11 3 14		0.27 0.23 40.08 36.70 38.10 0.00	N R R R R R R R R	R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOFConcern AntibioticSOFConcern AntibioticSOFConcern	200625_20 200585_20 200575_20 200595_20 200217_20 200207_20 200227_20 20025_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin Znd-4th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M M F	164437 338264 76636 70103 146739 76636	3718 6586 2868 3718	10131 17287 11 3 14 653		0.27 0.23 40.08 36.70 38.10 0.00	R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200207_20 200227_20 200027_20 200085_20 200075_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Ounolone Average Scrips PMPY (M/D-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M F F,M F,M F	164437 338264 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771		0.27 0.23 40.08 36.70 38.10 0.00	K R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOFConcern AntibioticSOFConcern AntibioticSOFConcern	200625_20 200585_20 200575_20 200595_20 200217_20 200207_20 200227_20 20025_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin Znd-4th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M M F	164437 338264 76636 70103 146739 76636	3718 6586 2868 3718	10131 17287 11 3 14 653		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12	K R R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200207_20 200227_20 200027_20 200085_20 200075_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Ounolone Average Scrips PMPY (M/D-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M F F,M F,M F	164437 338264 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771		0.27 0.23 40.08 36.70 38.10 0.00	M R R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200207_20 200227_20 200085_20 200085_20 200075_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	M F F,M F F,M F,M F	164437 338264 76636 70103 146739 76636 70103 146739	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12	K R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200207_20 200207_20 200227_20 200205_20 200005_20 200095_20 200055_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Outlondone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cophologonin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosgonin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosgonin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosgonin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosgonin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Averagion Znd-th Generation Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	M F F,M F F,M F,M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.00 0.10 0.13 0.12 0.07	M R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200227_20 200227_20 200025_20 200075_20 200075_20 200075_20 200052_20 200052_20 200042_20 200062_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihormycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin Athromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin Athromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin Athromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin Athromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin	Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	M F F,M F F,M F F,M F F,M F F F,M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 4277 427 427		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08	H R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200217_20 200227_20 200227_20 200085_20 200095_20 200095_20 200095_20 200095_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Cephalosporin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin Znd-th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin Znd-th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	F F,M F,M F,M F,M F,M F,M F,M F,M F,M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08	M R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200207_20 200227_20 200285_20 200085_20 200095_20 200095_20 200095_20 200052_20 200052_20 200052_20 200052_20 200052_20 200052_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ath	Total Total Total Total O-9 0-9	F F,M F,M F,M F,M F,M F,M F,M F,M F,M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477 932 630 555		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern AntibioticSOTConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200285 20 200075 20 200095 20 200095 20 200095 20 200095 20 200009 20 200009 20 200099 20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Anthrowycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atithromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Anoxiellin/Clavulanate Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Anoxiellin/Clavulanate Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Anoxiellin/Clavulanate Average Scrips PMPY (M/F) 0-9	Total Total Total Total Total 0-9	M F F,M M F F,M M F,F F,M M F F,M M F,M F F,M F F,M F F,M F F,M	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477 932 630		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.10 0.10 0.10	K R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200217_20 200217_20 200227_20 200227_20 200055_20 200055_20 200055_20 200055_20 200055_20 200042_20 200062_20 200062_20 20009_20 200099_20 200099_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 0-9 Antibiotics of Concern - Cephalosporin Zn-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin Zn-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin Zn-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	F,M F,M F,M F,M F,M F,M F,M F,M F F,M F F,M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477 932 630 555		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.00 0.10 0.10 0.10 0.10	M R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200095_20 20005_20005_20 20005_20000000000	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antiverage Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M M F F,M M F F,M F F,M M F F,M M F F,M M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76036 70103	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477 932 630 555		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.10 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200075 20 200075 20 200075 20 200075 20 200075 20 200072 20 200072 20 200052 20 200019 20 200019 20 200019 20 200019 20 200019 20 2000151 20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - O All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Althromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Althromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anthromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attolice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attolice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attolice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attolice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9	Total Total Total Total Total 0-9	M F F,M M F F,M M F,F F,M M F F,M M F,M F F,M F F,M F F,M F F,M	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636	3718 6586 2868 3718	10131 17287 11 3 14 653 771 1424 455 477 932 630 555		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.00 0.10 0.10 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	Я В В В В В В В В В В В В В
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200025_20 200095_20 200095_20 200095_20 200095_20 200095_20 200092_20 200092_20 200092_20 200092_20 200092_20 200151_20 200151_20 200151_20 200151_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Olimolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Co	Total Total Total Total Total Total 0-9	M F F,M M F F,M M F F,M F F,M M F F,M M F F,M M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 555 1185 0 0 0		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.08 0.10 0.10 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200025 20 200075 20 200095 20 200055 20 200052 20 200052 20 200052 20 200052 20 200059 20 200055 20 20055 20 200	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attendie Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9	Total Total Total Total Total Total 0-9	M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 70103 76636 70103 70103 76636 70103 70103 76636 70103 70100 70103 70105	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 93		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.08 0.10 0.10 0.10 0.10	M R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200025_20 200095_20 200095_20 200095_20 200095_20 200095_20 200092_20 200092_20 200092_20 200092_20 200092_20 200151_20 200151_20 200151_20 200151_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Olimolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athviet Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Co	Total Total Total Total Total Total 0-9	M F F,M M F F,M M F F,M F F,M M F F,M M F F,M M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 7014 7015	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 555 1185 0 0 0		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.08 0.10 0.10 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	R R R R R R R R R R R R R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern AntibioticSOIConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200025 20 200075 20 200095 20 200055 20 200052 20 200052 20 200052 20 200052 20 200059 20 200055 20 20055 20 200	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antihromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antice Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attendie Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9	Total Total Total Total Total Total 0-9	M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 70103 76636 70103 70103 76636 70103 70103 76636 70103 70100 70103 70105	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 93		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.08 0.10 0.10 0.10 0.10	н R R R R R R R R R R R R R	 R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200075 20 200075 20 200095 20 200095 20 200095 20 200062 20 200062 20 200092 20 200051 20 200019 20 200151 20 200151 20 200151 20 200118 20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - O All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atheolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Atholide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9	Total Total Total Total Total O-9	M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 7014 7015	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 93		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.08 0.08 0.08 0.10 0.10 0.10 0.10	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200207_20 200227_20 200227_20 200025_20 200095_20 200052_20 200052_20 200052_20 200052_20 200062_20 200062_20 200062_20 200062_20 200062_20 200105_20 200141_20 200141_20 200141_20 200141_20 200141_20 200142_20 200182_20 200182_20 200182_20 200182_20 200182_20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antibiotics and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antibiotics and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antibiotic Caulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antibiotic Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Antibicity Scrips PMPY (M) 0-9 Antibiotics of Concern - Antoxicillin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cilindamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cilindamycin Average Scrips PMPY (M) 0-9	Total Total Total Total Total Total Total Total O-9 0-9	M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F F,M F M F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 76636 76636 70103 76636 76757 76636 76757 76757 76636 767577 767577 7675777 76757777777777	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 93		0.27 0.23 40.08 36.70 38.10 0.00 0.10 0.13 0.12 0.07 0.08 0.07 0.08 0.08 0.10 0.10 0.10 0.10 0.10 0.10	M R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200075_20 200095_20 200095_20 200095_20 200042_20 200042_20 200042_20 200042_20 200092_20 200029_20 200029_20 200118_20 200110	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athrbonycin and Carthromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - AthroxicIIIn/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolid	Total Total Total Total Total Total O-9 0-9	M F F,M M F F,M F F,M F F F,M F F F,M M M F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739	3718 6586 2268 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 93		0.27 0.23 40.08 36.70 38.10 0.00 0.00 0.10 0.13 0.12 0.07 0.08 0.10 0.10 0.10 0.10 0.10 0.00 0.00	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOTConcern	200625 20 200585 20 200585 20 200595 20 200295 20 200217 20 200227 20 200227 20 200227 20 200095 20 200095 20 200095 20 200095 20 200095 20 200092 20 200092 20 20009 20 20009 20 20009 20 200019 20 20019 20 200191 20 200191 20 200118 20 200118 20 200118 20 200128 20 200194 20 200194 20 200194 20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authormycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authormycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authormycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authormycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Amoxiellin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Attibiotics of Concern - Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clandamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrip	Total Total Total Total Total Total 0-9	M F F,M M F F,M F F,M F F F,M F F F,M M M F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78551	3718 6586 2668 3718 6586	10111 17287 11 3 14 653 771 1424 455 630 555 1185 0 0 0 0 175 0 177 128 1293 121		0.27 0.23 0.23 40.08 36.70 38.10 0.00 0.00 0.00 0.10 0.12 0.03 0.12 0.03 0.12 0.03 0.10 0.10 0.10 0.10 0.10 0.00 0.00	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200075 20 200075 20 200075 20 200075 20 200075 20 200072	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Antibromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Antibromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Antibromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Antibromycin and Clarithromycin Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - AntoxicIIIIn/Clavulanate Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - AntoxicIIIIn/Clavulanate Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - AntoxicIIIIn/Clavulanate Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 0-9 Antibiotics of	Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78351 73033	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 93 175 0 1 1 21 45		0.27 0.23 36.70 0.81 0.00 0.00 0.00 0.00 0.10 0.10 0.1	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200055_20 200055_20 200055_20 200055_20 200055_20 200052_20 200052_20 200052_20 200052_20 200052_20 200052_20 200052_20 200052_20 200052_20 200118_20 200128_20 200100000000000000000000000000000000	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athotic Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Keolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibioti	Total 0.9	M F F,M M F F,M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F,M M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78551 73033 151384	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 630 555 1185 0 0 0 0 135 0 15 0 1 11 21 45 66		0.27 0.23 0.23 0.23 0.00 0.00 0.00 0.00 0.10 0.10 0.10 0.1	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOTConcern	200625 20 200585 20 200575 20 200575 20 200277 20 200277 20 200227 20 200227 20 200075 20 200095 20 200095 20 200095 20 200095 20 200092 20 200092 20 200092 20 200092 20 200092 20 200019 20 200092 20 200118 20 200118 20 200118 20 200128 20 200128 20 200218 20 200228 20 200228 20 200228 20 200228 20	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Awaithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cellolarwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Av	Total Total Total Total Total Total Total 0-9 0-17 10-17 10-17 10-17	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 73851 73033 151384 73851	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 0 0 1185 0 0 10 175 0 1 1 21 45 66 133		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.13 0.12 0.07 0.08 0.00 0.00 0.00 0.00 0.00 0.00	H R R R R R R R R R R R R R R R R R R R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200227_20 200227_20 200075_20 200095_20 200095_20 200095_20 200009_20 200009_20 200009_20 200019_20 200019_20 200151_20 200151_20 200118_20 200128_20 200218_20 200228_20 200228_20 200228_20 200008_20 200008_20 200008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_20 20008_	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Ollinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cupinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cupinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Athromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - AthroxicIIIn/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - AthroxicIIIn/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibio	Total Total Total Total Total Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76333 151384 78351 73033	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 932 630 555 1185 0 0 0 93 175 0 1 21 45 66 133 179		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.12 0.07 0.08 0.10 0.10 0.10 0.10 0.10 0.10 0.10	H R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625 20 200585 20 200585 20 200595 20 200295 20 200297 20 200227 20 200227 20 200227 20 200052 20 200051 20 200051 20 200151 20 200155 20 200155 20 20055 20 2	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Acithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Acithromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulanta Everage Scrips PMPY (M) 0-9 Antibiotics of Concern - Anoxiellin/Clavulanta Everage Scrips PMPY (M) 0-9 Antibiotics of Concern - Aktolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Clindamycin	Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-17 10-17 10-17 10-17 10-17	M F F,M M F F,M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F,M M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 73031 151384 73033 151384	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1624 455 630 555 1185 0 0 0 115 0 124 133 121 133 179 312		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.13 0.12 0.13 0.12 0.07 0.08 0.00 0.00 0.00 0.00 0.00 0.00	H R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625 20 200585 20 200575 20 200575 20 200575 20 20027 20 20027 20 20027 20 20027 20 20027 20 200075 20 200075 20 200075 20 200075 20 200075 20 200075 20 200027 20 20002 20 200019 20 200029 20 200019 20 200019 20 200118 20 200118 20 200118 20 200118 20 200128 20 200128 20 200128 20 200128 20 200128 20 20028 20 20028 20 20028 20 20028 20 20028 20 200076 20 200075 20 200075 20 200075 20 200075 20 200075 20 200075 20 200075 20 200075 20 20075 20 2	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Autoxicillin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Michard Average Scri	Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-17 10-17 10-17 10-17 10-17 10-17	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78351 73033 151384 73851 73851	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 500 555 1185 0 0 0 0 1 1 21 133 179 312 298		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.12 0.07 0.08 0.10 0.10 0.10 0.10 0.10 0.10 0.10	H R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200277_20 200227_20 200075_20 200095_20 200095_20 200095_20 200095_20 200092_20 200092_20 200092_20 200019_20 20019_20 20019_20 20019_20 200118_20 20005_20 200096_20 200090 2000090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200000 200000 200000 200000 2000000 2000000	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Aththromycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - AthoxicIIIn/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - MexicIIIn/Clavulante Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Misc Antibiotics of Concern Average Sc	Total 0.9 0.17 10.17 10.17 10.17 10.17	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78511 73033 151384 78351 73033 151384 78351 73033	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 630 555 1185 0 0 0 0 115 0 125 13 175 0 1 11 21 45 66 133 179 312 298 551		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.12 0.07 0.08 0.10 0.10 0.10 0.10 0.10 0.10 0.10	H R	R R
AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticUtilization AntibioticSOfConcern	200625_20 200585_20 200575_20 200575_20 200277_20 200277_20 200277_20 200227_20 200075_20 200095_20 200095_20 200095_20 200095_20 200092_20 200092_20 200092_20 200019_20 20019_20 20019_20 20019_20 200118_20 20005_20 200096_20 200090 2000090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200090 200000 200000 200000 200000 2000000 2000000	Average Scrips for Antibiotics of Concern PMPY (F) Average Scrips for Antibiotics of Concern PMPY (M/F) Percentage Antibiotics of Concern of All Antibiotic Scrips (M) Percentage Antibiotics of Concern of All Antibiotic Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Percentage Antibiotics of Concern of All Antibiotics Scrips (M/F) Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Caphalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin and Clarithromycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Authorwycin Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Autoxicillin/Clavulanate Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Ketolide Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Metolides of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 0-9 Antibiotics of Concern - Mick Anti	Total 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-9 0-17 10-17 10-17 10-17 10-17 10-17	M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F,M M F F F F F F F F F F F F F	164437 338264 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 76636 70103 146739 78351 73033 151384 73851 73851	3718 6586 2868 3718 6586	10131 17287 11 3 14 653 771 1424 455 477 500 555 1185 0 0 0 0 1 1 21 133 179 312 298		0.27 0.23 36.70 38.10 0.00 0.00 0.00 0.10 0.12 0.07 0.08 0.10 0.10 0.10 0.10 0.10 0.10 0.10	H R	R R

ChannelIndicationalAndCarbonMernigationalPerciga	MeasurementYear: 20			-								
matched<	Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount		PrescriptionLength	Rate	AuditDesignation	Status
MatchedyMatche					м					0.03	R	R
					F					0.05	R	R
bandom Disk of the started weak started by Disk of the started by Disk of					F,M			506			R	R
mathemmath					M			0		0.00	R	R
MathemMath					F			0		0.00	R	R
subsetmatrixmatr								0		0.00	R	R
NameNumber					M						R	ĸ
withord<					F						R	R
Index of any and part of any and part of any					F,M			243		0.02	R	R
sindiceMade dec Matrix Ma					M			4		0.00	R	R
NameN					F			3		0.00	R	R
Mathematical<				-	F,IVI			/		0.00	R	R
NameN					IVI r					0.02	R	R
member of the sectormember of the sector <th< td=""><td></td><td></td><td></td><td></td><td>F</td><td></td><td></td><td></td><td></td><td>0.03</td><td>R</td><td>R</td></th<>					F					0.03	R	R
MathemMath					F,IVI			-		0.02	R	R
InstantionMathematical discription of the Mark Mark Mark Mark Mark Mark Mark Mark					IVI r					0.01	R	R
Mathematical M					F						R	R
Matchell Matchell Matchell Matchell Matchell Matchell Matchell 											R	R
Mixed matrix Matrix <td></td> <td></td> <td></td> <td></td> <td>r ivi</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>n D</td> <td></td>					r ivi						n D	
Method ModelMethod Mark Mark Mark Mark Mark Mark Mark Mark					F E MA					0.10	n D	
Main 2000Main 2000Mathematication along into PMP (191 M)Sin 1NoNoSin 1Sin 1<					,					0.15	n D	
Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical 					IVI r					0.05	R	R
minuteminu					F					0.07	R	R
Matcade<					F,IVI			196		0.06	R	R
Mathematical solutionMathematical soluti					IVI r			0		0.00	R	R
Methode<					F			0		0.00	R	R
Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical Mathematical 	-				F,M			0		0.00	R	R
MethodMeth	-				IVI r					0.02	R	R
MethodMeth					F					0.04	R	R
Methand Metha					F,IVI			100		0.05	R	R
Makendo Method Method Method 					IVI E			1		0.00	R	R
Matheder SociesMatheder SociesMatheder Socies<					F F			1		0.00	n D	
Addex of SectorAddex of Sect						40141		1		0.00	n D	NA NA
Ambendsord1000 b1000 b					IVI r	0		0			R	NA NA
Addex of and conductor damage of MP (M) 54FF <t< td=""><td></td><td></td><td></td><td></td><td>F</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA NA</td></t<>					F	0		0			R	NA NA
Index of 2007.A balakie of cores. Capitalization bala discursto. Average Sign MPV [13:405.40600					F,IVI	0		0			R	NA NA
AdditectionObjection </td <td></td> <td></td> <td></td> <td></td> <td>IVI r</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA NA</td>					IVI r	0		0			R	NA NA
AmbienderSinderAmbiender <t< td=""><td></td><td></td><td></td><td></td><td>F</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA NA</td></t<>					F	0		0			R	NA NA
Index of ControlAnd Mathem Sol Contr					F,IVI	0		0			R	NA NA
Andersontioner Status Status <th< td=""><td></td><td></td><td></td><td></td><td>IVI r</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>1100</td></th<>					IVI r	0		0			R	1100
Antionation 20022 Antionation Annual (Computed Anerge Soft MMY (N) 13-40 34-0 M 0 0 0 0 <					F	0		0			R	1473
Athletes20012AthletesAthletesConcernAthletesSignMr(1) 35-40SignMr(1) 35-40SignMr(1) 35-40SignMr(1) 35-40Mr(1) 35-40					F,M	0		0			R	
Ambiestic ClocersAmbiestic ClocersAm					IVI r	0		0			R	1473
Andenet controlNotion <td></td> <td></td> <td></td> <td></td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td></td>					F	0		0			R	
Anderscord anderscord 					,	0		0			R	
Antibiotizionare1914 20Antibiotizi a franzen					IVI r	0		0			R	
Athlobic StormerMathlobic StormerMa					F	0		0			R	
Additional 20011.20 Multiplics of consentolignating having serging PMP (II) 35-49 35-49 F. 0 0 0 0<					.,	0		0			R	
Antibiotic/Concer 20131 20 Antibiotics of Concern - Jondamy in Average Scrips PMPY (M) 35-49 5-49 F.M 0					E E	0		0			n D	NA
AutibiotsOffConcen 200137 20 Autibiots of Concern - Mice Autibiotis of Concern Average Scrips PMP7 (M) 3-49 3-49 F.M 0 0 0 0 0 8 MA AutibiotsOffConcer 200177 20 Autibiotics of Concern - Mice Autibiotics of Concern Average Scrips PMP7 (M) 3-44 3-49 F.M 0 0 0 8 8.40 8.40 AutibiotsOffConcer 200177 20 Autibiotics of Concern - Mice A					F	0		0			R	NA NA
AntibilityConcer 2007 200 AntibilityConcer Note Antibility Concern-Mac Antibility Concern Awarge Scrips PMPY (M) 33-49 3-49 F.M 0 0 0 0 R N Antibility Concern Juntify Concern-Mac Antibility Concern-Mac Machibility Concern Awarge Scrips PMPY (M) 34-40 3-40 F.M 0 0 0 0 R N N Antibility Concern 200231.20 Antibility Concern Awarge Scrips PMPY (M) 50-44 50-44 F.M 0 0 0 0 R N N Antibility Concern 200231.20 Antibility Concern - Caphalogonin 2nd-th Generation Awarge Scrips PMPY (M) 50-44 50-44 F.M 0 0 0 0 R N N Antibility Concern 200059.20 Antibility Concern - Caphalogonin 2nd-th Generation Awarge Scrips PMPY (M) 50-44 50-44 F.M 0 0 0 0 N N N N N N N N N N N N N N N N N N <td< td=""><td></td><td></td><td></td><td></td><td>F,IVI</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA NA</td></td<>					F,IVI	0		0			R	NA NA
Antibiotis Of Concern - Nuis Antibiotis of Concern - Nuis Antibiotis of Concern - Quinolone Average Scrips PMPY (M) 50-64 55-69 F.M 0 <					IVI E	0	1	0			R D	NA
Antibiotis Oncoren - Quinolone Average Scrips PMPY (M) 50-6460-64M00<					EM	0	1	0			P	NA
Antibiotics/Concern 20021 2.0 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 50-64 50-64 F. 0 0 R NA Antibiotics/Concern 200231, 20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 R NA Antibiotics/Concern 20037, 20 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 R NA Antibiotics/Concern 20037, 20 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 R NA Antibiotics/Concern 200079, 20 Antibiotics of Concern - Antihromyrian ad Clarithromyria Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 R NA Antibiotics/Concern 200046, 20 Antibiotics of Concern - Antihromyrian ad Clarithromyrian Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 R NA Antibiotics/Concern 200012, 20 Antibiotics of Concern - Antihromyrian Average Scrips PMPY (M/F) 50-64 50-64 F.M					M	0		0			P	NA
Antibiotics/OffConcern Qu0331, 20 Antibiotics of Concern - Outploatopoin 2nd-th Generation Average Scrips PMPY (M) 50-64 S0-64 F.M 0 0 0 0 0 0 NA Antibiotics/OffConcern 20089, 20 Antibiotics of Concern - Cephalogoprin 2nd-th Generation Average Scrips PMPY (M) 50-64 50-64 F.O 0 0 0 R NA Antibiotics/OffConcern 20099, 20 Antibiotics of Concern - Cephalogoprin 2nd-th Generation Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 R NA Antibiotics/OffConcern 20009, 20 Antibiotics of Concern - Antithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA Antibiotics/OffConcern 20004, 20 Antibiotics of Concern - Antithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA Antibiotics/OffConcern 20004, 20 Antibiotics of Concern - Antithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA Antibiotics/OffConcern 20013, 20				50.04	F	0	1	0			R	1973
Antibiotics of Concern - Cephalogonin 2nd-4th Generation Average Scrips PMPY (M) 50-6450-64F00					F.M	0	1	0			R	
Antibiotics of Concern - Cephalosponia 2nd-4th Generation Average Scrips PMPY (f) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Concern - Cephalosponia 2nd-4th Generation Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Concern - Astithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 8 NA Antibiotics of Concern - Astithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 8 NA Antibiotics of Concern - Astithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Concern - Antibiotics of Concern - Antional Clarithromycin and Clarithromycin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Concern - Annoxillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Concern - Annoxillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 8 NA Antibiotics of Conce						0	1	0			P	
Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 0 0 0 8 MA Antibiotics of Concern - Asithmonycin and Clarithmonycin Average Scrips PMPY (M/F) 50-64 50-64 F.M 0					C .	0	1	0			P	
AntibioticsOfConcer200056_20Antibiotics of Concern - Attithromycin and Clarithromycin Average Scrips PMPY (M) 50-6450-64F000 <td></td> <td></td> <td></td> <td></td> <td>EM</td> <td>0</td> <td>1</td> <td>0</td> <td> </td> <td></td> <td>P</td> <td></td>					EM	0	1	0			P	
Antibiotics OfConcern - Altibiony and Clarithromy in a					.,	0		0			n D	
AntibioticsOffice20062.0Antibiotics of concert - Antionity in and Carithramy in and Ca					IVI r	0		0			R	
AntibioticsOfConcern 20023_20 Antibiotics of Concern - Amoskillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 0 R NA Antibiotics Of Concern - Amoskillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R R NA Antibiotics Of Concern - Amoskillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R R NA Antibiotics Of Concern - Amoskillin/Clavulanate Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R R NA Antibiotics Of Concern - Ketolide Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R R NA Antibiotics Of Concern - Ketolide Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R NA Antibiotics Of Concern - Ketolide Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA Antibiotics Of Concern - Clindamycin Average Scrips PMPY (M) 50-64 50-64 F 0 0 <					F	0		0			R	NA
Antibiotics of Concern - Amoskillin/Clavulanate Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 0 R NA Antibiotics of Concern - Amoskillin/Clavulanate Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 0 R NA Antibiotics of Concern - Amoskillin/Clavulanate Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 0 R NA NA Antibiotics of Concern - Ketolide Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 R NA NA Antibiotics of Concern - Ketolide Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 R NA NA Antibiotics of Concern - Ketolide Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 0 R NA NA Antibiotics of Concern - Clindamycin Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 R NA NA Antibiotics of Concern - Clindamycin Average Scrips PMPY ([F) 50-64 50-64 F.M 0 0 0 R NA NA					F,IVI	0		0			R	NA
Antibiotics of Concern 20033_20 Antibiotics of Concern - Amode Clinity (Lavulanate Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 0 0 0 R NA Antibiotics of Concern 20015_20 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 50-64 50-64 M 0 0 0 R NA Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA NA Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R R NA Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R R NA Antibiotics of Concern - Clindawycin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R R NA Antibiotics of Concern - Clindawycin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R R NA Antibiotics of Concern - Misc Antibiotics of Concern - Misc Antibiotics of Concern - Clindawycin Average Scrips PMPY (M/F) 50-64 50-64 <					IV1	0	1	0			R D	NA
Antibiotics Of Concern - Ketolide Average Scrips PMPY (M) 50-64 50-64 F. 0 0 0 0 0 8 NA Antibiotics Of Concern - Ketolide Average Scrips PMPY (M) 50-64 50-64 F. 0					Г Г М	0	1	0			R D	NA
Antibiotics Of Concern - Vetabilité Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 0 0 0 NA Antibiotics Of Concern - Vetabilité Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Vetabilité Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Clindamycin Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Clindamycin Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Clindamycin Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Clindamycin Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Misc Antibiotics of Concern Average Scrips PMPY (h) 50-64 50-64 F 0 0 0 8 NA Antibiotics Of Concern - Misc Antibiotics of					r,IVI	0		0			n	NA NA
AntibioticsOfConcern 200165_20 Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 0 0 R NA AntibioticsOfConcern 200122_20 Antibiotics of Concern - Cindamycin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA AntibioticsOfConcern 200122_20 Antibiotics of Concern - Cindamycin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA AntibioticsOfConcern 20012_20 Antibiotics of Concern - Cindamycin Average Scrips PMPY (N/F) 50-64 50-64 F 0 0 R NA AntibioticsOfConcern 20013_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 50-64 50-64 F 0 0 R R NA AntibioticsOfConcern 20013_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA AntibioticsOfConcern 20013_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 50-64 50-64 F 0 0 <td></td> <td></td> <td></td> <td></td> <td>IVI</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>110</td>					IVI	0		0			R	110
AntibioticsOfConcer 2012_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 0 0 MA AntibioticsOfConcer 200112_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 0 0 0 MA NA AntibioticsOfConcer 20013_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 0 0 0 0 NA AntibioticsOf Concern - Silos Antibiotics of Concern - Misc Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 50-64 50-64 FM 0 0 0 0 0 0 NA Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 50-64 50-64 M 0<					r	U		U			ĸ	
Antibiotics Of Concern 20112_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY ([9]: 50-64 50-64 F.M 0 0 0 8 NA Antibiotics Of Concern 20013_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY ([M]: 50-64 50-64 F.M 0 0 0 8 NA Antibiotics Of Concern 2018_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY ([M]: 50-64 50-64 F.M 0 0 0 8 MA Antibiotics Of Concern - Misc Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY ([S]: 50-64 50-64 F 0 0 0 8 MA					F,M	U		U			ĸ	1473
AntibioticsOffConcern 200132_00 Antibiotics of Concern - Clindarycin Average Scrips PMPY (M); 50-64 50-64 F.M 0.4 0					M	U		U			ĸ	
Antibilities Of Concern 20188_20 Antibilities of Concern - Misc Antibilities of Concern Average Scrips PMPY (M) 50-64 50-64 M 0 0 R NA Antibilities of Concern - Misc Antibilities of Concern Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA					r	U		U			ĸ	
Antibiotics Of Concern - Misc Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (F) 50-64 50-64 F. 0 Concern - Misc Antibiotics of Co					,	U		U			ĸ	
					M	U		U			ĸ	
Antibiotics of Longern – Mise Antibi					r	U		U			ĸ	NA
	AntibioticsUfConcern	200198_20	Anuplotics of Concern - Misc Antipiotics of Concern Average Scrips PMPY (M/F) 50-64	50-64	r,M	U	I	U			ĸ	NA

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

DetermMaterialAreDerivMaterial <th< th=""><th>MeasurementYear: 2</th><th>2020</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></th<>	MeasurementYear: 2	2020										
Mathematical Mathematical Marked Astronome Astron	Category	IndicatorKev	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
Deba Deba <t< td=""><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td>· · ••••• · · • • • • · · · 8•••</td><td></td><td>p</td><td>NA</td></t<>						0		0	· · ••••• · · • • • • · · · 8•••		p	NA
NameN					r.	0		0			2	110
DescriptionDescripti					F	0		-			R	INA
Depindent <td></td> <td></td> <td></td> <td></td> <td>F,M</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>					F,M	0		0			R	NA
MathemMath					м	0		0			R	NA
MathemMath	AntibioticsOfConcern				F	0		0			n	INA
MulticolitiesMulticolities: Advances index ind	AntibioticsOfConcern		Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) 65-74		F,M	0		0			R	100
NumberNumb	AntibioticsOfConcern	200057_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) 65-74	65-74	м	0		0			R	NA
DependenceDescriptionDescriptin	AntibioticsOfConcern	200047_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (F) 65-74	65-74	F	0		0			R	NA
DependenceDescriptionDescriptin	AntibioticsOfConcern	200067 20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M/F) 65-74	65-74	F.M	0		0			R	NA
Number of the state of the					M	0		0			R	NA
Mathema in the sector of th					C.	0		0			R.	
Mathef with a start of the					F	0		-			R	190
Mindsoff order. Samitary is a More is More is More is More is A sectorA is A is					.,	0		0			ĸ	
Discord D					м	0		0			R	NA
Mathematical matrix and print	AntibioticsOfConcern	200146_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (F) 65-74	65-74	F	0		0			R	NA
ImageMind	AntibioticsOfConcern	200166_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 65-74	65-74	F,M	0		0			R	NA
ImageMind	AntibioticsOfConcern	200123 20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 65-74	65-74	м	0		0			R	NA
SectorSect	AntibioticsOfConcern	200113 20		65-74	F	0		0			R	NA
Michael MartingMichael Martin					EM	0		0			P	NA
NameNote 300Note 300 </td <td></td> <td></td> <td></td> <td></td> <td>1,101</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>2</td> <td>110</td>					1,101	0		0			2	110
Delay Solution Delay Solution Delay Solution Sol					M	0		-			R	INA
NameN	randbioticsorconcern			0574	F	0		0			R	1100
NameN					F,M	0		0			R	1473
Anise of ControlNotice of ControlNo	AntibioticsOfConcern	200223_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (M) 75-84	75-84	м	0		0			R	NA
Anise of ControlNotice of ControlNo	AntibioticsOfConcern	200213_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 75-84	75-84	F	0		0			R	NA
Method ColumMethod ColumnColumn State					F.M	0		0			R	NA
DebuscherSolar, JournelSolar, JournelJourn					.,	0		0			R	
Index controlNomeNomeNomeNomeNomeNomeNomeNomeNomeNomeNo					r.	0		0			2	
Index of 2000Mode of 2000					F	0		-			R	INA
Debug Debug <th< td=""><td></td><td></td><td></td><td>75.04</td><td>1,00</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></th<>				75.04	1,00	0		0			R	NA
AuthorNote 2Note	AntibioticsOfConcern				м	0		0			R	NA
Actional Mathema SectorModels of Sector<	AntibioticsOfConcern	200048_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (F) 75-84	75-84	F	0		0			R	NA
Additional of and an additional damage into phyme (1)7-347.447.447.407.000<	AntibioticsOfConcern	200068_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M/F) 75-84	75-84	F,M	0		0			R	NA
Additional of and an additional damage into phyme (1)7-347.447.447.407.000<	AntibioticsOfConcern	200025 20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M) 75-84	75-84	м	0		0			R	NA
Index controlNomeNomeNomeNo <th< td=""><td>-</td><td></td><td></td><td>75-94</td><td>c</td><td>0</td><td></td><td>0</td><td></td><td></td><td>P</td><td>NA</td></th<>	-			75-94	c	0		0			P	NA
IndexidencySintyMindex decome-inductange ingramm (n) TableTableTable00					EM	0		0			P	NA
Debits Control District					F,IVI	0		0	-		n	1473
nebbox Displ. Motion of coress. Transport (mp MM 7):54 Pi-4 M I I <					м	0		0			ĸ	1473
Indication 2011,3 Matheway forum Matheway forum <td></td> <td></td> <td></td> <td></td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td></td>					F	0		0			R	
Instituctofficure2014.3Antibities of Concer Contange is for pAPPI (1)7-547-64700	AntibioticsOfConcern	200167_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) 75-84		F,M	0		0			R	NA
Indebaction 2011 J. J. Addects former: Including is Named Stop NPUT ID 75 4 7.4 V 0 0 0 0 <	AntibioticsOfConcern	200124_20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) 75-84	75-84	м	0		0			R	NA
Indebaction 2011 J. J. Addects former: Including is Named Stop NPUT ID 75 4 7.4 V 0 0 0 0 <	AntibioticsOfConcern	200114 20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (F) 75-84	75-84	F	0		0			R	NA
Industry Models of Concert. Name Analysis of Concert. Naman Analysis of Concert. Naman Analysis of Concert.				75-84	F.M	0		0			R	NA
Interface No.10 Attables of Coursen-Ause, along Inp MPI (1):54 7.46 7.0 0 0 0 0 0 0 Distlocat/Coursen 20020 J.20 Attables of Coursen-Ause, along MPI (1):54 7.46 7.40 0 0 0					,	0		0			P	NA
Intersection 2000, 20 Antipact of Concent - Marce Answergs Scipp MMPY (M) 79.44 7.4 M 0 0					r.	0		0			2	110
Intellistication 20212 June Antibiots of Contern - Quancine Average Strips PMP (1) B5+ B5 M 0 0 0 0 <td></td> <td></td> <td></td> <td></td> <td>F</td> <td>0</td> <td></td> <td>-</td> <td></td> <td></td> <td>R</td> <td>INA</td>					F	0		-			R	INA
Intellistic/Core 2014 J.2 Antibutics of Consern - Candidows Average Scips IMPV (1) B3- B3- F.A 0 0 0 B A Roblestic/Consern 20234 J.2 Antibutics of Consern - Candidows Average Scips IMPV (1) B3- B3- KA 0 0 8 A A Roblestic/Consern 20032 J.2 Antibutics of Consern - Candidows are spics IMPV (1) B3- B3+ KA 0 0 8 A A Roblestic/Consern 20032 J.2 Antibutics of Consern - Candidows are spics IMPV (1) B3+ B3+ KA 0 0 0 0 0 A <				75-84	F,M	0		0			R	NA
Intellistic/Concer 2024 /r Artibitics of Concern - Capital open 2-artis Scient PMV (M) B5+ 54 M 0 0 1 6 M Intellistics Concern 20092 /r Artibitics of Concern - Capital open 2-artis Scient PMV (M) B5+ 54 M 0 0 8 Match Intellistics Concern 20012 /r Artibitics of Concern - Capital open 2-artis Scient PMV (M) B5+ 55 F/A 0 0 8 Match Match 6 Match Match 8 Match Match Match 8 Match Match Match 8 Match Match 8 Match Match 8 Match Match <td></td> <td></td> <td></td> <td>85+</td> <td>м</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>				85+	м	0		0			R	NA
Intelligency Concerner 20082 20 Antibiology Concerner 65-m M 0 0 0 8 NA Numbers/Goncerner 20082 Antibiology Concerner Charlingen Concerner Singen Conce	AntibioticsOfConcern	200214_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (F) 85+	85+	F	0		0			R	NA
Intellistic/Concer2008_2.0Antibicity ConcernCybaloganian ConternCybaloganian Co	AntibioticsOfConcern	200234_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 85+	85+	F,M	0		0			R	NA
Inhibitical/Concer 2002.2.0 Anbiditics of Concern - Capabasgoni 204-UN (parent Antrage Scipp PMPY (M) 35 55 F.M 0 0 0 8 MA Inhibitics of Concern - Capabasgoni 244-UN contern - Capabasgoni 244-UN contern - Antrage Scipp PMPY (M) 35 54 M 0 0 0 8 MA Inhibitics of Concern - Attremy (na Cultitrony (na Arcage Scipp PMPY (M) 35+ 54 F 0 0 0 8 MA Inhibitics of Concern - Attremy (na Cultitrony (na Arcage Scipp PMPY (M) 35+ 54 F 0 0 0 8 MA Inhibitics of Concern - Antremy (na Cultitrony (na Arcage Scipp PMPY (M) 35+ 54 M 0 0 0 8 MA Inhibitics of Concern - Ancell (Chanaltan Arcage Scipp PMPY (M) 35+ 54 M 0 0 0 8 MA Inhibitics of Concern - Ancell (Chanaltan Arcage Scipp PMPY (M) 35+ 54 F 0 0 0 0 8 MA Inhibitics of Concern - Ancell (Chanaltan Arcage Scipp PMPY (M) 35+ 54 F 0 0 0 0	AntibioticsOfConcern	200092 20		85+	м	0		0			R	NA
Intellistic of Concern Analysis of Concern <td></td> <td></td> <td></td> <td>85+</td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>				85+	F	0		0			R	NA
Intelestics Construction Authority and Cultiformy Average Scips MPV (M) B5+ S1+ M 0 0 0 0 8 MA Antibiotics Construction Authority and Cultiformy Average Scips MPV (M) B5+ S1+ IA 0				95+	EM	0		0			P	NA
Intellistication Mathebits of Consern - Akthronych and Carthronych Average Scips PMPY (M) 78x 8% P 0 0 0 0 8 NA Attibitist Of Consern - Akthronych and Carthronych Average Scips PMPY (M) 78x 8% M 0 0 0 8 NA Attibitist Of Consern - Akthronych and Carthronych Average Scips PMPY (M) 78x 8% M 0 0 8 NA Attibitist Of Consern - Akthronych and Carthronych Average Scips PMPY (M) 78x 8% M 0 0 8 NA Attibitist Of Consern - Akthronych Average Scips PMPY (M) 78x 8% F 0 0 8 NA Attibitist Of Consern - Kettlide Average Scips PMPY (M) 78x 8% F 0 0 0 8 NA Attibitist Of Consern - Kettlide Average Scips PMPY (M) 78x 8% F 0 0 0 8 NA Attibitist Of Consern - Kettlide Average Scips PMPY (M) 78x 8% M 0 0 0 8 NA Attibitist Of Consern - Kettlide Average Scips PMPY (M) 78x 8% M					1,101	0		0			2	1473
Institució/Concent 2008/2 0.0 Antibiotics of Concent - Antibingts of Concent - Antibingts Sorgis PMPY (M S ⁺) S ⁺ F.M 0 0 0 0 8 MA Antibiotics Of Concent - Antibioti					M	0		-			R	
Antibiotics/Officient 20036, 20 Antibiotics of Concern - Anonsellin/(Calvalanta Average Scipps PMPY (M) 55- 55- M 0 0 0 0 0 0 NA Antibiotics/Officient 20036, 20 Antibiotics of Concern - Anonsellin/(Calvalanta Average Scipps PMPY (M) 55+ 55- F.M 0					F	0		0			R	
Antibicis/Cliconer 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 20016. 20 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td></td></t<>						0		0			R	
Antibicito/Clorent 20038.2 00 Antibicitor Clorent Antibicitor Clorent 85+ F.M 0 0 0 0<	AntibioticsOfConcern	200026_20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M) 85+	85+	м	0		0			R	NA
Antibicito/Clorent 20038.2 00 Antibicitor Clorent Antibicitor Clorent 85+ F.M 0 0 0 0<	AntibioticsOfConcern	200016_20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (F) 85+	85+	F	0		0			R	NA
Antibiotics/Concern Antibiotics of Concern-Netabile Average Scrips PMPY (M) BS+ BF M O O O B B B Antibiotics/Concern 2018 8.00 Antibiotics of Concern-Netabile Average Scrips PMPY (M/F) BS+ BS+ F,M O O O B B B A Antibiotics/Concern 2018 8.00 Antibiotics of Concern-Clindamy in Average Scrips PMPY (M/F) BS+ BS+ F,M O O O B B A Antibiotics/Concern 2013 5.20 Antibiotics of Concern-Clindamy in Average Scrips PMPY (M/F) BS+ BS+ F,M O O O B A A Antibiotics/Concern 2013 5.20 Antibiotics of Concern-Average Scrips PMPY (M/F) BS+ BS+ F,M O O O B A	AntibioticsOfConcern	200036_20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M/F) 85+	85+	F,M	0		0			R	NA
Antibiotics/Cloncern 200148 20 Antibiotics of Concern - Ketolike Average Scrips PMPY ([M] 55+ 55- F 0 0 0 0 8 NA Antibiotics/Cloncern 20015 20 Antibiotics of Concern - Clindamych Average Scrips PMPY ([M] 55+ 85+ M 0 0 0 8 NA Antibiotics/Cloncern 20015 20 Antibiotics of Concern - Clindamych Average Scrips PMPY ([M] 55+ 85+ F 0 0 0 8 NA Antibiotics/Cloncern 20015 20 Antibiotics of Concern - Clindamych Average Scrips PMPY ([M] 55+ 85+ F 0 0 0 0 8 NA Antibiotics/Cloncern 20013 20 Antibiotics of Concern - Nike Antibiotics of Concern - Nakes Antibi				85+	м	0		0			R	NA
AntibiotisOfConcern20016320Antibiotis of Concern - Lindamycin Average Scrips PMPY (M/F) BS+S5+F.M0000RNAAntibiotisOfConcern200125Antibiotis of Concern - Clindamycin Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern200135AntibiotisOf Concern - Clindamycin Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern200135AntibiotisOf Concern - Mich AntibiotisOf Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern200135AntibiotisOf Concern - Mich Antibiotis of Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern20013Antibiotis of Concern - Mich Antibiotis of Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern20201Antibiotis of Concern - Mich Antibiotis of Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern20201Antibiotis of Concern - Mich Antibiotis of Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern20201Antibiotis of Concern - Mich Antibiotis of Concern Average Scrips PMPY (M/F) BS+BS+F00RNAAntibiotisOfConcern20201Antibiotis of Concern - Quinolone Average Scrips PMPY (M/F) BS+BS+FN0RNAAntibiotisOfConcern2					F	0		0			R	NA
Antibiotics/Concern 20012 20 Antibiotics/Concern - Clindamycin Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA Antibiotics/Concern 20015 20 Antibiotics/Concern - Clindamycin Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA Antibiotics/Concern 20015 20 Antibiotics/Concern - Nick Antibiotics of Concern - Nerage Scrips PMPY (M) 85+ 85+ F 0 0 R NA Antibiotics/Concern 20015 20 Antibiotics/Concern - Nick Antibiotics of Concern Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA Antibiotics/Concern 20012 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA Antibiotics/Concern 20022 Antibiotics of Concern - Mick Antibiotics of Concern Average Scrips PMPY (M) FS 5+ 85+ F,M 0 0 R NA Antibiotics/Concern 200226 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) N/M Unknown M 0 0 R NA Antibiotics/Concern 200246 Antibi				0.51	E M	0		0			P	NA
Antibiotics/Ofconer200115, 20Antibiotics of Concern - Clindamycin Average Scrips PMPY (M/) 85+85+F.00008NAAntibiotics/Ofconer20013, 20Antibiotics of Concern - Misc Antibiotics of Concern - Marcage Scrips PMPY (M) 85+85+F.000					1,171	0		0			n	110
Antibiotics/Concern 20013_20 Antibiotics of Concern - Clindamycin Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 R NA Antibiotics/Concern 20019_20 Antibiotics of Concern - Misc Antibiotics of Concern - Merage Scrips PMPY (M/F) 85+ 85+ M 0 0 R NA Antibiotics/Concern 20021_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 R NA Antibiotics/Concern 20021_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 R NA Antibiotics/Concern 20022_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) NA Unknown M 0 0 R NA Antibiotics/Concern 20026_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 R NA Antibiotics/Concern 20034_20 Antibiotics of Concern - Caphalogonin 2nd-4H Generation Average Scrips PMPY (M/H) Unk Unknown F,M 0 0 R NA Antibiotics/Concern 20034_20 Antibiotics of C					IVI	U		-			K	NA
Antibiotics/Concern 200191_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 85+ 85+ M 0 0 R NA Antibiotics/Concern 200181_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (B 85+ 85+ F 0 0 R NA Antibiotics/Concern 20021_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) Ms 85+ F 0 0 R NA Antibiotics/Concern 20022_0 Antibiotics of Concern - Misc Antibiotics of Concern - Average Scrips PMPY (M) Ms Unknown M 0 0 R NA Antibiotics/Of Concern 200226_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) Unk Unknown F 0 0 R NA Antibiotics/Of Concern 200236_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M) Unk Unknown F 0 0 R NA Antibiotics/Of Concern 20034_20 Antibiotics of Concern - Cephalosporin 2nd-th Generation Average Scrips PMPY (M) Unk Unknown F 0 0 R NA Antibiotics/Concern 20014_20 Antibiot				051	F	0		0			N.	1100
Antibilitize/Concern 20181_20 Antibilitizes of Concern - Misc Antibilities of Concern Average Scrips PMPY (M/F) 85+ 85+ F 0 0 0 R NA Antibilitizes/Concern 20021_20 Antibilitizes of Concern - Misc Antibilities of Concern - Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 R NA Antibilitizes/Concern 20021_20 Antibilitizes of Concern - Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 R NA Antibilitizes/Concern 20021_20 Antibilitizes of Concern - Quinolone Average Scrips PMPY (M/F) Nt Unknown M 0 0 R NA Antibilitizes/Concern 20021_6_20 Antibilitizes of Concern - Quinolone Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R NA Antibilitizes/Of Concern 20036_20 Antibilitizes of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) Unk Unknown M 0 0 R NA Antibilitizes/Of Concern 20036_20 Antibilitizes of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) Unk Unknown M 0 R NA Antibilitizes/Of Concern 20				85+	F,M	0		0			R	NO.
AntibioticsOfConcern 20021_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 0 R NA AntibioticsOfConcern 20022_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 R NA AntibioticsOfConcern 20022_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) Unk Unknow M 0 0 0 R NA AntibioticsOfConcern 20032_20 Antibiotics of Concern - Caphalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 0 R NA AntibioticsOfConcern 20034_20 Antibiotics of Concern - Cephalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 R NA AntibioticsOfConcern 20034_20 Antibiotics of Concern - Cephalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 R NA AntibioticsOfConcern 20014_20 Antibiotics of Concern - Autinory in and Clarithromy in Areage Scrips PMPY (M/F) Unk Unknow F,M 0 0 R	AntibioticsOfConcern	200191_20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) 85+	85+	м	0		0			R	NA
AntibioticsOfConcern 20021_20 Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 0 R NA AntibioticsOfConcern 20022_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 R NA AntibioticsOfConcern 20022_20 Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F) Unk Unknow M 0 0 0 R NA AntibioticsOfConcern 20032_20 Antibiotics of Concern - Caphalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 0 R NA AntibioticsOfConcern 20034_20 Antibiotics of Concern - Cephalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 R NA AntibioticsOfConcern 20034_20 Antibiotics of Concern - Cephalogonin 2nd-4H Generation Average Scrips PMPY (M/F) Unk Unknow F,M 0 0 R NA AntibioticsOfConcern 20014_20 Antibiotics of Concern - Autinory in and Clarithromy in Areage Scrips PMPY (M/F) Unk Unknow F,M 0 0 R	AntibioticsOfConcern	200181_20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (F) 85+	85+	F	0		0			R	NA
Antibiotics/Ocneer20026 20Antibiotics of Concern - Quinolone Average Scrips PMPY (f) UnkUnknowM000008MAAntibiotics/Of Concern20026 20Antibiotics of Concern - Quinolone Average Scrips PMPY (f) UnkUnknowF000008MAAntibiotics/Of Concern20026 20Antibiotics of Concern - Quinolone Average Scrips PMPY (h/J) UnkUnknowF00008MAAntibiotics/Of Concern20036 20Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (h/J) UnkUnknowF0008MAAntibiotics/Of Concern20014 20Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (f) UnkUnknowF00 <td></td> <td></td> <td></td> <td>85+</td> <td>F,M</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>				85+	F,M	0		0			R	NA
AntibilitizsOfConcern 200216_20 Antibilitizs of Concern - Quinolone Average Scrips PMPY ([F] Unk Unknown F 0 0 0 R NA AntibilitizsOfConcern 20035_20 Antibilotiss of Concern - Quinolone Average Scrips PMPY ([M] Unk Unknown F,M 0 0 R NA AntibilotissOfConcern 20034_20 Antibilotiss of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY ([F] Unk Unknown M 0 0 R NA AntibilotissOfConcern 20034_20 Antibilotiss of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY ([F] Unk Unknown F 0 0 R NA AntibilotissOfConcern 20034_20 Antibilotiss of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY ([K] Unk Unknown F 0 0 R NA AntibilotissOfConcern 20034_20 Antibilotiss of Concern - Asithomycin and Clarithomycin Average Scrips PMPY ([M] Unk Unknown F 0 0 R NA AntibilotissOfConcern 20051_20 Antibilotiss of Concern - Asithomycin and Clarithomycin Average Scrips PMPY ([M] Unknown F 0 0 R NA AntibilotissOfConcern<				Unknown	м	0		0			R	NA
Antibiotics/Ofconern 20036 20 Antibiotics of Concern - Capitalogonin 2nd-4H Generation Average Scrips PMPY (M) Unk Unknow F,M 0					c.	0		0			n	
Antibiotics/Ofconer 20094, 20 Antibiotics of Concern - Acphalosporin 2nd-4th Generation Average Scrips PMPY (M) lu/k Unknown M 0 0 0 8 NA Antibiotics/OfConer 20084, 20 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M) Lu/k Unknown F 0 0 0 8 NA Antibiotics/OfConer 20014, 20 Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M)/F U/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/Lu/					r	0	I	0			<u>^</u>	1003
AntibiotsOfConcer 20084_20 Antibiots of Concern - Cephalogonin 2nd-4th Generation Average Scrips PMPY ((F) Unk Unknow F O O O O O NA AntibiotsOfConcer 20014_20 Antibiots of Concern - Cephalogonin 2nd-4th Generation Average Scrips PMPY (M) Unknow M O O O O R NA AntibiotsOfConcer 20010_20 Antibiots of Concern - Activorny cin and Clarithromycin Average Scrips PMPY (M) Unknow Unknow G O O O O O NA AntibiotsOfConcer 20051_20 Antibiots of Concern - Aztivornycin and Clarithromycin Average Scrips PMPY (M) Unknow Unknow F O O O O O O A AntibiotsOfConcer 20051_20 Antibiots of Concern - Aztivornycin and Clarithromycin Average Scrips PMPY (M) Unknow Unknow F O O O O O O O O O A AntibiotsOfConcer 20051_20 Antibiotsof Concern - Autivornycin and Clarithromycin Average Scrips PMPY (M) Unknow Unknow G O O O						U		U			к	
Antibiotics/Ocneer 20104_20 Antibiotics of Concern - Aciphalogs orin 2nd-4th Generation Average Scrips PMPY (M/) Flu M Unknow F,M 0 0 0 0 8 MA Antibiotics/Of Concern 200061_20 Antibiotics of Concern - Acithromycin and Clarithromycin Average Scrips PMPY (M) Unknow Unknow 6 0 0 0 R NA NA Antibiotics/Of Concern 200051_20 Antibiotics of Concern - Acithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknow F 0 0 0 R NA Antibiotics/Of Concern 200051_20 Antibiotics of Concern - Acithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknow F 0 0 R NA Antibiotics/Of Concern 200051_20 Antibiotics of Concern - Antikonicillin/Clavulanate Average Scrips PMPY (M/) Unk Unknow F 0 0 R NA Antibiotics/Of Concern 200012_20 Antibiotics of Concern - Anxiellin/Clavulanate Average Scrips PMPY (M/) Unknow Unknow F 0 0 R NA					м	0		0			R	NA
Antibiotics/Concern 2006_20 Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknow M 0 0 0 0 0 0 0 NA Antibiotics/Ofconern 20005_20 Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknow F 0 0 0 8 NA Antibiotics/Ofconern 2007_20 Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknow F 0 0 8 NA Antibiotics/Ofconern 2007_20 Antibiotics of Concern - Azithromycin Average Scrips PMPY (M) Unk Unknow F 0 0 8 NA Antibiotics/Ofconern 2007_20 Antibiotics of Concern - Azithromycin Average Scrips PMPY (M) Unk Unknow M 0 0 8 NA Antibiotics/Ofconern 2001_20 Antibiotics of Concern - Azithromycin Average Scrips PMPY (M) Unk Unknow M 0 0 8 NA Antibiotics/Ofconern 2001_8_20 Antibiotics of Concern - Amoxinillin/Clavukanate Average Scrips PMPY (F) Unk Un	AntibioticsOfConcern	200084_20	Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (F) Unk	Unknown	F	0		0			R	NA
AntibilitizeSOFConcern 20051_20 Antibilitizes of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (B) Unk Unknown F 0 0 0 R NA AntibilitizeSOFConcern 20071_20 Antibilitizes of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknown F,M 0 0 0 R NA AntibilitizeSOFConcern 20082 r0 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (M) Unk Unknown M 0 0 0 R NA AntibilitizeSOFConcern 20018_20 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (B) Unk Unknown M 0 0 0 0 R NA AntibilitizeSOFConcern 20018_20 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (F) Unk Unknown F 0 0 0 0 0 R NA	AntibioticsOfConcern	200104_20	Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F) Unk	Unknown	F,M	0		0			R	NA
AntibilitizeSOFConcern 20051_20 Antibilitizes of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (B) Unk Unknown F 0 0 0 R NA AntibilitizeSOFConcern 20071_20 Antibilitizes of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk Unknown F,M 0 0 0 R NA AntibilitizeSOFConcern 20082 r0 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (M) Unk Unknown M 0 0 0 R NA AntibilitizeSOFConcern 20018_20 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (B) Unk Unknown M 0 0 0 0 R NA AntibilitizeSOFConcern 20018_20 Antibilitizes of Concern - Amscillin/Clavulanate Average Scrips PMPY (F) Unk Unknown F 0 0 0 0 0 R NA	AntibioticsOfConcern	200061_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M) Unk	Unknown	м	0		0			R	NA
AntibioticsOfConcern 20071_20 Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 0 R NA AntibioticsOfConcern 20028_20 Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M/F) Unk Unknown M 0 0 R NA AntibioticsOfConcern 20018_20 Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (F) Unk Unknown F 0 0 R NA	AntibioticsOfConcern	200051 20		Unknown	F	0		0			R	NA
AntibioticsOfConcern 20028_20 Antibiotics of Concern - Amoxiciliin/Clavulanate Average Scrips PMPY (M) Unk Unknown M 0 0 0 R NA AntibioticsOfConcern 20018_20 Antibiotics of Concern - Amoxiciliin/Clavulanate Average Scrips PMPY (F) Unk Unknown F 0 0 R NA					F M	0		0			R	NA
AntibioticsOfConcern 200018_20 Antibiotics of Concern - Amosicillin/Clavulanate Average Scrips PMPY (F) Unk Unknown F 0 0 R NA						0		0			n	NA
					1v1	0		0			N.	1100
AntibioticsOfConcern 200038_20 Antibiotics of Concern - Amovicillin/Clavulanate Average Scrips PMPY (M/F) Unk Unknown (F,M 0 0 R NA					F	U		U			к	INA
	AntibioticsOfConcern	200038_20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M/F) Unk	Unknown	F,M	0		0			R	NA

MeasurementYear: 2020

Neasurementrear: 20											
Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
AntibioticsOfConcern	200160_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M) Unk	Unknown	м	0		0			R	NA
AntibioticsOfConcern	200150_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (F) Unk	Unknown	F	0		0			R	NA
AntibioticsOfConcern	200170_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F) Unk	Unknown	F,M	0		0			R	NA
AntibioticsOfConcern	200127_20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M) Unk	Unknown	м	0		0			R	NA
AntibioticsOfConcern	200117_20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (F) Unk	Unknown	F	0		0			R	NA
AntibioticsOfConcern	200137_20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M/F) Unk	Unknown	F,M	0		0			R	NA
AntibioticsOfConcern	200193_20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M) Unk	Unknown	м	0		0			R	NA
AntibioticsOfConcern	200183_20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (F) Unk	Unknown	F	0		0			R	NA
AntibioticsOfConcern	200203_20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F) Unk	Unknown	F,M	0		0			R	NA
AntibioticsOfConcern	200225_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (M)	Total	м	173827		56		0.00	R	R
AntibioticsOfConcern	200215_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (F)	Total	F	164437		106		0.01	R	R
AntibioticsOfConcern	200235_20	Antibiotics of Concern - Quinolone Average Scrips PMPY (M/F)	Total	F,M	338264		162		0.01	R	R
AntibioticsOfConcern	200093_20	Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M)	Total	м	173827		800		0.06	R	R
AntibioticsOfConcern	200083_20	Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (F)	Total	F	164437		995		0.07	R	R
AntibioticsOfConcern	200103_20	Antibiotics of Concern - Cephalosporin 2nd-4th Generation Average Scrips PMPY (M/F)	Total	F,M	338264		1795		0.06	R	R
AntibioticsOfConcern	200060_20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M)	Total	м	173827		864		0.06	R	R
AntibioticsOfConcern	200050 20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (F)	Total	F	164437		1351		0.10	R	R
AntibioticsOfConcern	200070 20	Antibiotics of Concern - Azithromycin and Clarithromycin Average Scrips PMPY (M/F)	Total	F,M	338264		2215		0.08	R	R
AntibioticsOfConcern	200027_20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M)	Total	м	173827		916		0.06	R	R
AntibioticsOfConcern	200017 20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (F)	Total	F	164437		971		0.07	R	R
AntibioticsOfConcern	200037 20	Antibiotics of Concern - Amoxicillin/Clavulanate Average Scrips PMPY (M/F)	Total	F.M	338264		1887		0.07	R	R
AntibioticsOfConcern	200159 20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M)	Total	M	173827		0		0.00	R	R
AntibioticsOfConcern	200149 20	Antibiotics of Concern - Ketolide Average Scrips PMPY (F)	Total	F	164437	1	0		0.00	R	R
AntibioticsOfConcern	200169_20	Antibiotics of Concern - Ketolide Average Scrips PMPY (M/F)	Total	F,M	338264		0		0.00	R	R
AntibioticsOfConcern	200126 20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M)	Total	м	173827		228		0.02	R	R
AntibioticsOfConcern	200116_20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (F)	Total	F	164437		290		0.02	R	R
AntibioticsOfConcern	200136 20	Antibiotics of Concern - Clindamycin Average Scrips PMPY (M/F)	Total	F.M	338264		518		0.02	R	R
AntibioticsOfConcern	200192 20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M)	Total	M	173827		4		0.00	R	R
AntibioticsOfConcern	200182 20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (F)	Total	F	164437		5		0.00	R	R
AntibioticsOfConcern	200202 20	Antibiotics of Concern - Misc Antibiotics of Concern Average Scrips PMPY (M/F)	Total	E.M.	338264		a		0.00	R	R
OtherAntibiotics	200283 20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) 0-9	0-9	M	76636		180		0.03	R	R
OtherAntibiotics	200273 20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (F) 0-9	0-9	F	70103		326		0.06	R	R
OtherAntibiotics	200293 20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) 0-9	0-9	F.M	146739		506		0.04	R	R
OtherAntibiotics	200316_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M) 0-9	0-9	M	76636		0		0.00	R	R
OtherAntibiotics	200306 20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (F) 0-9	0-9	F	70103		0		0.00	R	R
OtherAntibiotics	200326_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M/F) 0-9	0-9	F.M	146739		0		0.00	R	R
OtherAntibiotics	200250 20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) 0-9	0-9	м	76636		295		0.05	R	R
OtherAntibiotics	200240_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (F) 0-9	0-9	F	70103		348		0.06	R	R
OtherAntibiotics	200240_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M/F) 0-9	0-9	E M	146739		643		0.05	R	R
OtherAntibiotics	200349 20	All Other Antibiotics - Lincosamide Average Scrips PMPY (M) 0-9	0-9	M	76636		0		0.00	•	P
OtherAntibiotics	200339_20	All Other Antibiotics - Lincosamide Average Scrips PMP1 (W) 0-9	0-9	5	70103		0		0.00	•	P
OtherAntibiotics	200359_20	All Other Antibiotics - Lincosamide Average Scrips PMP1 (1) 0-9 All Other Antibiotics - Lincosamide Average Scrips PMP2 (M/F) 0-9	0-9	F.M	146739		0		0.00	•	P
OtherAntibiotics	200335_20	All Other Antibiotics - Encostinue Average Scrips PWP (M) 0-9 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) 0-9	0-9	M	76636		2		0.00	•	P
OtherAntibiotics	200382_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (F) 0-9	0-9	5	70103		2		0.00	•	P
OtherAntibiotics	200372_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (P) 0-9	0-9	F,M	146739		5		0.00	<u> </u>	0
OtherAntibiotics	200392_20	All Other Antibiotics - Mactolide (not aztri of clarini) Average Scrips PMPF (W/F) 0-9	0-9	M	76636		2016		0.32	<u> </u>	0
OtherAntibiotics	200448_20	All Other Antibiotics - Penicillin Average Scrips PMP1 (W) 0-9	0-9	r IVI	70103		1981		0.32	<u> </u>	0
OtherAntibiotics	200458_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 0-9	0-9	F.M	146739		3997		0.34	<u> </u>	0
OtherAntibiotics	200438_20	All Other Antibiotics - Penicinin Average Scrips PMPT (W/P) 0-9	0-9	r,ivi M	76636		3337		0.00	<u>~</u>	n
			0-9	r.			16		0.00	R	R
OtherAntibiotics OtherAntibiotics	200471_20 200491_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 0-9	0-9	F F.M	70103 146739		16		0.00	R	R
		All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 0-9	0-9	F,M					0.00	R	R
OtherAntibiotics OtherAntibiotics	200415_20 200405_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) 0-9	0-9	IVI E	76636 70103		29		0.00	n	n D
OtherAntibiotics OtherAntibiotics	200405_20 200425_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (F) 0-9	0-9	F.M.	70103		19		0.00	n	n D
	200425_20 200284_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) 0-9	0-9	F,M M	146739 78351	1	48	L	0.00	n	n
OtherAntibiotics OtherAntibiotics	200284_20 200274_20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) 10-17	10-17	IVI r		1			0.05	к р	R D
		All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (F) 10-17	-	F.M.	73033		339		0.06	ĸ	ĸ
OtherAntibiotics	200294_20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) 10-17	10-17	.,	151384		503			R	R
OtherAntibiotics	200317_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M) 10-17	10-17	M	78351		3		0.00	R	ĸ
OtherAntibiotics	200307_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (F) 10-17	10-17	г г ма	73033		0		0.00	n	n
OtherAntibiotics	200327_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M/F) 10-17		F,M			3		0.00	к р	ĸ
OtherAntibiotics	200251_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) 10-17	10-17	M	78351		236		0.04	ĸ	R
OtherAntibiotics	200241_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (F) 10-17	10-17	F	73033		331		0.05	ĸ	R
OtherAntibiotics	200261_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M/F) 10-17	10-17	F,M	151384		567		0.04	ĸ	ĸ
OtherAntibiotics	200350_20	All Other Antibiotics - Lincosamide Average Scrips PMPY (M) 10-17	10-17	M	78351		U		0.00	ĸ	ĸ
OtherAntibiotics	200340_20	All Other Antibiotics - Lincosamide Average Scrips PMPY (F) 10-17	10-17	F	73033		U		0.00	ĸ	к
OtherAntibiotics	200360_20	All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 10-17	10-17	F,M	151384		0		0.00	R	R
OtherAntibiotics	200383_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) 10-17	10-17	M	78351		20		0.00	R	R
OtherAntibiotics	200373_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (F) 10-17	10-17	F	73033		1		0.00	R	R
OtherAntibiotics	200393_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) 10-17	10-17	F,M	151384		21		0.00	R	R
OtherAntibiotics	200449_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M) 10-17	10-17	м	78351		720		0.11	R	R
OtherAntibiotics	200439_20	All Other Antibiotics - Penicillin Average Scrips PMPY (F) 10-17	10-17	F	73033		894		0.15	R	R
OtherAntibiotics	200459_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 10-17	10-17	F,M	151384		1614		0.13	R	R
OtherAntibiotics	200482_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 10-17	10-17	м	78351		269		0.04	R	R
OtherAntibiotics	200472_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 10-17	10-17	F	73033		376		0.06	R	R
OtherAntibiotics	200492_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 10-17	10-17	F,M	151384		645		0.05	R	R

MeasurementYear: 2020

SuchS		020										
Scheder<	Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
momentmome	OtherAntibiotics	200416_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) 10-17	10-17	м	78351		36		0.01	R	R
momentmome	OtherAntibiotics	200406_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (F) 10-17	10-17	F	73033		498		0.08	R	R
Schell	OtherAntibiotics	200426_20		10-17	F,M	151384		534		0.04	R	R
SampleSam	OtherAntibiotics	200285_20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) 18-34	18-34	м	18840		51		0.03	R	R
SubsetSubs	OtherAntibiotics	200275_20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (F) 18-34	18-34	F	21301		150		0.08	R	R
NameNormNormeNormeNormeNormeNormeNormeNormeNormeNormeNormNormeNormNormeNormeNormeNormeNormeNormNormeNormNormNorm </td <td>OtherAntibiotics</td> <td>200295_20</td> <td>All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) 18-34</td> <td>18-34</td> <td>F,M</td> <td>40141</td> <td></td> <td>201</td> <td></td> <td>0.06</td> <td>R</td> <td>R</td>	OtherAntibiotics	200295_20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) 18-34	18-34	F,M	40141		201		0.06	R	R
BandB	OtherAntibiotics	200318_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M) 18-34	18-34	М	18840		0		0.00	R	R
InstructureIndex </td <td>OtherAntibiotics</td> <td>200308_20</td> <td>All Other Antibiotics - Aminoglycoside Average Scrips PMPY (F) 18-34</td> <td>18-34</td> <td>F</td> <td>21301</td> <td></td> <td>0</td> <td></td> <td>0.00</td> <td>R</td> <td>R</td>	OtherAntibiotics	200308_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (F) 18-34	18-34	F	21301		0		0.00	R	R
Sharker<	OtherAntibiotics	200328_20	All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M/F) 18-34	18-34	F,M	40141		0		0.00	R	R
matched<	OtherAntibiotics	200252_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) 18-34	18-34	м	18840		35		0.02	R	R
Band Band	OtherAntibiotics	200242_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (F) 18-34	18-34	F	21301		143		0.08	R	R
NameN	OtherAntibiotics	200262_20	All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M/F) 18-34	18-34	F,M	40141		178		0.05	R	R
matrixmatr	OtherAntibiotics	200351_20	All Other Antibiotics - Lincosamide Average Scrips PMPY (M) 18-34	18-34	M	18840		0		0.00	R	R
SubsetSubs	OtherAntibiotics	200341_20		18-34	F	21301		0		0.00	R	R
SubsetSubs	OtherAntibiotics	200361_20	All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 18-34	18-34	F,M	40141		0		0.00	R	R
Stand <th< td=""><td>OtherAntibiotics</td><td>200384_20</td><td>All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) 18-34</td><td>18-34</td><td>M</td><td>18840</td><td></td><td>0</td><td></td><td>0.00</td><td>R</td><td>R</td></th<>	OtherAntibiotics	200384_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) 18-34	18-34	M	18840		0		0.00	R	R
SinceSinceMax and water based part of any	OtherAntibiotics	200374 20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (F) 18-34	18-34	F	21301		12		0.01	R	R
Backed matrix Backed matrix	OtherAntibiotics	200394 20		18-34	F,M			12		0.00	R	R
SolutionSoluti	OtherAntibiotics	200450 20		18-34	M	18840		122		0.08	R	R
SolutionSoluti					F	21301				0.14	R	R
SolutionSoluti	OtherAntibiotics			18-34	F.M					0.11	R	R
SubmatSubm	OtherAntibiotics			18-34	M	18840		84		0.05	R	R
SolutionSolutionNon-state<	OtherAntibiotics			18-34	F	21301		91	1	0.05	R	R
SectorSect					F,M					0.05	R	R
WarderWarderWarder warder ward	OtherAntibiotics				M					0.02	R	R
Sold and and sold sold sold sold sold sold sold sol					F					0.36	R	R
Solder Mathematication of the stand of t					F M					0.20	R	R
Danal with and any share and any					.,	0		0		0.20	R	NA
SummerSumm					F	0		0			R	NA
BandsetBandsetBandset Advances/sequence/					F M	0		0			R	NA
BondsetBindBindFinBind <th< td=""><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></th<>						0		0			R	NA
Other AdditionOther AdditionAddition AdditionSet and					F	0		0			R	NA
Band band band band band band band band b					E.M	0		0			R	NA
Denome Denom					.,	0		0			R	NA
DemonstrationStatic and Contracting Static and Contracting Static and Sta					F	0		0			R	NA
DenketiksDisplayAlphar kelleks: -localing kerge ig VPR (VI) 3-4-1.6-1.0-0 <th< td=""><td></td><td></td><td>8</td><td></td><td>F M</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></th<>			8		F M	0		0			R	NA
DankabaseSDB12All Data Autoback-based spice for MP(1) 5:4I.4I.4I.0I					M	0		0			R	NA
DenkembleSD12,0I diber Antonenis Ancergatory MPV (M):54-0I 40I 40II <th< td=""><td></td><td></td><td></td><td></td><td>E</td><td>0</td><td></td><td>0</td><td></td><td></td><td></td><td>NA</td></th<>					E	0		0				NA
DenkemiseDisplayAlphe Answers-Macuale joint Amergion Marry (1974)14014000 </td <td></td> <td></td> <td></td> <td></td> <td>EM</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td></td> <td>NA</td>					EM	0		0				NA
Denomination2007.3Al Colume Analysics, Marcing Instructurelly Average Strong MAPU [13:4-95-40700						0		0				NA
Denkebisities2003: 20All Other Absolutes- Inscription Agency Steps PAPY (1) 54-95407409. <td>othen indibiodes</td> <td></td> <td></td> <td></td> <td>E</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td></td> <td>NA</td>	othen indibiodes				E	0		0				NA
OmerAndboord 20043. jou Al Other Andboord- Prescription Argenes Group PMP (M) 33-49 34-00 M O O O B </td <td></td> <td></td> <td></td> <td></td> <td>ENA</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R.</td> <td>1473</td>					ENA	0		0			R.	1473
Discretation2044 and Automators - Parcella Auerges Storp PMP (1) 3-5-45-4600 <th< td=""><td></td><td></td><td></td><td></td><td></td><td>0</td><td></td><td>0</td><td></td><td></td><td>n</td><td>101</td></th<>						0		0			n	101
Description20043 0All One Andelects - Provide Ansages Gript PMV (10) 33-915-9////00 <td></td> <td></td> <td></td> <td></td> <td>E</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td></td> <td></td>					E	0		0				
Onder-disportsOnder-disports-intergright wight of 3-4 into a sector					ENA	0		0			R.	
Diter AutorDiter Auto					,	0		0			n	NA
Dider Aublicks - Tetraychine Average Script AMPY (M1) 3-6435-40M00 <th< td=""><td></td><td></td><td></td><td></td><td>E E</td><td>0</td><td></td><td>0</td><td></td><td></td><td>n</td><td>NA</td></th<>					E E	0		0			n	NA
Observations Deparations29049 30All other Autobacts. Akeer absist primer (M) 35-49540M00 <td></td> <td></td> <td></td> <td></td> <td>ENA</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R.</td> <td></td>					ENA	0		0			R.	
Observations Observations Devenda					.,	0		0			n	NA
Other Antibiotics 20082 20 AI Other Antibiotics - Montoly Sciegn PMP (Mr) 35-91 5-90 F.M O O O D B					E E	0		0			n	NA
Other Attibitities Other Attibities Automation is subscription is Average Scrips PMPY (M) 50-64 Sofe M C C R M Other Attibities 20027 20 All Other Attibities - Absorbable Sulforamide Average Scrips PMPY (M/) 50-64 Sofe A F.M 0 0 0 C R R N Other Attibities 20027 20 All Other Attibities - Absorbable Sulforamide Average Scrips PMPY (M/) 50-64 Sofe A M 0 0 C R N N Other Attibities 20032 0 All Other Attibities - Attionatios - Anninglycoside Average Scrips PMPY (M/) 50-64 Sofe A M 0 0 C R N N Other Attibities 20032 0 All Other Attibities - Strips PMPY (M/) 50-64 Sofe A M 0 0 0 C R N N Other Attibities 20024 20 All Other Antibities - Strips PMPY (M/) 50-64 Sofe A F 0 C R N N N N N N N N N N N					F FA	0		0			n	NA
Other Antibidits Differentiation Different					F,IVI	0		0			n	NA NA
Other AntibioticsAll Other Antibiotics-Absorbable Subnamide Average Scrips PMP (M) 50-6450-64M00					r.v.	0	ł	0			0	NA
Other Antibiotis 20037 0.0 All Other Antibiotis - Aminoglycoide Average Scrips PMPY (M) 50-64 0.64 M 0					C MA	0	ł	0			0	NA
OtherAntilioticsAll Other Antibiotics- Annineg/roside Average Scrips PMPY (b) 50-6490-64F.00008NAOtherAntiliotics20032 0.20All Other Antibiotics- Annineg/roside Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20024 20All Other Antibiotics- 1st Generation Cephalosporin Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20024 20All Other Antibiotics- 1st Generation Cephalosporin Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20032 20All Other Antibiotics- Incosamide Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20033 20All Other Antibiotics- Incosamide Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20035 20All Other Antibiotics- Incosamide Average Scrips PMPY (b) 50-6450-64F.0008NAOtherAntibiotics20035 20All Other Antibiotics- Macrolide (not atth or clarth) Average Scrips PMPY (h) 50-6450-64F.00008NAOtherAntibiotics20035 20All Other Antibiotics- Macrolide (not atth or clarth) Average Scrips PMPY (h) 50-6450-64F.000000NAOtherAntibiotics20035 20All Other Antibiotics- Macrolide (not atth or clarth) Average Scrips PMPY (h) 50-64					1,00	0	ł	0			n	100
Other Antibiotics 20332 Q2 All Other Antibiotics - Antionglycoside Average Scrips PMPY (M/S) 0-64 50-64 F.M 0 0					E C	0	<u>}</u>	0			P	110
OtherAntibiotics 200254_20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) 50-64 50-64 F 0 <					C MA	0	ł	0			0	
OtherAntibotics20024 420All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (h] 50-6450-64F.M00000RNAOtherAntibiotics20035 20All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (h) 50-6450-64M00 <td></td> <td></td> <td></td> <td></td> <td>,</td> <td>0</td> <td>l</td> <td>0</td> <td></td> <td></td> <td>n</td> <td>NA</td>					,	0	l	0			n	NA
OtherAntibiotics 200264_20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M/F) 50-64 50-64 F.M. 0 0 0 0 R NA OtherAntibiotics 20035_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 50-64 50-64 F.O. 0 0 R NA OtherAntibiotics 20033_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 50-64 50-64 F.O. 0 R NA OtherAntibiotics 20036_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 50-64 50-64 F.O. 0 R NA OtherAntibiotics 20036_20 All Other Antibiotics - Macrolide (not azith or clarith Average Scrips PMPY (M) 50-64 50-64 F.O. 0 R NA OtherAntibiotics 20036_20 All Other Antibiotics - Macrolide (not azith or clarith Average Scrips PMPY (M) 50-64 50-64 F.O. 0 R NA OtherAntibiotics 20035_20 All Other Antibiotics - Sericing PMPY (M) 50-64 50-64 F.O. 0 R NA OtherAntibiotics 20045_20 </td <td></td> <td></td> <td></td> <td></td> <td>1V1</td> <td>0</td> <td>l</td> <td>0</td> <td> </td> <td></td> <td>n</td> <td>INA NA</td>					1V1	0	l	0			n	INA NA
OtherAntibiotics 200352 All Other Antibiotics- Lincosamide Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 0 R NA OtherAntibiotics 200342_20 All Other Antibiotics- Lincosamide Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 200362_20 All Other Antibiotics- Lincosamide Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 200362_20 All Other Antibiotics- Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 200376_20 All Other Antibiotics- Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 200376_20 All Other Antibiotics- Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 200452_20 All Other Antibiotics- Pencillin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R					F	0		0			R	NA
OtherAntibiotics20343_20All Other Antibiotics-Lincosamide Average Scrips PMPY (M) 50-6450-64F.M00000RNAOtherAntibiotics20363_20All Other Antibiotics-Lincosamide Average Scrips PMPY (M) 50-6450-64F.M000					.,	0		0			R	INA NA
OtherAntibiotics 200363_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 0 0 0 R NA OtherAntibiotics 200363_20 All Other Antibiotics - Macrolide (not atth or clarith Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 R NA OtherAntibiotics 200376_20 All Other Antibiotics - Macrolide (not atth or clarith Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 200376_20 All Other Antibiotics - Macrolide (not atth or clarith Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Sencillin Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Sencillin Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Pencillin Average Scrips PMPY (M) 50-64 50-64 F 0 0					M	0		-			R	NA
OtherAntibiotics 20038 6 20 All Other Antibiotics-Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 F 0 0 0 R NA OtherAntibiotics 20037 6 20 All Other Antibiotics-Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20037 6 20 All Other Antibiotics-Macrolide (not azith or clarith) Average Scrips PMPY (M) 50-64 50-64 FM 0 0 R NA OtherAntibiotics 20045 20 All Other Antibiotics-Pencillin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 R NA OtherAntibiotics 20045 20 All Other Antibiotics-Pencillin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 R NA OtherAntibiotics 20042 20 All Other Antibiotics-Pencillin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 R NA OtherAntibiotics 20045 20 All Other Antibiotics-Pencillin Average Scrips PMPY (M) 50-64 50-64 FM 0 0 R NA NA </td <td></td> <td></td> <td></td> <td></td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>					F	0		0			R	NA
OtherAntibiotics 20376_20 All Other Antibiotics-Macrolide (not aith or clarith) Average Scrips PMPY (/F) 50-64 50-64 FM 0 0 0 R NA OtherAntibiotics 20039_20 All Other Antibiotics-Macrolide (not aith or clarith) Average Scrips PMPY (/H) 50-64 50-64 FM 0 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics-Pencilill Average Scrips PMPY (MJ 50-64 50-64 M 0 0 0 R NA OtherAntibiotics 2042_20 All Other Antibiotics-Pencilill Average Scrips PMPY (MJ 50-64 50-64 FM 0 0 0 R NA OtherAntibiotics 2042_20 All Other Antibiotics-Pencilill Average Scrips PMPY (MJ 50-64 50-64 FM 0 0 0 R NA OtherAntibiotics 2045_20 All Other Antibiotics-Tetracycline Average Scrips PMPY (MJ 50-64 50-64 FM 0 0 0 0 R NA OtherAntibiotics 2045_20 All Other Antibiotics-Tetracycline Average Scrips PMPY (MJ 50-64 50-64 F 0 0 0 0 0 0 NA </td <td></td> <td></td> <td></td> <td></td> <td>F,M</td> <td>0</td> <td></td> <td>0</td> <td> </td> <td></td> <td>R</td> <td>INA NA</td>					F,M	0		0			R	INA NA
OtherAntibiotics 200396_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 200462_2.0 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 200462_2.0 All Other Antibiotics - Tetrazycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Tetrazycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20045_2.0 All Other Antibiotics - Tetrazycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA					M	0		U			ĸ	NA
OtherAntibiotics 200452.20 All Other Antibiotics- Pencillin Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 0 0 0 M NA OtherAntibiotics 200452.00 All Other Antibiotics- Pencillin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 0 0 0 NA NA OtherAntibiotics 200452.00 All Other Antibiotics- Pencillin Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 0 0 RA NA OtherAntibiotics 200452.00 All Other Antibiotics- Tetrazyciline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 0 RA NA OtherAntibiotics 200452.00 All Other Antibiotics- Tetrazyciline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 0 RA NA OtherAntibiotics 200452.00 All Other Antibiotics- Tetrazyciline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 0 RA NA <td< td=""><td></td><td></td><td></td><td></td><td>F</td><td>U</td><td></td><td>U</td><td> </td><td></td><td>ĸ</td><td>NA</td></td<>					F	U		U			ĸ	NA
OtherAntibuotics 20042_20 All Other Antibuotics - Pencillin Average Scrips PMPY (F) 50-64 50-64 F 0 0 0 R NA OtherAntibuotics 20042_20 All Other Antibuotics - Pencillin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 0 R NA OtherAntibuotics 200452_20 All Other Antibuotics - Pencillin Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibuotics 200452_20 All Other Antibuotics - Tetracycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibuotics 200452_20 All Other Antibuotics - Tetracycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibuotics 200452_20 All Other Antibuotics - Tetracycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibuotics 200492_20 All Other Antibuotics - Tetracycline Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA Oth						U		U			ĸ	NA
OtherAntibiotics 200462_20 All Other Antibiotics - Penciellin Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 0 0 R NA OtherAntibiotics 20048_20 All Other Antibiotics - Tetrazycilne Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20048_20 All Other Antibiotics - Tetrazycilne Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Tetrazycilne Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Tetrazycilne Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Tetrazycilne Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M/F) 50-64 50-64 F 0 0 R NA OtherAntibio	othen indibiodes				M	U		U	ļ		ĸ	NA
Other Antibiotics 200485_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 R NA Other Antibiotics 200475_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 0 R NA Other Antibiotics 200495_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA Other Antibiotics 200495_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA Other Antibiotics 20049_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 R NA OtherAntibiotics 20049_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) 50-64 50-64 F 0 0 0					F	0	<u> </u>	0			R	1973
OtherAntibiotics 200475_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 50-64 50-64 F.M 0 0 0 R NA OtherAntibiotics 20045_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 20045_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 50-64 50-64 F.M 0 0 R NA OtherAntibiotics 200419_20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (F) 50-64 50-64 F 0 0 R NA						0	<u> </u>	0			R	1473
OtherAntibiotics 20049_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 50-64 50-64 F.M 0 0 0 R All All OtherAntibiotics 20049_20 All Other Antibiotics - Misc Antibioti					м	0		0			R	
Other Antibiotics 200419_20 All Other Antibiotics - Misc Antibiotics Average Scrips PMPY (M) 50-64 50-64 M 0 0 0 R NA Other Antibiotics 200409_20 All Other Antibiotics - Misc Antibiotic					F	0		0			R	
Other Antibiotics 200409_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (F) 50-64 50-64 F 0 0 R NA	OtherAntibiotics				,	0		0			R	NA
	OtherAntibiotics				М	0		0			R	NA
Other Antibiotics 200429_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) 50-64 50-64 F,M 0 R NA	OtherAntibiotics				F	0		0			R	NA
	OtherAntibiotics	200429_20	All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) 50-64	50-64	F,M	0		0			R	NA

Balan Balan <t< th=""><th>MeasurementYear: 20</th><th>120</th><th></th><th></th><th>1</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	MeasurementYear: 20	120			1							
Bacher	Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	PrescriptionConcernCount	PrescriptionCount	PrescriptionLength	Rate	AuditDesignation	Status
Both Both <t< td=""><td>OtherAntibiotics</td><td>200288 20</td><td>All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) 65-74</td><td>65-74</td><td>м</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></t<>	OtherAntibiotics	200288 20	All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) 65-74	65-74	м	0		0			R	NA
	OtherAntibiotics	200278 20		65-74	F	0		0			R	NA
Balle Barlath Barlath <th< td=""><td>OtherAntibiotics</td><td>200298 20</td><td></td><td>65-74</td><td>F.M.</td><td>0</td><td></td><td>0</td><td></td><td></td><td>B</td><td>NA</td></th<>	OtherAntibiotics	200298 20		65-74	F.M.	0		0			B	NA
Name Name <th< td=""><td>OtherAntibiotics</td><td></td><td></td><td></td><td>M</td><td>0</td><td></td><td>0</td><td></td><td></td><td>B</td><td>NA</td></th<>	OtherAntibiotics				M	0		0			B	NA
Balan Birland Birla	OtherAntibiotics			65-74	F	0		0			B	NA
DataDiamD	OtherAntibiotics			65-74	F M	0		0			R	NA
NameN					M	0		0			P	NA
BorneyBorn					с.	0		0			P	NA
Name					F F	0		0			n D	
mathemmath					,	0		0			R	
MatherMath					IVI F	0		0			R	NA
NameN					F	0		0			R	NA
ImageMatrixMatri					F,M	0		0			R	NA
BanderSet and any and any					м	0		0			R	NA
BandB					F	0		0			R	NA
BandB					F,M	0		0			R	NA
Bank del bankBank del bank hande h					м	0		0			R	
BanderBand	OtherAntibiotics				F	0		0			R	
BeachesSelect Set Set Set Set Set Set Set Set Set Se	OtherAntibiotics		All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 65-74		F,M	0		0			R	NA
BedderSolve descent sequence of sequence	OtherAntibiotics	200486_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 65-74	65-74	м	0		0			R	NA
IndexModelModel and Answer and any and any	OtherAntibiotics	200476_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 65-74	65-74	F	0		0			R	NA
black black black black black blackSole black 	OtherAntibiotics	200496_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 65-74	65-74	F,M	0		0			R	NA
black black black black black blackSole black black blackSole black blackSole black blackSole black blackSole black blackSole black blackSole blackSole black blackSole black blackSole blackSole black blackSole black blackSole black blackSole black blackSole black blackSole black blackSole blackSole blackSole black blackSole bl	OtherAntibiotics	200420_20		65-74	М	0		0			R	NA
BackedsetSold Sold Sold Sold Sold Sold Sold Sold	OtherAntibiotics				F	0		0			R	NA
Bind Bind	OtherAntibiotics				F,M	0		0			R	NA
BacketomSint PointSint Point <t< td=""><td>OtherAntibiotics</td><td></td><td></td><td></td><td></td><td>0</td><td>1</td><td>0</td><td></td><td></td><td>R</td><td>NA</td></t<>	OtherAntibiotics					0	1	0			R	NA
BachadorBin MarkanMarkan Analysing Markan Analysing Markan Analysing Markan Mar	OtherAntibiotics				F	0		0			R	NA
spaceSpace <th< td=""><td></td><td></td><td></td><td></td><td>E.M.</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></th<>					E.M.	0		0			R	NA
BandwardSolity and proceedings and proceeding and proceedings and proceeding a					1, WI	0		0			P	NA
Band Band					C .	0		0			R	NA
SystemSyst					F	0		0			R	NA NA
methode<	othen intibiotics			75 04	F,IVI	0		0			K	1100
binderSind <th< td=""><td></td><td></td><td></td><td></td><td>IVI</td><td>0</td><td></td><td>-</td><td></td><td></td><td>R</td><td>NA</td></th<>					IVI	0		-			R	NA
BandwardBandbar					F	0		0			R	NA
Bandard B					.,	0		0			R	NA
BindlessSolds					м	0		0			R	NA
minutanceMode 1Mode 1M					F	0		0			R	NA
markades0071 al40 Data AddresManage for part Part Part A7.44AA000 <td></td> <td></td> <td></td> <td></td> <td>F,M</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>					F,M	0		0			R	NA
methadion1000 mbMode mb <td></td> <td></td> <td></td> <td></td> <td>м</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>					м	0		0			R	NA
machanal m	OtherAntibiotics				F	0		0			R	NA
mathemDistance	OtherAntibiotics	200398_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) 75-84	75-84	F,M	0		0			R	NA
Imach discSold ASold ASold ASold ASold ASold AACABABBB	OtherAntibiotics	200454_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M) 75-84	75-84	м	0		0			R	NA
Dimensional State J. 2004 J. 200 All Other Abelasiss - Transports, Marry Strug, MMP (17) 54 7.54 F. 0 0 0 0 <t< td=""><td>OtherAntibiotics</td><td>200444_20</td><td>All Other Antibiotics - Penicillin Average Scrips PMPY (F) 75-84</td><td>75-84</td><td>F</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></t<>	OtherAntibiotics	200444_20	All Other Antibiotics - Penicillin Average Scrips PMPY (F) 75-84	75-84	F	0		0			R	NA
model biol2007All Other Materials - Practices Marge Sign MMT (M) 75-475-476000 <th< td=""><td>OtherAntibiotics</td><td>200464_20</td><td>All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 75-84</td><td>75-84</td><td>F,M</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></th<>	OtherAntibiotics	200464_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 75-84	75-84	F,M	0		0			R	NA
Dependencies2004740 UP Andelesci-strain-dependencies (sing MPV (M2) 5:445:44M000 <t< td=""><td>OtherAntibiotics</td><td>200487_20</td><td>All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 75-84</td><td>75-84</td><td>м</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></t<>	OtherAntibiotics	200487_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 75-84	75-84	м	0		0			R	NA
Dimensional <b< td=""><td>OtherAntibiotics</td><td>200477_20</td><td>All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 75-84</td><td>75-84</td><td>F</td><td>0</td><td></td><td>0</td><td></td><td></td><td>R</td><td>NA</td></b<>	OtherAntibiotics	200477_20	All Other Antibiotics - Tetracycline Average Scrips PMPY (F) 75-84	75-84	F	0		0			R	NA
Imburdenci2001.30All ther Arbitics - Mice A	OtherAntibiotics	200497 20		75-84	F,M	0		0			R	NA
Dimension20041.20All Outer Antibiotic - Marca Hole Marrage Scrips PMP (1) 75-447-847-847-800 <td>OtherAntibiotics</td> <td>200421 20</td> <td></td> <td>75-84</td> <td>м</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>	OtherAntibiotics	200421 20		75-84	м	0		0			R	NA
mbmm	OtherAntibiotics			75-84	F	0		0			B	NA
DimentationalDisplayAll Dimentational Asynchroges Sing PMP (195+Sing ANoOOOOSing ANoDimentationalAl Dimentational Asynchroges Sing PMP (1975+Sing AA <t< td=""><td></td><td></td><td></td><td></td><td>F M</td><td>0</td><td></td><td>0</td><td></td><td></td><td>B</td><td>NA</td></t<>					F M	0		0			B	NA
ImputationNote of the sector of						0		0			P	NA
Unber-Able 1000-0000All Obder-Able 1000-0000 Average Scrips PMPY (M) 55-6-FF00<					E .	0		0			P	NA
Dimensional Solution 20033 20 Al Other Antibiotics - Animoglycoside Average Scrips PMPY (M S ⁴) S ⁴ F.M 0 0 0 0 8 8 8 Dimensional Solution 20033 20 Al Other Antibiotics - Animoglycoside Average Scrips PMPY (MF) S ⁴ S ⁴ F.M 0 0 0 8 8 8 Dimensional Solution 20037 20 Al Other Antibiotics - Animoglycoside Average Scrips PMPY (MF) S ⁴ S ⁴ F.M 0 0 8 8 8 0 0 8 8 8 8 6 0 0 8 8 8 8 0 0 0 8 8 8 8 8 0 0 0 8 8 8 8 8 0 0 0 8 8 8 8 8 0 0 0 0 0 8 8 8 8 8 8 8 0 0 0 0 0 0 0 0 <td></td> <td></td> <td></td> <td></td> <td>F E MA</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>n D</td> <td>NA NA</td>					F E MA	0		0			n D	NA NA
Dimensional Solution Other Antibiotics - namingly code Average Scrips PMPY ([P] S5- S + F A O O O B					F,IVI	0		0			R	NA NA
Dimentifyind20033 20All Other Antibiotics Animogeneous Anargae Scrips PMPY (M/B 35+65+67-00					IVI r	0		0			R	NA
Dependentities 200257 20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) 85+ 85+ F 0 0 0 0 </td <td></td> <td></td> <td></td> <td></td> <td>F AA</td> <td>0</td> <td>1</td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>					F AA	0	1	0			R	NA
20247 20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (I) 85+ 85+ F.M 0 0 0 0 0 R NA Under Antibiotics - 100 Service - 1st Generation Cephalosporin Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Incosamide Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Incosamide Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Macrolide (not atith or clarith) Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Macrolide (not atith or clarith) Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Macrolide (not atith or clarith) Average Scrips PMPY (M/P) 85+ 85+ F.M 0 0 0 0 R NA Under Antibiotics - Macrolide (not atith or clarith) Average Scrips PMPY (M/P) 85+					r,IVI	0	1	0			0	NA
State F.M. O O O R NA Diter Antibiotics 20035 (2) All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 85+ 85+ F.M. O O R NA Diter Antibiotics 20035 (2) All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 85+ 85+ F.M. O O R NA Diter Antibiotics 20036 (2) All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) 85+ 85+ F.M. O O R NA DiterAntibiotics 20036 (2) All Other Antibiotics - Macrolide (not ath or clarith) Average Scrips PMPY (M/F) 85+ 85+ F.M. O O R R NA DiterAntibiotics 20039 (2) All Other Antibiotics - Macrolide (not ath or clarith) Average Scrips PMPY (M/F) 85+ 85+ F.M. O 0 R NA DiterAntibiotics 20039 (2) All Other Antibiotics - Macrolide (not ath or clarith) Average Scrips PMPY (M/F) 85+ 85+ F.M. O 0 R NA DiterAntibiotics 20045 (2) All Other Antibiotics - P				0.5.	IV1	0		U			ĸ	INA
2014 All Other Antibiotics - Lincosamide Average Scrips PMPY (M) 85+85+M00	othen intibiotics	200247_20		100	F	0		U			ĸ	110
DeterAntibiotics20034 20All Other Antibiotics - Lincosamide Average Scrips PMPY (h] 55+85+F.M00<					F,M	U		U			к	
Dimendition2086 20All Other Autobics - Luncounde Average Scrips PMPY (M/F) BS+BS+FA000<					M	0		0			R	_
Dimensional DependenciesQ0389.20Al Other Anabiotics - Maccide (not alther outlith) Average Scrips PMPY (M) BS+B5+MOOOMMMMDimensional DimensionalQ0379.20Al Other Anabiotics - Maccide (not alth or clarith) Average Scrips PMPY (M) BS+B5+F.MOOOOMMMMDimensional DimensionalQ0455.20Al Other Anabiotics - Pencillin Average Scrips PMPY (M) BS+B5+F.MOOOMMMMMDimensional DimensionalQ045.20Al Other Anabiotics - Pencillin Average Scrips PMPY (M) BS+B5+F.MOOOMMMMMDimensional DimensionalQ045.20Al Other Anabiotics - Pencillin Average Scrips PMPY (M) BS+B5+F.MOOOMM </td <td></td> <td></td> <td></td> <td></td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td></td>					F	0		0			R	
DeterAntibiotics20037All Other Antibiotics - Macrolide (not aith or clarith) Average Scrips PMPY (/F) 85+85+F.00008NADiterAntibioticsAll Other Antibiotics - Macrolide (not aith or clarith) Average Scrips PMPY (/F) 85+85+F.M0008NANADiterAntibiotics2004520All Other Antibiotics - Pencillin Average Scrips PMPY (M/BS+85+F.M0008NANADiterAntibiotics2004520All Other Antibiotics - Pencillin Average Scrips PMPY (M/BS+85+F.M00008NANADiterAntibiotics2004520All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) 85+85+F.M00008NANADiterAntibiotics2004520All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 85+85+F.M00008NANADiterAntibiotics2004520All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 85+85+F.M000008NANADiterAntibiotics2004520All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 85+85+F.M0000000000000000000000000000000000000<	OtherAntibiotics				,	0		0			R	NA
All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 0 R NA Uther Antibiotics - Social Librority - Vencillan Average Scrips PMPY (M) 85+ 85+ M 0 0 0 0 8 NA Uther Antibiotics - Vencillan Average Scrips PMPY (M) 85+ 85+ F 0 0 0 8 NA Uther Antibiotics - Vencillan Average Scrips PMPY (M) 85+ 85+ F 0 0 0 8 NA Other Antibiotics - Vencillan Average Scrips PMPY (M) 85+ 85+ F 0 0 8 NA Uther Antibiotics - Tetracycline Average Scrips PMPY (M) 55+ 85+ F,M 0 0 0 8 NA Uther Antibiotics - Tetracycline Average Scrips PMPY (M) 55+ 85+ F,M 0 0 0 8 NA Uther Antibiotics - Tetracycline Average Scrips PMPY (M) 55+ 85+ F 0 0 0 8 NA UtherAntibiotics - Divers - Tetracycline Average Scrips PMPY (M) 55+ 85+ F 0 0 8 NA NA <	OtherAntibiotics			05.	М	0	ļ	0			R	NA
20d45_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M) 85+ 85+ M 0 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d45_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 R NA 1therAntibiotics 20d42_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 R	OtherAntibiotics			85+	F	0		0			R	NA
2014 201 All Other Antibiotics - PencieIIIIn Average Scrips PMPY ([K] 85+ 85+ F.M 0 0 0 0 R NA 2014eAntibiotics 20045 20 All Other Antibiotics - PencieIIII Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 20045 20 All Other Antibiotics - PencieIIII Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 20045 20 All Other Antibiotics - Tetracycline Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 20045 20 All Other Antibiotics - Tetracycline Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 20045 20 All Other Antibiotics - Tetracycline Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 20045 20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R NA 2014eAntibiotics 20042 20 All Other Antibiotics Average Scrips PMPY ([K]; 85+ 85+ F.M 0 0 0 R <	OtherAntibiotics	200399_20	All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) 85+	85+	F,M	0		0			R	NA
2014 All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 0 8 NA Uther Antibiotics 20048 20 All Other Antibiotics - Tetracycillin Average Scrips PMPY (M/F) 85+ 85+ M 0 0 0 8 NA NA UtherAntibiotics 20048 20 All Other Antibiotics - Tetracycillin Average Scrips PMPY (M/F) 85+ 85+ F 0 0 0 8 NA UtherAntibiotics 20049 20 All Other Antibiotics - Tetracycillin Average Scrips PMPY (M/F) 85+ 85+ F 0 0 8 NA UtherAntibiotics 20049 20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M/F) 85+ 85+ F.M 0 0 0 8 NA UtherAntibiotics 20042 20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (F) 85+ 85+ F.M 0 0 0 8 NA UtherAntibiotics 20042 20 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (F) 85+ 85+ F.M 0 0 0 8 NA UtherAntibiotics 20042 20 All Other Antibiotics -	OtherAntibiotics	200455_20	All Other Antibiotics - Penicillin Average Scrips PMPY (M) 85+	85+	М	0		0			R	NA
DtherAntibiotics 20045_20 All Other Antibiotics - Penciellin Average Scrips PMPY (M/F) 85+ 85+ F.M 0 0 0 0 8 MA Uther Antibiotics All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 85+ 85+ M 0 0 0 0 0 0 0 NA Uther Antibiotics Tetracycline Average Scrips PMPY (M/F) 85+ 85+ F 0 <td>OtherAntibiotics</td> <td>200445_20</td> <td>All Other Antibiotics - Penicillin Average Scrips PMPY (F) 85+</td> <td>85+</td> <td>F</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>	OtherAntibiotics	200445_20	All Other Antibiotics - Penicillin Average Scrips PMPY (F) 85+	85+	F	0		0			R	NA
20048_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ M 0 0 0 0 0 M M 200478_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0 0 0 0 0 0 0 NA 20ther Antibiotics - Tetracycline Average Scrips PMPY (M) 85+ 85+ F 0	OtherAntibiotics	200465_20		85+	F,M	0		0			R	NA
DtherAntibiotics 200472 All Other Antibiotics - Tetracycline Average Scrips PMPY (f) 85+ 85+ F.M 0 0 0 0 0 R NA DtherAntibiotics 200482.0 All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) 85+ 85+ F.M 0 0 0 0 R NA DtherAntibiotics 200482.0 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M) 85+ 85+ F.M 0 0 0 0 R NA DtherAntibiotics 20042.2.0 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M) 85+ 85+ F.M 0 0 0 R NA DtherAntibiotics 20042.2.0 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M) 85+ 85+ F.M 0 0 0 R NA DtherAntibiotics 20042.2.0 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M) 78+ 85+ F.M 0 0 0 R NA DtherAntibiotics 20042.2.0 All Other Antibiotics - Nisc Antibiotic Average Scrips PMPY (M) 78+	OtherAntibiotics			85+	М	0		0			R	NA
DtherAntibiotics 20048_20 All Other Antibiotics - Tetracyline Average Scrips PMPY (M/F) 85+ 85+ F.M 0 0 0 0 8 MA DtherAntibiotics 20042_20 All Other Antibiotics - Atlisca Atliabitica Average Scrips PMPY (M/S) 85+ 85+ F.M 0 0 0 0 8 MA DtherAntibiotics 20042_20 All Other Antibiotics Average Scrips PMPY (M/S) 85+ 85+ F.M 0 0 0 0 8 MA DtherAntibiotics 20042_20 All Other Antibiotics Average Scrips PMPY (M/S) 85+ 85+ F.M 0 0 0 0 8 MA DtherAntibiotics 20032_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/S) 85+ 85+ F.M 0 0 0 0 8 MA MA DtherAntibiotics 20032_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/S) MM Manown F.M 0 0 0 0 MA MA DtherAntibiotics 20232_20 All Other Antibiotics -	OtherAntibiotics			85+	F	0	1	0	İ		R	NA
Date Antibiotis Qud2_20 All Other Antibiotis-Asscantibiotic Average Scrips PMP (M) 85+ 85+ M O O O M M M Date Antibiotis 20412.00 All Other Antibiotis-Asscantibiotic Average Scrips PMP (M) 85+ 85+ FM 0 0 0 0 0 M M M Date Antibiotis 2042.00 All Other Antibiotis-Asscantibiotic Average Scrips PMP (M) 85+ 85+ FM 0 0 0 0 M <td>OtherAntibiotics</td> <td></td> <td></td> <td>85+</td> <td>F.M</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td>R</td> <td>NA</td>	OtherAntibiotics			85+	F.M	0		0			R	NA
DeterAntibiotisty 200412_20 All Other Antibiotisty-Misc Antibiotisty-Misc Antibiotisty-Misc Antibiotisty Support (P(S)S+ 85+ F.M 0 Control 0 Control 0 Control R NA Uther Antibiotisty 200432_00 All Other Antibiotisty-Misc Antibiotisty-Misc Antibiotisty Support (P(S)S+ 85+ F.M 0 Control 0 Control R NA DireAntibiotisty 200432_00 All Other Antibiotisty-Misc Antibiotisty Support (P(S)S+ 85+ F.M 0 Control 0 Control R NA DireAntibiotisty 20022_00 All Other Antibiotisty-Support (P(F)MINH Unknown M 0 0 0 R NA DireAntibiotisty 20022_00 All Other Antibiotisty-Subport (P(F) Unknown Vinnown F 0 0 0 0 R NA	OtherAntibiotics	200.000_20			M	0	1	0	1		R	100.5
DtherAntibiotics 200432_00 All Other Antibiotics-Misc Antibiotic Average Scrips PMPY (M/F) 85+ 85+ F,M 0 0 0 0 R NA DtherAntibiotics 20029_20 All Other Antibiotics-Absorbable Sulfonamide Average Scrips PMPY (M) Unk Unknown M 0 0 0 R NA DtherAntibiotics 20029_20 All Other Antibiotics-Absorbable Sulfonamide Average Scrips PMPY (F) Unk Unknown F 0 0 0 0 R NA					F	0	1	-			B	NA
DtherAntibiotics 20032_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) Unk Unknown M 0 0 0 R NA DtherAntibiotics 20032_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (F) Unk Unknown F 0 0 R NA					Е М	0	1	0			P	NA
200282_20 All Other Antibioties: - Absorbable Sulfonamide Average Scrips PMPY (F) Unk Unknown F 0 0 R NA					.,	0	1	0	1		P	NA
					r.	0		0			R	NA NA
unerantulouous 1200302_20 jail unerantulouus - Aassorbabile suitonamilee Averäge scrips PMPY (M/+) Unk Unknown (P,M U					F	0		0			R	N/A
	outerAntibiotics	200302_20	All Other Andolotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) Unk	UNKNOWN	r,IVI	U	1	ν	1		n	NA

OtherAntibiotis 200325_20 All Other Antibiotis - Aminoglycoside Average Scrips PMPY (f) Unk Unknown M 0	AuditDesignation Stat NA NA I NA
OtherAntibiotics 200315 20 All Other Antibiotics Amingly coside Average Scrips PMPY (F) Unk Unknown F 0 <	NA
DiterAntibiotics 200335 20 All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M) Luk Unkown F.M 0	NA
DiterAntibiotics 200259 20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) Unk Unknown M 0 <t< td=""><td>NA I NA I NA</td></t<>	NA I NA
OtherAntibiotis 200249 All Other Antibiotiss - 1st Generation Cephalosporin Average Scrips PMPY (M/F) Unk Unknown F.M 0	NA I NA
OtherAntibiotis 200269 20 All Other Antibiotis - Lincosamide Average Scrips PMPY (M/F) Unk Unknown F,M 0	С
OtherAntibiotis 200358_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M) Unk Unknown M 0	NA
OtherAntibiotics 200348_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (F) Unk Unknown F_M 0 0 0 0 R OtherAntibiotics 200368_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 200391_20 All Other Antibiotics - Macroile (not azith or clarith) Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 200391_20 All Other Antibiotics - Macroile (not azith or clarith) Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 200401_20 All Other Antibiotics - Macroile (not azith or clarith) Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 20047_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 200467_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) Unk Unknown F_M 0 0 R OtherAntibiotics 200467_20 All Other	NA NA L NA
OtherAntibiotics 200368_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) Unk Unknown F,M 0	R NA R NA R NA R NA R NA R NA R NA
OtherAntibiotics 200391_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) Unk Unknown M 0 <td< td=""><td>R NA R NA R NA R NA R NA R NA R NA</td></td<>	R NA R NA R NA R NA R NA R NA R NA
OtherAntibiotics 200381_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (F) Unk Unknown F.M 0 0 0 0 R OtherAntibiotics 200401_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotics 200407_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotics 20047_20 All Other Antibiotics - Pencillin Average Scrips PMPY (F) Unk Unknown F.M 0 0 R OtherAntibiotics 200467_20 All Other Antibiotics - Pencillin Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotics 200467_20 All Other Antibiotics - Verarge Scrips PMPY (M/F) Unk Unknown F.M 0 0 R R OtherAntibiotics 200462_20 All Other Antibiotics - Verarge Scrips PMPY (M/F) Unk Unknown F.M 0 0 R R OtherAntibiotics 200402_20 All Other Antibio	k NA k NA k NA k NA k NA k NA
OtherAntibiotics 200401_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) Unk Unknown F,M 0	k NA k NA k NA k NA k NA
OtherAntibiotics 200457_20 All Other Antibiotics - PenicIIIIn Average Scrips PMPY (M) Unk Unknown M 0	R NA R NA R NA R NA R NA
OtherAntibiotis 20047_20 All Other Antibiotis - Penicillin Average Scrips PMPY (F) Unk Unknown F. 0 0 0 R OtherAntibiotis 200467_20 All Other Antibiotis - Penicillin Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 200467_20 All Other Antibiotis - Teracycline Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 200402_02 All Other Antibiotis - Teracycline Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 200402_02 All Other Antibiotis - Teracycline Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 20042_02 All Other Antibiotis - Verage Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 20042_02 All Other Antibiotis - Merage Scrips PMPY (M/F) Unk Unknown F.M 0 0 R OtherAntibiotis 200414_20 All Other Antibiotics - Marka Antibiotic Average Scrips PMPY (M/F) Unk Unknown F.M	R NA R NA R NA R NA
OtherAntibiotics 200467_20 All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 0 0 R OtherAntibiotics 200490_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) Nak Unknown M 0 0 0 R OtherAntibiotics 200480_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) Nak Unknown F 0 0 R R OtherAntibiotics 200500_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) Unk Unknown F 0 0 R R OtherAntibiotics 200500_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) Unk Unknown F.M 0 0 R R OtherAntibiotics 20044_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/ INk Unknown F 0 0 R R OtherAntibiotics 20044_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F 0 0 R R OtherAntibiotics	R NA R NA R NA
OtherAntibiotics 200490_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) Unk Unknown M 0	NA R NA
OtherAntibiotis 200480_20 All Other Antibiotis - Tetracycline Average Scrips PMPY (F) Unk Unknown F. 0.1 0.1 0.1 R OtherAntibiotis 20050_20 All Other Antibiotis - Tetracycline Average Scrips PMPY (M/F) Unk Unknown F.M 0.4 0.1 0.1 R OtherAntibiotis 20042_0 All Other Antibiotics - Markage Scrips PMPY (M/F) Unk Unknown F.M 0.4 0.4 R OtherAntibiotis 20044_20 All Other Antibiotics - Markage Scrips PMPY (M/G) Unk Unknown F.M 0.4 0.4 R OtherAntibiotis 20044_20 All Other Antibiotics - Markatibiotic Average Scrips PMPY (M/F) Unk Unknown F.M 0.4 0.4 R OtherAntibiotis 20044_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F.M 0.4 0.4 R OtherAntibiotis 20043_20 All Other Antibiotics - Absorbabile Sufforamide Average Scrips PMPY (M/F) Unk Unknown F.M 0.4 73827 0.6 0.4 0.0 0.03 R	NA NA
OtherAntibiotics 20050_20 All Other Antibiotics - Interacycline Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 0 0 R OtherAntibiotics 20042_0 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/I) Unk Unknown M 0 0 0 0 0 R OtherAntibiotics 20044_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (P) (Duk Unknown F,M 0 0 0 R R OtherAntibiotics 20044_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (P) (Duk Unknown F,M 0 0 0 R R OtherAntibiotics 20043_40 All Other Antibiotics - Masc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 0 0 R OtherAntibiotics 20043_40 All Other Antibiotics - Masc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 0 0 R OtherAntibiotics 200291_40 All Other Antibiotics - Masc Antibiotics - Masc Average Scrips PMPY (M/F) Unk Unknown	
OtherAntibiotics 200424_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) Unk Unknown M 0 0 0 R OtherAntibiotics 200414_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) Unk Unknown F 0 0 R OtherAntibiotics 200434_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F 0 0 R OtherAntibiotics 200434_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F/M 0 0 R OtherAntibiotics 200434_20 All Other Antibiotics - Misc Antibiot	NA
OtherAntibiotics 200414_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (F) Unk Unknown F 0 0 R R OtherAntibiotics 20043_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M)(F) Unk Unknown F,M 0 0 R OtherAntibiotics 200291_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) Total M 173827 395 0.03 R	1011
OtherAntibiotics 200434_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M/F) Unk Unknown F,M 0 0 6 R OtherAntibiotics 200291_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) Total M 17827 395 0.03 R	NA NA
OtherAntibiotics 200291_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M) Total M 17827 395 0.03 R	NA NA
	NA NA
	R
OtherAntibiotics 200281_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (F) Total F 164437 815 0.06 R	R
OtherAntibiotics 200301_20 All Other Antibiotics - Absorbable Sulfonamide Average Scrips PMPY (M/F) Total F,M 338264 1210 0.04 R	R
OtherAntibiotics 200324_20 All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M) Total M 173827 3 0.00 R	R
OtherAntibiotics 200314_20 All Other Antibiotics - Aminoglycoside Average Scrips PMPY (F) Total F 164437 0 0 0.00 R	R
OtherAntibiotics 200334_20 All Other Antibiotics - Aminoglycoside Average Scrips PMPY (M/F) Total F,M 338264 3 0.00 R	R
OtherAntibiotics 200258_20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M) Total M 173827 566 0.0.4 R	R
0therAntibiotics 200248_20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (F) Total F 164437 822 0.0.6 R	R
OtherAntibiotics 200268_20 All Other Antibiotics - 1st Generation Cephalosporin Average Scrips PMPY (M/F) Total F,M 338264 1388 0.05 R	R
OtherAntibiotics 200357_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M) Total M 173827 0 0.00 R	R
OtherAntibiotics 200347_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (F) Total F 164437 0 0 0.00 R	R
OtherAntibiotics 200367_20 All Other Antibiotics - Lincosamide Average Scrips PMPY (M/F) Total F,M 338264 0 0.00 R	R
OtherAntibiotics 200390_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M) Total M 173827 22 0.00 R	R
OtherAntibiotics 200380_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (F) Total F 164437 16 0.00 R	R
OtherAntibiotics 200400_20 All Other Antibiotics - Macrolide (not azith or clarith) Average Scrips PMPY (M/F) Total F,M 338264 38 0.00 R	R
OtherAntibiotics 200456_20 All Other Antibiotics - Penicillin Average Scrips PMPY (M) Total M 173827 2858 0.20 R	R
OtherAntibiotics 200446_20 All Other Antibiotics - Penicillin Average Scrips PMPY (F) Total F 164437 3121 0.23 R	R
OtherAntibiotics 200466_20 All Other Antibiotics - Penicillin Average Scrips PMPY (M/F) Total F.M 338264 \$979 0.21 R	R
OtherAntibiotics 200489_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M) Total M 173827 353 0.02 R	R
OtherAntibiotics 200479_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (F) Total F 164437 483 0.04 R	R
OtherAntibiotics 200499_20 All Other Antibiotics - Tetracycline Average Scrips PMPY (M/F) Total F,M 338264 836 0.03 R	R
OtherAntibiotics 20043_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (M) Total M 173827 91 0.01 R	R
OtherAntibiotics 200413_20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPY (F) Total F 164437 1156 0.08 R	R
OtherAntibiotics 20043 20 All Other Antibiotics - Misc Antibiotic Average Scrips PMPP (M/F) Total F,M 338264 1247 0.04 R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

MeasurementYear: 2020															
Category	IndicatorKey	IndicatorName	Age	MemberCount	OutlierMemberCount	OutlierRate	Denominator	ObservedCount	ObservedRate	ExpectedCount	ExpectedRate	CountVariance	OE	AuditDesignation	Status
PlanAllCauseReadmissions	202014_20	(18-44)	18-44	239	24	100.42	226	23	10.18	18.7026	8.28	17.0963	1.2298	R	R
PlanAllCauseReadmissions	202015_20	(45-54)	45-54	0	0		0	0		0.0000		0.0000		R	NA
PlanAllCauseReadmissions	202016_20	(55-64)	55-64	0	0		0	0		0.0000		0.0000		R	NA
PlanAllCauseReadmissions	202025_20	(18-64)	18-64	239	24	100.42	226	23	10.18	18.7026	8.28	17.0963	1.2298	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	Rate	AuditDesignation	Status
Enrollment	201006_20	Male (<1)	0-1	М	3672	306	R	R
Enrollment	201005_20	Female (<1)	0-1	F	3764	314	R	R
Enrollment	201007_20	Total (<1)	0-1	F,M	7436	620	R	R
Enrollment	200928_20	Male (1-4)	1-4	М	29582	2465	R	R
Enrollment	200927_20	Female (1-4)	1-4	F	27619	2302	R	R
Enrollment	200929_20	Total (1-4)	1-4	F,M	57201	4767	R	R
Enrollment	200970_20	Male (5-9)	5-9	М	43394	3616	R	R
Enrollment	200969_20	Female (5-9)	5-9	F	38720	3227	R	R
Enrollment	200971_20	Total (5-9)	5-9	F,M	82114	6843	R	R
Enrollment	200931_20	Male (10-14)	10-14	М	47523	3960	R	R
Enrollment	200930_20	Female (10-14)	10-14	F	43160	3597	R	R
Enrollment	200932_20	Total (10-14)	10-14	F,M	90683	7557	R	R
Enrollment	200934_20	Male (15-17)	15-17	М	30828	2569	R	R
Enrollment	200933_20	Female (15-17)	15-17	F	29873	2489	R	R
Enrollment	200935_20	Total (15-17)	15-17	F,M	60701	5058	R	R
Enrollment	200937_20	Male (18-19)	18-19	М	12839	1070	R	R
Enrollment	200936_20	Female (18-19)	18-19	F	12810	1068	R	R
Enrollment	200938_20	Total (18-19)	18-19	F,M	25649	2137	R	R
Enrollment	200940_20	Male (20-24)	20-24	М	5862	489	R	R
Enrollment	200939_20	Female (20-24)	20-24	F	8204	684	R	R
Enrollment	200941_20	Total (20-24)	20-24	F,M	14066	1172	R	R
Enrollment	200949_20	Male (25-29)	25-29	М	139	12	R	R
Enrollment	200948_20	Female (25-29)	25-29	F	287	24	R	R
Enrollment	200950_20	Total (25-29)	25-29	F,M	426	36	R	R
Enrollment	200952_20	Male (30-34)	30-34	М	0	0	R	R
Enrollment	200951_20	Female (30-34)	30-34	F	0	0	R	R
Enrollment	200953_20	Total (30-34)	30-34	F,M	0	0	R	R
Enrollment	200955_20	Male (35-39)	35-39	М	0	0	R	R
Enrollment	200954_20	Female (35-39)	35-39	F	0	0	R	R
Enrollment	200956_20	Total (35-39)	35-39	F,M	0	0	R	R
Enrollment	200958_20	Male (40-44)	40-44	М	0	0	R	R
Enrollment	200957 20	Female (40-44)	40-44	F	0	0	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	Rate	AuditDesignation	Status
Enrollment	200959_20	Total (40-44)	40-44	F,M	0	0	R	R
Enrollment	200961_20	Male (45-49)	45-49	М	0	0	R	R
Enrollment	200960_20	Female (45-49)	45-49	F	0	0	R	R
Enrollment	200962_20	Total (45-49)	45-49	F,M	0	0	R	R
Enrollment	200973_20	Male (50-54)	50-54	М	0	0	R	R
Enrollment	200972_20	Female (50-54)	50-54	F	0	0	R	R
Enrollment	200974_20	Total (50-54)	50-54	F,M	0	0	R	R
Enrollment	200976_20	Male (55-59)	55-59	М	0	0	R	R
Enrollment	200975_20	Female (55-59)	55-59	F	0	0	R	R
Enrollment	200977_20	Total (55-59)	55-59	F,M	0	0	R	R
Enrollment	200979_20	Male (60-64)	60-64	М	0	0	R	R
Enrollment	200978_20	Female (60-64)	60-64	F	0	0	R	R
Enrollment	200980_20	Total (60-64)	60-64	F,M	0	0	R	R
Enrollment	200988_20	Male (65-69)	65-69	М	0	0	R	R
Enrollment	200987_20	Female (65-69)	65-69	F	0	0	R	R
Enrollment	200989_20	Total (65-69)	65-69	F,M	0	0	R	R
Enrollment	200991_20	Male (70-74)	70-74	М	0	0	R	R
Enrollment	200990_20	Female (70-74)	70-74	F	0	0	R	R
Enrollment	200992_20	Total (70-74)	70-74	F,M	0	0	R	R
Enrollment	200994_20	Male (75-79)	75-79	М	0	0	R	R
Enrollment	200993_20	Female (75-79)	75-79	F	0	0	R	R
Enrollment	200995_20	Total (75-79)	75-79	F,M	0	0	R	R
Enrollment	200997_20	Male (80-84)	80-84	М	0	0	R	R
Enrollment	200996_20	Female (80-84)	80-84	F	0	0	R	R
Enrollment	200998_20	Total (80-84)	80-84	F,M	0	0	R	R
Enrollment	201000_20	Male (85-89)	85-89	М	0	0	R	R
Enrollment	200999_20	Female (85-89)	85-89	F	0	0	R	R
Enrollment	201001_20	Total (85-89)	85-89	F,M	0	0	R	R
Enrollment	201003_20	Male (90+)	90+	М	0	0	R	R
Enrollment	201002_20	Female (90+)	90+	F	0	0	R	R
Enrollment	201004_20	Total (90+)	90+	F,M	0	0	R	R
Enrollment	201012_20	Male (Unknown)	Unknown	М	0	0	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	Age	Gender	MemberMonths	Rate	AuditDesignation	Status
Enrollment	201011_20	Female (Unknown)	Unknown	F	0	0	R	R
Enrollment	201013_20	Total (Unknown)	Unknown	F,M	0	0	R	R
Enrollment	201009_20	Male	Total	М	173839	14487	R	R
Enrollment	201008_20	Female	Total	F	164437	13703	R	R
Enrollment	201010_20	Total	Total	F,M	338276	28190	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

Category IndicatorKey IndicatorName

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	MemberCount	Rate	AuditDesignation	Status
Enrollment	200778_20	Alabama	4	4	R	R
Enrollment	200779_20	Alaska	0	0	R	R
Enrollment	200781_20	Arizona	1	1	R	R
Enrollment	200782_20	Arkansas	0	0	R	R
Enrollment	200783_20	California	0	0	R	R
Enrollment	200784_20	Colorado	0	0	R	R
Enrollment	200786_20	Connecticut	0	0	R	R
Enrollment	200787_20	Delaware	0	0	R	R
Enrollment	200788_20	District of Columbia	0	0	R	R
Enrollment	200790_20	Florida	2	2	R	R
Inrollment	200791_20	Georgia	28317	28317	R	R
Inrollment	200793_20	Hawaii	0	0	R	R
nrollment	200794_20	Idaho	0	0	R	R
Inrollment	200795_20	Illinois	2	2	R	R
Inrollment	200796_20	Indiana	0	0	R	R
Inrollment	200797_20	Iowa	0	0	R	R
Inrollment	200798_20	Kansas	0	0	R	R
Inrollment	200799_20	Kentucky	0	0	R	R
Inrollment	200800_20	Louisiana	0	0	R	R
inrollment	200801_20	Maine	0	0	R	R
nrollment	200802_20	Maryland	0	0	R	R
inrollment	200803_20	Massachusetts	1	1	R	R
nrollment	200804_20	Michigan	1	1	R	R
nrollment	200805_20	Minnesota	0	0	R	R
Inrollment	200806_20	Mississippi	1	1	R	R
inrollment	200807_20	Missouri	0	0	R	R
Inrollment	200808_20	Montana	0	0	R	R
Inrollment	200809_20	Nebraska	0	0	R	R
Inrollment	200810_20	Nevada	1	1	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	MemberCount	Rate	AuditDesignation	Status
Enrollment	200811_20	New Hampshire	0	0	R	R
Enrollment	200812_20	New Jersey	2	2	R	R
Enrollment	200813_20	New Mexico	0	0	R	R
Enrollment	200814_20	New York	0	0	R	R
Enrollment	200815_20	North Carolina	2	2	R	R
Enrollment	200816_20	North Dakota	0	0	R	R
Enrollment	200817_20	Ohio	0	0	R	R
Enrollment	200818_20	Oklahoma	0	0	R	R
Enrollment	200819_20	Oregon	0	0	R	R
Enrollment	200821_20	Pennsylvania	1	1	R	R
Enrollment	200823_20	Rhode Island	0	0	R	R
Enrollment	200824_20	South Carolina	0	0	R	R
Enrollment	200825_20	South Dakota	0	0	R	R
Enrollment	200826_20	Tennessee	2	2	R	R
Enrollment	200827_20	Texas	3	3	R	R
Enrollment	200829_20	Utah	0	0	R	R
Enrollment	200830_20	Vermont	0	0	R	R
Enrollment	200832_20	Virginia	0	0	R	R
Enrollment	200833_20	Washington	0	0	R	R
Enrollment	200834_20	West Virginia	0	0	R	R
Enrollment	200835_20	Wisconsin	0	0	R	R
Enrollment	200836_20	Wyoming	0	0	R	R
Enrollment	200780_20	American Samoa	0	0	R	R
Enrollment	200789_20	Federated States of Micronesia	0	0	R	R
Enrollment	200792_20	Guam	0	0	R	R
Enrollment	200785_20	Commonwealth of Northern Marianas	0	0	R	R
Enrollment	200822_20	Puerto Rico	0	0	R	R
Enrollment	200831_20	Virgin Islands	0	0	R	R
Enrollment	200820_20	Other	0	0	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	MemberCount	Rate	AuditDesignation	Status
Enrollment	200828_20	Total	28340	28340	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Category	IndicatorKey	IndicatorName	MemberCount	Denominator	Rate	AuditDesignation	Status
SpokenSource	201850_20	Spoken Language Preferred for Health Care - Health Plan	0	33474	0.00	R	R
SpokenSource	201845_20	Spoken Language Preferred for Health Care - CMS/State	33474	33474	100.00	R	R
SpokenSource	201853_20	Spoken Language Preferred for Health Care - Other Third-Party	0	33474	0.00	R	R
WrittenSource	201843_20	Preferred Language for Written Materials - Health Plan	0	33474	0.00	R	R
WrittenSource	201842_20	Preferred Language for Written Materials - CMS/State	33470	33474	99.99	R	R
WrittenSource	201844_20	Preferred Language for Written Materials - Other Third-Party	4	33474	0.01	R	R
OtherSource	201830_20	Other Language Needs - Health Plan	0	33474	0.00	R	R
OtherSource	201829_20	Other Language Needs - CMS/State	0	33474	0.00	R	R
OtherSource	201831_20	Other Language Needs - Other Third-Party	33474	33474	100.00	R	R
SpokenPreferred	201849_20	Spoken Language Preferred for Health Care - Percent English	33233	33474	99.28	R	R
SpokenPreferred	201852_20	Spoken Language Preferred for Health Care - Percent Non-English	204	33474	0.61	R	R
SpokenPreferred	201847_20	Spoken Language Preferred for Health Care - Percent Declined	0	33474	0.00	R	R
SpokenPreferred	201857_20	Spoken Language Preferred for Health Care - Percent Unknown	37	33474	0.11	R	R
WrittenPreferred	201822_20	Language Preferred for Written Materials - Percent English	33229	33474	99.27	R	R
WrittenPreferred	201824_20	Language Preferred for Written Materials - Percent Non-English	208	33474	0.62	R	R
WrittenPreferred	201820_20	Language Preferred for Written Materials - Percent Declined	0	33474	0.00	R	R
WrittenPreferred	201828_20	Language Preferred for Written Materials - Percent Unknown	37	33474	0.11	R	R
OtherPreferred	201835_20	Other Language Needs - Percent English	0	33474	0.00	R	R
OtherPreferred	201837_20	Other Language Needs - Percent Non-English	0	33474	0.00	R	R
OtherPreferred	201833_20	Other Language Needs - Percent Declined	0	33474	0.00	R	R
OtherPreferred	201841_20	Other Language Needs - Percent Unknown	33474	33474	100.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

Measurement	'ear: 2020						
Category	IndicatorKey	IndicatorName	MemberCount	Denominator	Rate	AuditDesignation	Status
RaceSource	202356_20	Race - Health Plan	0	33474	0.00	R	R
RaceSource	202354_20	Race - CMS/State	33474	33474	100.00	R	R
RaceSource	202358_20	Race Other Direct	0	33474	0.00	R	R
RaceSource	202355_20	Race Direct Total	33474	33474	100.00	R	R
RaceSource	202357_20	Race Indirect Total	0	33474	0.00	R	R
RaceSource	202359_20	Race Unknown Total	0	33474	0.00	R	R
EthnicitySource	202340_20	Ethnicity - Health Plan	0	33474	0.00	R	R
EthnicitySource	202338_20	Ethnicity - CMS/State	33474	33474	100.00	R	R
EthnicitySource	202342_20	Ethnicity Other Direct	0	33474	0.00	R	R
EthnicitySource	202339_20	Ethnicity Direct Total	33474	33474	100.00	R	R
EthnicitySource	202341_20	Ethnicity Indirect Total	0	33474	0.00	R	R
EthnicitySource	202343_20	Ethnicity Unknown Total	0	33474	0.00	R	R
RaceEthnicity	202404_20	White - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202406_20	White - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202410_20	White - Unknown Ethnicity	16441	33474	49.12	R	R
RaceEthnicity	202402_20	White - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202408_20	White - Total	16441	33474	49.12	R	R
RaceEthnicity	202321_20	Black or African American - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202323_20	Black or African American - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202319_20	Black or African American - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202327_20	Black or African American - Unknown Ethnicity	14064	33474	42.01	R	R
RaceEthnicity	202325_20	Black or African American - Total	14064	33474	42.01	R	R
RaceEthnicity	202301_20	American-Indian and Alaska Native - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202303_20	American-Indian and Alaska Native - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202299_20	American-Indian and Alaska Native - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202307_20	American-Indian and Alaska Native - Unknown Ethnicity	82	33474	0.24	R	R
RaceEthnicity	202305_20	American-Indian and Alaska Native - Total	82	33474	0.24	R	R
RaceEthnicity	202311_20	Asian - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202373_20	Total - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202313_20	Asian - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202375_20	Total - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202379_20	Total - Unknown Ethnicity	33474	33474	100.00	R	R
RaceEthnicity	202317_20	Asian - Unknown Ethnicity	66	33474	0.20	R	R
RaceEthnicity	202371_20	Total - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202309_20	Asian - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202315_20	Asian - Total	66	33474	0.20	R	R
RaceEthnicity	202377_20	Total - Total	33474	33474	100.00	R	R
RaceEthnicity	202347_20	Native Hawaiian and Other Pacific Islanders - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202349_20	Native Hawaiian and Other Pacific Islanders - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202345_20	Native Hawaiian and Other Pacific Islanders - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202353 20	Native Hawaiian and Other Pacific Islanders - Unknown Ethnicity	32	33474	0.10	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear:	2020
measurementream	

Category	IndicatorKey	IndicatorName	MemberCount	Denominator	Rate	AuditDesignation	Status
RaceEthnicity	202351_20	Native Hawaiian and Other Pacific Islanders - Total	32	33474	0.10	R	R
RaceEthnicity	202363_20	Some Other Race - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202365_20	Some Other Race - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202361_20	Some Other Race - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202369_20	Some Other Race - Unknown Ethnicity	1424	33474	4.25	R	R
RaceEthnicity	202367_20	Some Other Race - Total	1424	33474	4.25	R	R
RaceEthnicity	202384_20	Two or More Races - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202386_20	Two or More Races - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202382_20	Two or More Races - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202390_20	Two or More Races - Unknown Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202388_20	Two or More Races - Total	0	33474	0.00	R	R
RaceEthnicity	202394_20	Unknown - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202396_20	Unknown - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202392_20	Unknown - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202400_20	Unknown - Unknown Ethnicity	1365	33474	4.08	R	R
RaceEthnicity	202398_20	Unknown - Total	1365	33474	4.08	R	R
RaceEthnicity	202331_20	Declined - Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202333_20	Declined - Not Hispanic or Latino	0	33474	0.00	R	R
RaceEthnicity	202329_20	Declined - Declined Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202337_20	Declined - Unknown Ethnicity	0	33474	0.00	R	R
RaceEthnicity	202335_20	Declined - Total	0	33474	0.00	R	R

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

IndicatorKey IndicatorName MemberCount Rate AuditDesignation Status Category 202472 20 HMO Medicaid 8692731 8692731 HMO R R нмо 202471 20 HMO Commercial 1311580 1311580 R R HMO 202474 20 HMO Medicare 1139359 1139359 R R нмо 202469 20 HMO Exchange 471237 471237 R R нмо 202475 20 HMO Other 0 0 R R нмо **HMO** Total 11614907 R 202470 20 11614907 R 334 PPO 202486 20 PPO Medicaid 334 R R PPO 202485 20 27402814 27402814 R R **PPO Commercial** PPO 202488 20 **PPO Medicare** 625795 625795 R R PPO 202483 20 PPO Exchange 735269 735269 R R PPO 202489 20 **PPO Other** 0 0 R R PPO 202484 20 PPO Total 28764212 28764212 R R POS 202479 20 POS Medicaid R Ω 0 R POS 202478 20 **POS Commercial** 1440559 1440559 R R POS 202481 20 POS Medicare 0 R R POS 112540 R R 202476 20 POS Exchange 112540 POS 202477 20 **POS Total** 1553099 1553099 R R POS 202482 20 **POS Other** 0 0 R R FFS 202465 20 **FFS** Medicaid 0 0 R R FFS **FFS** Commercial 238285 238285 R R 202464 20 FFS 202467 20 596030 596030 R R FFS Medicare FFS 202463 20 **FFS** Total 834315 R 834315 R FFS 202468 20 **FFS** Other R 0 0 R EPO 0 202459 20 **EPO Commercial** R R 0 EPO 0 0 R R 202460 20 **EPO Exchange** EPO 202461 20 **EPO** Other 0 0 R R EPO 202462 20 **EPO** Total 0 0 R R 202490 20 All Reporting Products Total 42766533 42766533 R R Total

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020

AMGP Georgia Managed Care Company, Inc. d/b/a Amerigroup Community Care (Org ID: 7359, Sub ID: 12792, Medicaid, Special Area: Georgia, Special Project: GA 360, Contract Number:)

MeasurementYear: 2020